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ABSTRACT
INTRODUCTION
!
Anthracycline chemotherapy is the cornerstone of breast cancer treatment. Anthracyclines possess 
potent anti-tumor properties, and their benefits are confirmed by a considerable body of evidence. 
However, their efficacy is undermined by dose dependent cardiotoxicity that mandates close 
monitoring of cardiac function: the method of choice for monitoring cardiac function is 
transthoracic echocardiography.
! Resting left ventricular (LV) ejection fraction (LVEF) is the key echocardiographic 
parameter used to monitor anthracycline-induced cardiotoxicity. However, LVEF is a coarse 
measure of systolic function with numerous limitations that constrain its use for monitoring 
cardiotoxicity. The recent development of a novel echocardiographic technique, myocardial strain 
imaging, may provide a more sensitive, accurate and reproducible measurement of LV function 
and therefore improve measures aimed at countering cardiotoxicity. The aim of this research was 
to investigate myocardial strain imaging by comparison with LVEF, for potentially earlier detection 
of LV dysfunction, in breast cancer patients treated with anthracyclines.
METHOD
Anthracycline naïve breast cancer patients were prospectively studied; 78 in the short-term over 3 
months, and 50 in the intermediate term over 12 months. All patients were treated with standard 
regimens containing anthracyclines. Echocardiograms were performed at 4 time points; 1) within 7 
days before commencing chemotherapy, 2) within 7 days of completing chemotherapy, 3) 6 months 
after, and 4) 12 months after chemotherapy. The echocardiographic images, together with other 
relevant clinical data acquired were analyzed. Two-dimensional (2D) LVEF (measured by 
Simpson’s method), and myocardial strain imaging (measured by 2D speckle tracking 
echocardiography (2DSTE)) were most thoroughly investigated.
RESULTS
Global and regional longitudinal LV systolic strain was significantly reduced in the short-term; 
global longitudinal strain decreased from -17.7% to -16.3% (p < 0.01) with 48% of global 
measurements reduced by >10%. In contrast, no reduction in LVEF >10% after chemotherapy was 
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observed. Conventional Doppler, tissue Doppler and myocardial strain imaging measurements of 
diastolic function were also altered within 7 days of completing chemotherapy. The changes in 
diastolic function were associated with reduced systolic function - reduced early diastolic strain 
rate (E-Sr) being most strongly predicted by reduced post chemotherapy systolic strain.
! In the intermediate-term, systolic function remained significantly reduced 6 months after 
treatment, and the reduced systolic strain 7 days after and 6 months after treatment occurred non-
uniformly within the LV. In the majority of participants, LV dysfunction was noted to be transient, 
with strain values returning to normal by 12 months. Mean global longitudinal systolic strain 
values at the 4 time points were: -19.0% ± 2.3%, -17.5% ± 2.3%, -18.2% ± 2.2%, -19.1% ± 1.9%. 
Persistently reduced systolic strain 12 months after anthracyclines was observed in 16% of 
participants, and was associated with significantly higher cumulative anthracycline doses.
CONCLUSION
Left ventricular systolic and diastolic dysfunction were detected using myocardial strain imaging 
within 7 days of completion of anthracycline chemotherapy, without a similar discernible change 
in LVEF. In the majority of participants, LV systolic dysfunction was noted to be transient, with 
strain values returning to normal 12 months after treatment. However, LV systolic strain was 
persistently reduced in 16% of participants 12 months after anthracyclines, and was associated 
with significantly higher cumulative anthracycline doses. 
!
! Myocardial strain imaging is more sensitive than LVEF for the early detection and 
intermediate term monitoring of LV systolic function following anthracycline chemotherapy. 
Myocardial strain imaging may aid in the identification of those with preclinical LV dysfunction, 
and in the development of improved monitoring protocols.
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CHAPTER 1
INTRODUCTION
1.1 MOTIVATION AND AIM OF THE THESIS 
Cancer survival rates have greatly improved in the last decade due to refined conventional 
treatments and the development of new therapies (Jemal et al., 2011). However, improved survival 
has come at a cost; significant side effects are often related to treatment - cardiotoxicity being 
among the most serious (Sawyer, Peng, Chen, Pentassuglia, & Lim, 2010). Anthracycline agents are 
a model case in point: anthracyclines have powerful anti-tumor properties that have been central 
in the improved life expectancy for victims of numerous cancers, especially breast cancer (Gianni 
et al., 2008). Unfortunately, the effectiveness of anthracyclines in breast cancer treatment is 
undermined by their adverse effects on non-malignant cells, including cardiac myocytes (Singal & 
Iliskovic, 1998; Singal, Li, Kumar, Danelisen, & Iliskovic, 2000).
!
! The cardiotoxic potential of anthracycline chemotherapy means that the focus of breast 
cancer treatment has been recast. As treatment most often involves anthracyclines, the aim is no 
longer to simply overcome malignancy: treatment now involves close monitoring of cardiac 
function before, during and after their use (Bird & Swain, 2008). The method of choice for 
monitoring cardiotoxicity in most centers is transthoracic echocardiography, the most popular 
imaging method for measuring cardiac anatomy and function (Bird & Swain, 2008; Yu, Sanderson, 
Marwick, & Oh, 2007). Although echocardiography has matured via extensive technical advances 
over six decades, there remains the need for further development. Encouragingly, novel 
innovations promise exciting further developments. 
!
! Currently, the most common echocardiographic method for assessing left ventricular 
(LV) systolic function is the measure of two-dimensional (2D) LV ejection fraction (LVEF), which 
provides the fraction of LV volume ejected in systole (see figure 1.1A) (Jurcut et al., 2008; Lang et 
al., 2005). It is widely acknowledged however, that LVEF has a number of significant limitations. 
LVEF is dependent upon 2D image quality; if images are poor, accuracy is reduced (Otterstad, 
2002). It also requires simplified assumptions about cardiac geometry that are used during 
measurement - if LV geometry is atypical or abnormal, the measurement is open to error 
(McGowan & Cleland, 2003). LVEF is also limited by the loading conditions on the heart (Bellenger 
et al., 2000). For example, an LVEF of 55% is normal in the majority of patients, however it is not 
normal in a patient with severe mitral valve regurgitation.
The recent development of a semi-automated echocardiographic technique, myocardial 
strain imaging, may provide more sensitive, accurate and reproducible measurements of LV 
systolic function (Marwick & Narula, 2009). Strain is a measure of myocardial deformation that 
represents the percentage change in length of a section of myocardium from its original length (see  
figure 1.1B) (Sengupta et al., 2007). Segmental LV dysfunction often precedes global dysfunction 
and is not captured by the LVEF; importantly, strain is able to measure both segmental and global 
myocardial deformation (Gorcsan & Tanaka, 2011). Furthermore, the muscular anatomy of the LV 
is complex; strain imaging is ideally suited to measuring LV function as it enables multiplane 
quantification of myocardial deformation (Geyer et al., 2010; Gorcsan & Tanaka, 2011).
! Figure 1.1A Illustration of the change in LV volume. 
! LVEF = (LVEDV - LVESV) / LVEDV
! (where: LVEDV is the left ventricular end diastolic volume 
! (indicated by the broken line), and LVESV is the left 
! ventricular end systolic volume (indicated by the unbroken 
! line)).
Figure 1.1B Illustration of myocardial strain measurement. An area of the LV myocardium is 
first highlighted and then shown in focus: Strain (%) = △l / lo (where: △l is the change in length 
and lo is the original length).
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The value of myocardial strain imaging in routine clinical practice is yet to be fully 
realized. One area in which it may be of great benefit is in the collaboration between cardiology 
and oncology, when breast cancer involves anthracycline chemotherapy. Specific to anthracycline-
induced cardiotoxicity, when a significant reduction in LVEF is demonstrated, functional 
deterioration can proceed quickly (Jurcut et al., 2008). Therefore, the early detection of LV 
dysfunction that enables the timely introduction of measures aimed at counteracting toxicity is 
important. Myocardial strain imaging, with its ability to measure systolic and diastolic function, 
may permit early detection of subclinical regional or global cardiotoxicity.
At the commencement of this thesis, data demonstrating that the early detection of 
cardiotoxicity using strain imaging may alter clinical prognosis was absent. Such data would 
facilitate modification of chemotherapy together with the introduction of therapy to minimize the 
impact of cardiotoxicity. The aim of this research was to investigate LV function in breast cancer 
patients treated with anthracyclines using both LVEF and myocardial strain imaging. To do so, 
images were acquired at specific time points; before, immediately after, and 6 and 12 months after 
chemotherapy. The echocardiographic images, together with other relevant data were analyzed, 
and the findings are presented in the following chapters of this thesis.
1.2 ORGANIZATION OF THE THESIS
Structured research was undertaken, with observations from the research published at appropriate 
times during the course of the study. Therefore, a large part of the thesis comprises peer reviewed 
published work. The chapters that contain published work are presented as they were accepted for 
publication, with the exception of minor differences in formatting (such as figure numbering and 
the referencing style) to ensure cohesion within the thesis. Referencing throughout the thesis is in 
American Psychological Association (APA) style.
The opening pages, introduction, background and concluding chapters, together with 
some supplementary material have been combined with the published work in order to unify the 
thesis. An outline of the structure of the thesis is provided in figure 1.2, which highlights the 
chapters that contain published work. A brief description of the contents of each chapter (apart 
from the present chapter) follows figure 1.2.
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PRELIMINARY REMARKS 
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Figure 1.2 Diagram outlining the structure of the thesis with published work highlighted grey.
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CHAPTER 2
The thesis is centered on echocardiography and anthracycline chemotherapy: essential background 
information about echocardiography is outlined in this chapter. More specifically, 
echocardiography has developed via a growing awareness of certain key principles for the 
observation and application of sound energy. This chapter begins with a description of a number 
of these key principles. Important advances in the development of ultrasound imaging, specifically 
echocardiography, are detailed next. Finally, developments in the measurement of LV function by 
echocardiography are discussed. (Detailed information about anthracyclines is given in chapter 3).
CHAPTER 3 
This chapter consists of two parts. In part A, the published review article ‘the potential role of 
echocardiographic strain imaging for evaluating cardiotoxicity due to cancer therapy’ is presented. 
Due to the editorial limitations on the length and the number of references that could be used in 
the published review, and as 3 years have elapsed since the publication of the original review, 
additional information is presented in part B. With specific reference to anthracycline 
chemotherapy, the development of myocardial strain imaging, strain imaging methodology, and 
the potential benefit of utilizing strain imaging for evaluating cardiotoxicity, chapter 3 provides a 
comprehensive literature review.
CHAPTER 4 
In this chapter, the published findings from analysis of LV systolic function using LVEF and strain 
imaging made immediately prior and immediately after anthracycline chemotherapy in the first 
fifty-two consecutive breast cancer patients are presented. Following a brief preamble, the chapter 
is presented as it was accepted for publication starting with the abstract, followed by the 
introduction, methods, results, conclusion and all references cited in the chapter.  
CHAPTER 5 
During the analysis of LV systolic function made immediately after anthracycline treatment, it was 
evident that an analysis of LV diastolic function would be a logical extension of the research. This 
is due to the complementary roles that both phases of the cardiac cycle play to ensure optimal 
cardiac performance. The published findings from analysis of diastolic function made immediately 
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before and immediately after anthracycline chemotherapy are presented in this chapter. As per 
chapter 4, this chapter is presented as it was accepted for publication and includes the abstract, 
introduction, methods, results, conclusion and a list of all references used in the chapter.
CHAPTER 6 
The data from measurements of LV systolic function made during the extended follow-up of 
participants are presented in this chapter - data from 52 participants followed for 12 months with 
echocardiography at four time points. These results are therefore the necessary extension of the 
earlier findings, and provide longer-term measurements of LV systolic function after 
anthracyclines. In keeping with the two chapters immediately prior, the findings are presented as 
they were accepted for publication and include the abstract, introduction, methods, results, 
conclusion and a list of all references cited in the chapter.
CHAPTER 7 
Anthracyclines are one of several agents used in the treatment of breast cancer. This chapter details 
the interesting and pertinent case of a 45-year-old female breast cancer patient who developed 
heart failure during treatment with trastuzumab which was administered following completion of 
anthracyclines. LVEF and myocardial strain measurements were made during her treatment for 
heart failure and during the reintroduction of trastuzumab therapy. As per the published article, 
the chapter includes an abstract, patient history, discussion and references.
CHAPTER 8 
A summary of the entire thesis and a discussion of the key findings from the research begin this 
final chapter. Conclusions that can be drawn, limitations and questions that arise from the research 
are presented. Chapter 8 ends with a discussion of future research. 
APPENDICES 
Ethics approval details, participant information and consent forms, and conference proceedings 
(abstract publications) are included as appendix items.
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CHAPTER 2
BACKGROUND
Preamble
As described in chapter 1, the primary aim of this thesis is the evaluation of cardiac function in 
breast cancer patients treated with potentially cardiotoxic chemotherapy. More specifically, 
echocardiographic myocardial strain imaging was investigated, for potentially earlier detection of 
LV dysfunction, in breast cancer patients treated with anthracycline chemotherapy. As such, the 
thesis is centered on echocardiography and anthracycline chemotherapy. 
! Echocardiography uses ultrasound to create real-time images of the heart (J. K. Oh, Seward, 
J.B., Tajik, A.J., 2007). It has matured by way of extensive technical advances (outlined in this 
chapter), which continue to provide improvements to current applications and for the 
development of newer ones. Once cumbersome machines with suboptimal images have evolved 
into user-friendly and sophisticated diagnostic instruments (Newman & Rozycki, 1998). 
Echocardiography has a well established role in routine clinical cardiology, and is increasingly 
used for monitoring patients where concerns exist about the potential impact of treatment on 
cardiac function.
!
! This chapter begins with a description of essential principles for the observation and 
application of ultrasound. Medical ultrasound imaging has benefited from a growing awareness of 
these principles via the collaboration of a variety of disciplines including engineering, physics, 
medicine and physiology (Newman & Rozycki, 1998). A description of certain milestones in the 
study of sound and important advances in the development of ultrasound imaging, specifically 
echocardiography, are then detailed. Finally, developments in the measurement of left ventricular 
systolic function by echocardiography (up to the introduction of myocardial strain imaging) are 
discussed. A detailed description of strain imaging and anthracycline chemotherapy is presented 
in chapter 3.
2.1 PHYSICAL PRINCIPLES OF ULTRASOUND
2.1.1 ULTRASOUND WAVES
Ultrasound is mechanical energy transmitted through an elastic medium (Armstrong & Ryan, 
2010). Its propagation occurs via the vibration of particles within the medium, parallel to the line 
of propagation. The vibration of particles gives rise to alternating areas of higher pressure densely 
packed particles (areas of compression), and lower pressure areas of less densely packed particles 
(areas of rarefaction). Thus, ultrasound is a longitudinal, compressional pressure wave (see figure 
2.1) (Kremkau, 2011). 
Figure 2.1. Illustration of the propagation of sound. Areas of high and low pressure are 
represented. Wavelength is determined by the frequency. The amplitude of the waveform is also 
shown. (Adapted from Armstrong & Ryan 2010).
! The sum of one compression and one rarefaction of an ultrasound wave represents one 
cycle, and the distance between two similar points along the wave equals one wavelength (see 
figure 2.1). The frequency of the sound wave is the number of wavelengths per unit time. 
Therefore, wavelength and frequency are inversely related, and their product is the velocity of the 
sound wave (Kremkau, 2011):
! v = ⨍ ⋋ (where: v = velocity, ⨍ = frequency, ⋋= wavelength) 
! The velocity at which the ultrasound wave travels is directly related to the stiffness of the 
medium. Ultrasound travels at a higher velocity through dense media (e.g. bone), and at a lower 
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velocity through less dense tissue (e.g. adipose tissue) (Armstrong & Ryan, 2010; Gent, 1997). The 
velocity of ultrasound within most soft tissue is very similar, approximately 1540 m/sec, which 
greatly aids the use of ultrasound for diagnostic imaging (Otto, 2004). Ultrasound wavelength is 
important in diagnostic imaging because: 1) image resolution is no greater than 1 to 2 wavelengths 
(usually about 1 mm) and 2) the depth of penetration is directly related to the wavelength - where 
shorter wavelengths penetrate a shorter distance than longer ones (Otto, 2004).
!
! When sound waves move through air at an appropriate frequency, they are audible to the 
human ear (Armstrong & Ryan, 2010) (Jenkins, 2010). Ultrasound is the portion of the sound 
spectrum whose frequencies are above the audible limit of human hearing, that is those greater 
than 20,000 cycles per second (20,000 Hz) (Butler, 2009). The frequencies used in diagnostic 
ultrasound imaging are between 1 million and 20 million Hertz (1 - 20MHz) (Otto, 2004).
2.1.2 INTERACTION OF ULTRASOUND AND TISSUE
Reflection of sound waves is likely the most important interaction in ultrasound imaging (Gent, 
1997). Reflection is the term used to describe the interaction between an incident ultrasound wave 
with tissue, that results in some or all of the wave reversing its direction (Bulter, 2009). The angle of 
approach of an incident sound wave and the angle of the reflected wave are always the same: 
reflection is described as being perpendicular (when the incident wave is related to the tissue by an 
angle of 90°) or oblique (when related by an angle other than 90°) (see figure 2.2)(Gent, 1997). The 
amount of ultrasound energy reflected at the interface of two media is proportional to the acoustic 
mismatch of the media - the greater the mismatch, the more energy is reflected (Gent, 1997). If the 
acoustic impedance of the two tissues is known, the percentage of the ultrasound beam reflected 
can be calculated (using the following formula (Cobbold, 2007)): 
! R = [Z2 - Z1 / Z2 + Z1]2 (where: R = the fraction of the ultrasound beam reflected, Z = the acoustic 
! impedance of the tissue)
! As an ultrasound beam moves away from its source through tissue, it meets an array of big 
and small interfaces, each of which affects its transmission. These interactions can be broadly 
categorized as specular reflections or scattered reflections. Specular reflections are produced by 
reflectors that are larger than the wavelength of the ultrasound beam. This interaction results in a 
relatively angle-dependent reflection, whereby the optimal return of ultrasound waves back 
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toward the source, occurs when the ultrasound beam is perpendicular (90°) to the tissue 
(Armstrong & Ryan, 2010; Otto, 2004).
Figure 2.2  Depiction of: a) perpendicular reflection and transmission of an ultrasound wave at a 
tissue interface, and b) oblique reflection and transmission of an ultrasound wave at a tissue 
interface where the velocity of propagation in medium 1 is greater than medium 2.
! In contrast, scattered reflections are produced by reflectors that are smaller than the 
ultrasound beam wavelength. The reflections that result are scattered in different directions, and 
the amount of energy that returns to the ultrasound transducer (at the source of the ultrasound 
beam) is significantly less than the energy that returns from specular reflectors. Scattering has 
important clinical significance; scattered reflections contribute to the visualisation of surfaces 
parallel to the ultrasound beam and add to the ‘texture’ of grey-scale images (Armstrong & Ryan, 
2010). The term speckle is used to describe the tissue-ultrasound interaction that results from a 
large number of small reflectors, and this important interaction is discussed further in chapter 3 
where speckle tracking echocardiography is described.
!
! As scattering results in the reflection of ultrasound in different directions, it contributes to 
the attenuation (the decline) of the signal strength as it travels through tissue. Refraction, the 
deviation of an ultrasound wave as it passes through tissue, is another interaction that can enhance 
or compromise image formation (Gent, 1997; Otto, 2004). The most important factor related to the 
attenuation of the ultrasound beam is frequency, where lower ultrasound frequencies penetrate 
further into the tissue (attenuate less) than higher frequencies (Kremkau, 2011). In general, the 
attenuation of ultrasound in soft tissue observes the following rule (Gent, 1997):
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! Attenuation = 1dB / cm / MHz (where dB = decibels, cm = centimeters, MHz = megahertz)
! Thus, techniques for improving image resolution (including increased transducer 
frequency) must be balanced with those for reducing attenuation (including reducing transducer 
frequency) to ensure optimal image quality.
2.2 VISUALIZING SOUND
Sound is mechanical energy that surrounds and informs nature. Sound waves with a frequency 
between 20Hz and 20kHz can be sensed by the human ear. An 18th century Italian scientist, 
Lazzaro Spalzani, is referred to as the father of ultrasound; he was the first to describe the use of 
sound in nature that is inaudible to the human ear by demonstrating that bats use reflected 
ultrasound to navigate in the dark (Krishnamoorthy, Sengupta, Gentile, & Khandheria, 2007).
!
! In the early nineteenth century the Swiss physicist Jean-Daniel Colladon determined the 
speed of sound in water. His simple technique involved striking an underwater bell while 
simultaneously igniting gunpowder: the time between the sight of the gunpowder smoke and the 
sound of the bell and were recorded at a distance of 10 miles and used to make the calculation 
(which proved a very accurate measurement). This advancement provided a greater appreciation 
of underwater acoustics and sound transmission, and was central in the later development of  
SONAR (Sound Navigation and Ranging) (Newman & Rozycki, 1998). 
!
! In the middle of the nineteenth century, Swiss astronomer Christian Doppler, sought to 
explain how the observed frequencies of light waves are affected by the relative motion of the 
source and the detector (Goetz, 2010). After further development by contemporary scientists, it 
was discovered that the (Doppler) effect he sought to describe was applicable to sound as well as 
to light. The Doppler effect is used in many fields of science and medicine, including current 
ultrasound imaging (Newman & Rozycki, 1998). (In modern clinical echocardiography, the 
Doppler shift (the difference between received and transmitted frequencies) is most frequently 
used to measure the velocity of blood flow, and measured by the modified Doppler equation 
(Anderson, 2002): 
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! V = C (± △ ⨍) / 2 ⨍o cos " (where: C = the speed of sound in soft tissue, ± △ ⨍ = the Doppler 
! frequency shift (Hz), ⨍o = the transmitted frequency, cos " = the angle between the ultrasound beam 
! and blood flow))
! In the late nineteenth century, French brothers Pierre and Jacques Currie, made a discovery 
that was not immediately related to the study of sound energy, but one that would later prove very 
important. They observed that when pressure was applied to quartz crystals, an electric charge 
was generated in proportion to the force applied to it. This phenomenon was called 
Piezoelectricity (after the Greek word Piezo which means ‘to press’) and was essential in the 
development of the ultrasound transducer, and remains important for the transduction of 
mechanical into electrical energy (Newman & Rozycki, 1998).
!
! Two historically important events are regarded as having provided significant motivation 
for the establishment of SONAR technology in the early 20th century. The first was the sinking of 
the RMS Titanic, the second was the quest for naval superiority in World War I (Newman & 
Rozycki, 1998). Furthermore, in the middle of the 20th century, reflected radio waves were used in 
World War II to detect enemy airplanes, a technology termed RADAR (Radio Detection and 
Ranging) (Newman & Rozycki, 1998). 
2.3 THE DEVELOPMENT OF ECHOCARDIOGRAPHY
Echocardiography is the discipline that uses ultrasound to study the structure and function of the 
heart and great vessels (Armstrong & Ryan, 2010). Its has been described as the most important 
advance in diagnostic cardiology since the discovery of X-rays (Roelandt, 2000). The above 
mentioned milestone paved the way for the development of echocardiography, which in many 
aspects occurred together with developments in other disciplines that utilize ultrasound for 
diagnostic imaging. Echocardiography’s relatively short but interesting history, is briefly described 
below. 
2.3.1 THE BEGINNING
Motivated by the success of X-ray imaging in medicine, Austrian neurologist Karl Theo Dussik, 
was the first to attempt to utilize ultrasound for diagnosis in the early 1940s. He endeavored to 
outline the ventricles of the brain, but had limited success due to the highly reflective nature of the 
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skull bones (Krishnamoorthy et al., 2007). Shortly after, German physicist Wolfe Dieter Keidel, 
envisaged the use of ultrasound for recording the rhythmic volume variation of the heart. 
However, like Dussik, he met with significant technical difficulties and did not persevere in his 
efforts (Singh & Goyal, 2007).
!
! In the early and mid 1940s, ultrasound was first used to determine the integrity of non-
biological material (e.g. steel) at the University of Michigan, and researchers at the Naval Medical 
Research Institute in Maryland determined the speed of sound in soft biological tissue (Newman & 
Rozycki, 1998). Numerous technical advances occurred in the 1950’s; Piezoelectricity was used by 
Hans Jaffe in ultrasound transducers, and techniques to improve the coupling of transducers to 
patients were developed by researchers in the U.S., Europe and Japan (Newman & Rozycki, 1998).
!
! John Julian Wild and Douglas Howry are regarded as two of the most important early 
figures in ultrasound. Wild published measurements on the thickness of the bowel wall 
determined by ultrasound as early as 1950, and the identification of thigh and breast tumors in 
1952 (Newman & Rozycki, 1998). In contrast, Howry was concerned with the applied theory of 
ultrasound and the development of equipment, rather than clinical applications. For example, 
Howry demonstrated that B-mode (brightness-mode) images display the most intense reflections 
from tissue interfaces that are perpendicular to the ultrasound beam (Newman & Rozycki, 1998).
!
! Cardiologist Inge Edler and physicist Hellmuth Hertz are considered first among the 
pioneers of echocardiography. In the early 1950s, the Swedish duo undertook their first 
experiments using ultrasound to image cardiac anatomy and function. Their research provided 
important insights; they demonstrated that the interface between the muscular heart wall and its 
blood-filled chambers could be identified, that the thickness of the interventricular septum could 
be measured, and that mitral stenosis and mitral regurgitation could be differentiated with 
ultrasound (Edler & Lindstrom, 2004). 
!
! Edler and Hertz also developed a method of continuously recording echoes from moving 
cardiac structures. Echoes from nonmoving structures appeared as straight lines on film, while 
those from moving structures changed position in parallel with the motion of structures from 
which they were reflected (Edler & Lindstrom, 2004; Singh & Goyal, 2007). This significant 
development is now known as the motion mode (M-mode) technique, and is still utilized in 
modern echocardiography (see figure 2.3).
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Figure 2.3 An early M-mode image published by Edler and Hertz: AM = anterior mitral leaflet, IVS 
= interventricular septum, LVO = left ventricular outflow tract, M = posterior wall of the LVO. 
(Adapted from Edler & Lindstrom, 2004).
! While image acquisition was slow and display resolution was marginal, the 1960s was a 
decade during which ultrasound gained wider respect within the medical community. Real-time 
imaging was now seen as the way of the future; Hertz and Abserg published two-dimensional (2D) 
cardiac images (Asberg, 1967; Hertz, 1967), the first commercially available ultrasound machines 
was manufactured and used by Hoffman and Hollander in the late 1960s for gynecological 
imaging (Levi, 1997), and Nicholas Bom and his colleagues developed a linear scanner that made 
real-time imaging a reality (Armstrong & Ryan, 2010).
2.3.2 CONSOLIDATION
The more extensive use of echocardiography came in the 1960s (Feigenbaum, 1996). Harvey 
Feigenbaum, an American cardiologist, was captivated by echocardiography when he realized that 
a pericardial effusion could be imaged, and shortly after he made measurements of the LV using 
the M-mode technique (Feigenbaum, Popp, Chip, & Haine, 1968). While his initial work found 
limited approval, he was convinced of the potential of cardiac ultrasound; he initiated the first 
training program in cardiac ultrasound, and is credited with providing it with the name 
‘echocardiography’ (Feigenbaum, 1996; Singh & Goyal, 2007).
!
! Japanese researchers, including Shigeo Satomura, used Doppler technology, based on the 
change in frequency of reflected signals from moving structures, to examine blood flow within the 
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heart in the late 1950s (Feigenbaum, 1996). The principles and applications of pulse-wave and 
continuous-wave Doppler were developed in the 1970s, however the breakthrough in Doppler did 
not come until 1980, through research that demonstrated the value of Doppler technology in the 
assessment of aortic stenosis (Baker, Rubenstein, & Lorch, 1977; Feigenbaum, 1996; Hatle, 
Angelsen, & Tromsdal, 1980). Japanese researchers, including Ryozo Omoto, were also 
instrumental in the development of color Doppler imaging, which further advanced the 
haemodynamic assessment possible with echocardiography (Omoto et al., 1984). Color Doppler 
quickly became, and remains, an essential part of echocardiographic imaging (see figure 2.4).
Figure 2.4 Apical long axis image with color Doppler. Blood flow travels toward the transducer 
(red) from the left atrium (LA), through the mitral valve (MV) and into the left ventricle (LV). Flow 
away from the transducer (blue) in the LV outflow tract (LVOT) does not go beyond the closed 
aortic valve (AV). 
! Real time 2D imaging in the clinical setting had been the goal of cardiologists and 
engineers worldwide, and became a reality in the late 1970s and early 1980s (Armstrong & Ryan, 
2010). With this advance came vastly superior spatial resolution. Other developments in 
transducer technology also enhanced image quality; one notable example is harmonic imaging, 
which uses the relationship of reflected waves to the fundamental frequency of the ultrasound 
signal to exclude artifactual echoes (Belohlavek et al., 1998; Mulvagh, Foley, Belohlavek, & Seward, 
1998). The use of contrast agents in echocardiography improved cardiac chamber visualization 
thereby improving diagnostic information, especially in patients with suboptimal images 
(Krishnamoorthy et al., 2007). This approach, which began with an incidental observation, is 
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currently most widely used for the detection of intra-cardiac shunts (Feigenbaum, 1996; Gramiak, 
Shah, & Kramer, 1969).
2.3.3 THE MODERN ERA
Tissue Doppler imaging (TDI) is a more recent echocardiographic development that has 
established its place in clinical echocardiography over the past decade. In contrast to other 
techniques that utilize Doppler to measure blood flow, in this case Doppler is used to measure 
tissue velocities (see figure 2.5). The TDI technique benefits from the fact that cardiac muscle 
moves at lower velocities than blood, but produce signals of a considerably higher amplitude, 
meaning that information regarding myocardial velocities can be obtained without contamination 
from blood-flow velocities (Krishnamoorthy et al., 2007).
Figure 2.5 Tissue Doppler Imaging (TDI) of the mitral annulus from the apical 4 chamber view. S’ 
represents the systolic myocardial velocity, the E’ represents the early diastolic myocardial velocity, 
the A’ represents the late diastolic myocardial velocity. 
! TDI is used to evaluate both LV systolic function (S’ velocity) and diastolic function (E’ and 
A’ velocities) (see figure 2.5). However, its primary use is in the assessment of LV diastolic 
function, as it is particularly well suited to estimating LV relaxation in early diastole (E’). The ratio 
of the early transmitral filling velocity (E) to E’ is a surrogate measure of the LV end diastolic 
pressure (Marwick, 2003). It has prognostic value in the assessment of systolic function post 
myocardial infarction and in heart failure patients, and it provides valuable information in patients 
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who have received resynchronization therapy (via an implantable dual chamber pacemaker) (Yu, 
Sanderson, Marwick, & Oh, 2007). However, like other Doppler techniques, TDI has a number of 
limitations; these include the need to ensure a parallel orientation between the ultrasound beam 
and the direction of myocardial motion and its inability to account for tethering from adjacent 
tissue (Geyer et al., 2010).
! ! Improvements in transducer technology and computing power have been essential 
to the development of three-dimensional echocardiography (3DE). Most recently, the development 
of the matrix-array transducer (with its elements arranged in a rectangular grid) has made real-
time 3DE a reality (Picard, Popp, & Weyman, 2008). 3DE has been shown to represent and quantify 
LV volume and function more accurately than single plane and 2D approaches (Siu et al., 1995). 
Yet, despite its many attractive features, 3DE is yet to become part of routine clinical 
echocardiography due to a number of limitations. Image quality in real-time 3DE is often poor 
(and the acquisition time for high quality images is considerable), and variations in cardiac rhythm 
and respiration are often difficult to redress (Picard et al., 2008). 
2.4 MEASURING LEFT VENTRICULAR SYSTOLIC FUNCTION
From its inception, measuring LV systolic function has been an integral part of echocardiography. 
The first M-mode images, recorded by Edler and Hertz, displayed the movement of the posterior 
left ventricular (LV) wall (Edler & Lindstrom, 2004). Advancements in imaging technology have 
improved the measurement of systolic function considerably, however, the quest for a more 
accurate measurement of global and regional systolic function remains a major focus in 
echocardiography. 
2.4.1 MOTION MODE (M-MODE) MEASUREMENTS
M-mode was the first method employed to measure LV systolic function, and was the technique of 
choice until the late 1970s (Picard et al., 2008). The M-mode method takes advantage of the change 
in LV internal dimensions in each cardiac cycle to measure stroke volume, and correlates favorably 
with angiography in normal shaped hearts (see figure 2.6). However, in conditions causing marked 
LV dilatation, or in those with significant regional wall motion abnormalities, the linear M-mode 
measurements are limited (Kronik, Slany, & Mosslacher, 1979; Teichholz, Kreulen, Herman, & 
Gorlin, 1976).
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Figure 2.6  M-mode image and measurements of LV systolic function acquired from the parasternal 
long-axis view. 1 IVSd = interventricular septum (diastole), 2 LVIDd = LV internal dimension 
(diastole), 3 LVPWd = LV posterior wall (diastole), 4 IVSs = interventricular septum (systole), 5 = 
LVIDd = LV internal dimension (systole), 6 LVPWs LV posterior wall (systole).
2.4.2 DOPPLER MEASUREMENTS
The introduction of Doppler during echocardiography’s infancy brought an additional means for 
measuring left ventricular function. Doppler enables the measurement of volumetric flow (based 
on the principle that flow is directly proportional to the cross-sectional area (CSA) of the chamber 
and the mean velocity of the moving fluid (see figure 2.7)) (Anderson, 2002; Armstrong & Ryan, 
2010). Doppler allows indices like stroke volume and cardiac output to be measured using the 
following equations (Anderson, 2002):
! SV = CSA × VTI (where: SV = stroke volume (cc), CSA = cross sectional area (cm2), VTI = the 
! distance a column of  blood flows each stroke (the velocity time integral)
! CO = SV × hr / 1000 (where: SV = stroke volume, hr = heart rate)
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A)! ! ! ! ! ! ! B)
Figure 2.7 A and B Images and calculations used to measure stroke volume from the left 
ventricular outflow tract. A) LVOT measurement acquired from the parasternal short axis view, 
B) velocity time integral (VTI) recorded in the LVOT from the apical 5 chamber view.
! Doppler measurements are an integral component of the majority of echocardiographic 
examinations, although they always involve multiple steps and are often limited by potential 
sources of error. The two most important sources of error shown in figure 2.7 are 1) in the 
determination of the CSA of the LVOT because the formula used to make the calculation assumes 
circular geometry of the LVOT (when in reality it is usually elliptical) and 2) the failure to optimize 
the Doppler angle (Armstrong & Ryan, 2010).
!
! Another Doppler based method for the measurement of LV systolic function is the LV dP/
dt. Using the spectral display of the mitral regurgitation jet, the rate at which the pressure 
increases within the ventricle can be measured. However, two important limitations mean that this 
technique has limited application; these are 1) increased LA pressure and 2) an inadequate Doppler 
signal (when there is poor alignment of the Doppler beam with the regurgitant jet direction, which 
is often the case with eccentric jets of regurgitation, or when there is insufficient mitral 
regurgitation) (Anderson, 2002). 
2.4.3 TWO DIMENSIONAL (2D) MEASUREMENTS
The inception of real-time 2D echocardiography in the early 1980s brought superior spatial 
resolution for determining LV size and function (Armstrong & Ryan, 2010). Quantitative methods 
were soon introduced to aid 2D measurements. Initially, the single or biplane plane area length 
method was used to make LV volume and ejection fraction measurements. Recommendations and 
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normal values for this method were established, however its primary limitation, LV asymmetry, 
meant its application was limited (Anderson, 2002; Schiller et al., 1989). More recently, the biplane 
method of discs (Simpson’s method) has been introduced, and it remains the method 
recommended by the American Society of Echocardiography and the European Association of 
Echocardiography (Lang et al., 2005), and is the most widely used quantitative method to assess 
LV systolic function in clinical practice.
!
! Despite its wide use, it is generally acknowledged that LVEF has a number of significant 
limitations. LVEF is dependent upon image quality - poor images reduce its accuracy; and while 
developments such as higher frequency transducers and harmonic imaging have led to improved 
quality, this limitation remains (Bellenger et al., 2000; Malm, Frigstad, Sagberg, Larsson, & 
Skjaerpe, 2004; Otterstad, Froeland, St John Sutton, & Holme, 1997). Another major limitation is the 
simplified assumptions about cardiac geometry that are used during measurement - if LV 
geometry is atypical or abnormal, the measurement is open to error (McGowan & Cleland, 2003). 
LVEF is also limited by the loading conditions on the heart (Otterstad et al., 1997), which together 
with other factors, is described in greater detail in the following chapters of the thesis, where LVEF 
is contrasted with newer echocardiographic techniques.
! !
! Abnormalities in myocardial contractility occur when myocardial perfusion is impaired 
because of coronary artery disease. Echocardiography is the most widely used and practical 
technique for evaluating patients in this setting (J. K. Oh, Seward, J.B., Tajik, A.J., 2007). The wall 
motion score index (WMSI), which involves  assigning a score to each region of the left ventricle 
based on contractility, is the qualitative method recommended for evaluating the extent of regional 
(segmental) wall motion abnormality (Schiller et al., 1989). While this method is subjective, it 
correlates closely with other methods used to estimate the size and site of the perfusion defect (J. 
K. Oh et al., 1996), however its application is largely confined to the evaluation of regional 
(segmental) LV wall motion.
2.4.4 TISSUE DOPPLER MEASUREMENTS
The M-mode, real-time 2D imaging, spectral and colour Doppler techniques detailed above, have 
significantly improved the analysis of LV systolic function. They allow important information 
related to changes in LV shape, LV volume, and haemodynamics (Marwick & Narula, 2009). 
However, the limitations described above indicate that these techniques are restricted in their 
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ability to measure myocardial mechanics. The introduction of TDI, a method capable of measuring 
tissue velocities, was an important advance in this regard. 
TDI, outlined in section 2.3.3, is most widely used in the assessment of LV diastolic function. It is 
also used in the assessment of systolic function: mitral annular S’ is a simple measurement to 
record, which represents the systolic myocardial velocity (see image 2.2) (Marwick, 2003). 
However, like other Doppler techniques, TDI has a number of limitations, which include the need 
to ensure a parallel orientation between the ultrasound beam and the direction of myocardial 
motion (Picard et al., 2008). Perhaps the most significant limitation in its use for measuring LV 
systolic function is its inability to account for tethering from adjacent tissue (Geyer et al., 2010).
2.4.5 MYOCARDIAL STRAIN IMAGING
The recent development of a semi-automated echocardiographic technique, myocardial strain 
imaging, may provide a more sensitive and accurate measurement of LV systolic function. Strain 
enables the measurement of both segmental (regional) and global myocardial deformation in 
multiple planes (Geyer et al., 2010). It has been shown to be of value in the identification of 
hypertrophic and infiltrative cardiomyopathies, and in the detection of subclinical dysfunction 
before a noticeable decrease in LVEF (Koyama & Falk, 2010; Serri et al., 2006; Weidemann et al., 
2003). 
! Myocardial strain imaging is at the forefront of echocardiographic imaging technology, 
though its value in routine clinical practice is yet to be fully realized. Myocardial strain is detailed 
extensively in the remainder of the thesis. In the literature review its technical aspects are 
described, and in the subsequent chapters the results of research utilizing strain imaging for 
potentially earlier detection of LV dysfunction in breast cancer patients treated with anthracycline 
chemotherapy are presented. 
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CHAPTER 3 (PART A) 
LITERATURE REVIEW
Preamble
Echocardiography currently plays an important role in the surveillance of patients treated with 
potentially cardiotoxic anti-cancer agents. The present literature review describes this role, and 
outlines the potential benefits of myocardial strain imaging in this setting. The chapter is divided 
into two parts - A and B. In part A, the review article entitled ‘The potential role of 
echocardiographic strain imaging for evaluating cardiotoxicity due to cancer therapy’ is presented 
as accepted for publication (with only minor differences, such as figure numbering, to the 
published article to ensure continuity with the rest of the thesis). Due to the editorial constraints, 
the length of the review and the number of references included were limited, therefore an 
additional section (part B) has been added to the thesis. There is limited overlap of material in the 
two chapters, and together they provide a comprehensive literature review.
THE POTENTIAL ROLE OF ECHOCARDIOGRAPHIC STRAIN IMAGING 
FOR EVALUATING CARDIOTOXICITY DUE TO CANCER THERAPY
Published in: Heart, Lung and Circulation 2011; 20: 3-9
ABSTRACT
Refinements to conventional treatment and the development of new therapies have led to 
significant improvements in cancer survival. Yet, many frontline cancer treatments continue to be 
hindered by their significant side effects, among which cardiotoxicity is particularly important. 
Therefore, the focus of cancer management has changed; treatment is no longer aimed solely at 
overcoming malignancy, but emphasizes early identification and treatment of potential side effects. 
In this regard, the cardiotoxic potential of certain anticancer agents mandate close monitoring of 
cardiac function, and the method of choice for monitoring is transthoracic echocardiography. 
While this method has its limitations, a newer echocardiographic technique called myocardial 
strain imaging has the potential to detect early sub-clinical changes in cardiac function due to 
cardiotoxicity. Strain analysis has been the subject of several recent studies to evaluate its potential 
in monitoring cardiotoxicity, and this article reviews the recent literature and explores the potential 
role of myocardial strain imaging in cancer management and avenues for future research.
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3A.1 INTRODUCTION
Refinements to conventional treatment regimens and the development of new cancer therapies 
have led to significant improvements in cancer survival. For example, the five-year relative 
survival rate for breast cancer has risen from 75% in 1977 to 89% in 2004 and for leukemia and non-
Hodgkin lymphoma from 42% in 1977 to 58% in 2004 ("Cancer Statistics 2009 Presentation," 2009). 
However, the efficacy of many frontline cancer treatments continues to be hindered by their 
significant side effects. 
!
! Thus, the focus of cancer management has changed; treatment is no longer aimed solely at 
overcoming malignancy, but emphasizes early identification and treatment of potential side effects. 
Specifically, the cardiotoxic potential of agents routinely used in the treatment of breast cancer, 
leukemia and non-Hodgkin lymphoma mandate close monitoring of cardiac function before, 
during, and after their use (Bird & Swain, 2008; Singal & Iliskovic, 1998). 
!
! Transthoracic echocardiography (TTE) is the method of choice for monitoring cardiac 
function in clinical practice (Jurcut et al., 2008a). Currently, evaluation of cardiac function by TTE 
involves measuring left ventricular ejection fraction (LVEF), a coarse measure of systolic function 
that has numerous limitations. Newer echocardiographic techniques have enhanced the capability 
to detect cardiotoxicity at an early stage; in this regard, myocardial strain imaging promises to be 
particularly useful. Strain imaging has been the subject of several recent studies to evaluate its 
potential in monitoring cardiotoxicity, and this article reviews the recent literature and explores the 
potential role of strain imaging in cancer management and avenues for future research.
3A.2 CHEMOTHERAPY AGENTS AND CARDIOTOXICITY
Anthracyclines were discovered four decades ago (Arcamone, Franceschi, Penco, & Selva, 1969), 
and remain among the most widely prescribed anti-cancer agents.  They possess highly effective 
antineoplastic properties and are used to treat both adults and children; yet their efficacy is 
undermined by a potential life threatening cardiotoxicity (Lefrak, Pitha, Rosenheim, & Gottlieb, 
1973; Shan, Lincoff, & Young, 1996; Singal, Li, Kumar, Danelisen, & Iliskovic, 2000). 
!
! Cardiomyopathy and heart failure from anthracyclines are dependent upon several 
treatment and patient related factors of which the cumulative administered dose is most critical. In 
adults the incidence of heart failure induced by doxorubicin (an anthracycline) varies from 4% to 
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5% at a cumulative dose of 500-550 mg/m2, to 36% at a cumulative dose 600 mg/m2 or more 
(Singal & Iliskovic, 1998; Swain, Whaley, & Ewer, 2003).   Current treatment protocols pay careful 
attention to cumulative chemotherapy dosage with administration now by infusion rather than by 
bolus ("Anthracyclines and mitoxantrone - cumulative dose cardiac toxicity,," 2009). Furthermore, 
as previous anthracycline therapy as well as mediastinal irradiation increases the risk of 
cardiotoxicity (Swain et al., 2003), consideration of previous treatments is important. 
!
! Risks factors that predict cardiotoxicity, other than those inherent to anthracycline 
administration have been identified; they include the extremes of age (< 4 years and > 60 years), 
significant hypertension, female gender and malnutrition (Grenier & Lipshultz, 1998; Singal & 
Iliskovic, 1998). In patients with metastatic breast cancer, poor performance status and a higher 
body weight are factors with significant predictive value (Dranitsaris et al., 2008). While not 
definitively proven, cardiovascular risk factors such as diabetes and smoking history, also seem 
likely to increase risk regardless of cancer type.
!
! Despite extensive investigation, the mechanism responsible for the cardiotoxic effect of 
anthracyclines remains unknown (Gianni et al., 2008). It is clear that anthracyclines damage the 
myocyte, yet the timing of the cardiotoxic effect is variable (Bird & Swain, 2008; Gianni et al., 2008). 
Cardiotoxicity may occur early (within weeks), late (months later) or very late (years) after 
uncomplicated treatment (Shan et al., 1996). At present, anthracycline induced cardiotoxicity is 
particularly relevant given the growing number of long-term survivors of childhood cancer 
(particularly leukemia), and given the variable temporal presentation of cardiotoxicity.
!
! More recently it has been found that a new immunotherapeutic agent, trastuzumab 
(Herceptin), used to treat breast cancer patients with overexpression of human epidermal growth 
factor receptor 2 (HER-2)/neu, also has cardiotoxic potential (Piccart-Gebhart et al., 2005; Slamon 
et al., 2001). As with anthracyclines, the precise mechanism for trastuzumab induced cardiotoxicity 
remains unclear. Anthracycline exposure is clearly important – cardiotoxicity is worse if 
trastuzumab is administered in parallel with, rather than following anthracyclines (Rayson et al., 
2008). However, the classic ultrastructural changes in myocytes with anthracycline toxicity is not 
seen in trastuzumab toxicity (Hare et al., 2009), thereby implying a different pathophysiological 
process. In this regard, it should be noted that HER2/neu receptors play an important role in 
promoting cell survival during induced myocardial stress (Rayson et al., 2008).
!
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! While formal estimates of the incidence of cardiotoxicity consequent to anthracyclines and 
trastuzumab are variable, its occurrence is of practical importance (Gianni et al., 2008). Given the 
improved survival of treated patients, it is likely that morbidity and mortality related to 
anthracycline cardiotoxicity will rise based on the following: 1) significant injury can occur even 
with (therapeutic) low-dose anthracycline treatment; 2) the techniques currently employed to 
monitor toxicity are insensitive to subclinical cardiac damage; 3) effective cardio-protection is not 
systematically administered and 4) ventricular impairment may become evident years after 
treatment (Shan et al., 1996).
3A.3 CLASSIFYING CARDIOTOXICITY
The mechanisms of cardiotoxicity associated with the use of anthracyclines and trastuzumab are 
clearly different. The toxic effect induced by anthracyclines is dose related and is not reversible, 
while that induced by trastuzumab is not dose related and regarded as being largely reversible 
(Hayes & Picard, 2006). In light of this, it has been proposed that any resultant cardiac dysfunction 
be classified as follows: dysfunction induced by anthracyclines is type 1 chemotherapy related 
cardiac dysfunction (CRCD); and the dysfunction induced by trastuzumab is type 2 CRCD (Ewer 
& Lippman, 2005). 
!
! However, having reviewed the findings of 5 major adjuvant trastuzumab trials, Telli et al 
call into question the theory of reversibility (Telli, Hunt, Carlson, & Guardino, 2007). They agree 
that improvements in LV function, indicated by improved LVEF may occur in the short-term after 
withholding treatment. Yet they regard the long-term follow-up in these subjects to be insufficient 
to determine true reversibility over the longer term. Furthermore, they also note that most of the 
trastuzumab trials focus largely on reporting severe symptomatic heart failure, thereby neglecting 
asymptomatic declines in LVEF. This concern seems prudent given that mild asymptomatic LV 
dysfunction increases the risk of congestive heart failure (CHF) by five times (Wang et al., 2003). 
!
! Recognizing distinct cases of type 1 CRCD (dysfunction induced by anthracyclines) and 
type 2 CRCD (dysfunction induced by trastuzumab when used without an anthracycline) may 
allow cancer therapy to be based on more refined cardiac risk assessment. However, as most breast 
cancer regimens for HER2/neu positive patients involve treatment with both agents; this system of 
classification may have limited practical clinical application. 
!
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! Nevertheless, in time classifying cardiotoxicity may well prove to be clinically valuable. For 
now, given that trastuzumab therapy is recent and long term follow up is limited, it appears 
reasonable to reserve judgment regarding the long term reversibility of trastuzumab. Thus, the 
early detection and monitoring of cardiac dysfunction remains essential.
3A.4 ECHOCARDIOGRAPHY: CURRENT STANDARDS AND LIMITATIONS
The close monitoring of cardiac function is an important part of managing patients receiving these 
agents. At present, resting left ventricular ejection fraction (LVEF) by 2-dimensional (2D) 
echocardiography is the key parameter used to identify and monitor cardiotoxicity (Jurcut et al., 
2008a) (see figure 3A.1). LVEF has been validated by comparison with a variety of reference 
standards, and clear guidelines regarding its acquisition and calculation are published (Lang et al., 
2005). Moreover, LVEF provides a single numerical value making comparisons with previous 
results easy.
A)! ! ! ! ! ! ! ! B)
Figure 3A.1 LVEF measurement involves tracing the LV endocardial border in two orthogonal 
planes, at end diastole, A) (LVEDV) and end systole, B) (LVESV) enabling calculation of the 
percentage of volume ejected as: LVEF = (LVEDV – LVESV) / LVEDV. In the example shown, the 
endocardial border has been traced at end systole in the apical 4 chamber view.
! However, despite its established diagnostic and prognostic value, LVEF has numerous 
limitations. LVEF relies on simplified assumptions about cardiac geometry, hence if the geometry is 
atypical or abnormal, the measurement is open to error (McGowan & Cleland, 2003). Additionally, 
LVEF is dependent upon the 2D image quality and on identification of the ‘true’ LV apex (Malm, 
Frigstad, Sagberg, Larsson, & Skjaerpe, 2004; Otterstad, 2002). LVEF is a measure of global function 
and is therefore unable to detect subtle regional alterations in myocardial mechanics, and it is 
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influenced by variable preload and afterload conditions (Marwick, 2006). Furthermore, LVEF 
measurement lacks reproducibility; the coefficient of variation being ~ 15% for interobserver 
variability with test retest variation of ~ 12% (Otterstad, 2002). While a reduced LVEF increases 
mortality, mild to moderate reductions are not always associated with symptoms (Gianni et al., 
2008). With specific regard to anthracycline induced cardiotoxicity, once a clear reduction in LVEF 
can be demonstrated, functional deterioration proceeds rapidly (Jurcut et al., 2008).
!
! More recently it has been established that heart failure can result from abnormalities of 
diastolic function, where LVEF is relatively preserved (Zile, 2002). That is, heart failure results from 
abnormalities that limit cardiac filling and ejection; LVEF may be preserved, while clear signs and 
symptoms of heart failure are manifest (Gottdiener et al., 2002; Hunt et al., 2009). In this light, the 
findings of a small prospective study of 26 participants are of considerable interest. Stoddard et al. 
showed that prolonged Doppler-derived isovolumetric relaxation time (an indicator of diastolic 
function) preceded and reliably predicted anthracycline-induced systolic dysfunction (as measured 
by LVEF) (Stoddard et al., 1992). However, larger studies and the criteria for monitoring early 
changes based on measures of diastolic function in this patient group are lacking and necessary.
3A.5 ECHOCARDIOGRAPHY: NEWER DEVELOPMENTS
The recent development of semi-automated, myocardial strain imaging, provides a more sensitive 
and reproducible measurement of left ventricular (LV) function. Strain imaging is a measure of 
cardiac muscle deformation that is expressed as 1) Strain: the percentage of change from the 
original dimension, and 2) Strain rate: the strain per unit of time (Jurcut et al., 2008b; Yu, 
Sanderson, Marwick, & Oh, 2007) (see figure 3A.2). Normal ranges for strain imaging have been 
established, with moderately superior reproducibility values than LVEF (the reproducibility values 
for strain measurement are reported to vary from 5.5% to 9.5% (Marwick et al., 2009; Sun et al., 
2004)).
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Figure 3A.2 Strain (%): defined as percentage change from the original length. Strain rate (s-1): the 
instantaneous velocity difference at two points (V1 and V2) divided by the distance (d) between 
them. (Adapted from Jurcut et al. 2008b).
! Importantly, strain imaging enables both regional and global assessment of cardiac 
function. The former frequently precedes global dysfunction, and as discussed earlier, is not 
captured by the LVEF. Unlike measurement of LVEF, strain does not rely on assumptions about 
cardiac geometry, it can be made in instances where 2D image quality is compromised, and strain 
imaging also enables evaluation throughout the cardiac cycle, that is it measures systolic and 
diastolic function (Ganame et al., 2007) (see figure 3A.3). A recently published work suggests global 
2D strain and strain rate to be superior predictors of impaired LV filling than the E/E’ ratio (the 
current standard measure), highlighting the likely value of strain imaging in the assessment of 
diastolic function (Dokainish, Sengupta, Pillai, Bobek, & Lakkis, 2008). 
A)! ! ! ! ! ! ! ! B)
Figure 3A.3 2D speckle tracking, (A) longitudinal and (B) radial strain (%) measurement: The 
colored lines represent measurements of regional myocardial deformation (the dotted line on the 
longitudinal strain image represents their ‘global’ average (all taken from the 2D image at the top 
left)). ECG at the bottom shows measurements can be made throughout the cardiac cycle.
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! It has been demonstrated in several disease states, that strain imaging can detect subclinical 
dysfunction before a noticeable decrease in LVEF (Serri et al., 2006). What is not clear is the longer 
term clinical relevance of a reduced strain measure, when LVEF is unchanged (Eidem, 2008). In the 
case of anthracyclines and trastuzumab (as these agents are clearly potentially cardiotoxic) it is 
likely that strain measurement will be more sensitive to subtle damage to the myocardial 
ultrastructure, which would otherwise only be confirmed histologically. 
! !
! Currently, strain measurement is not always a feature of standard ultrasound equipment 
and strain analysis algorithms differ among manufacturers, making comparison between 
measurements on different ultrasound systems difficult. Strain imaging requires image acquisition 
at high frame-rates and careful attention to gain settings in order to minimize noise interference 
(Leung & Ng, 2010). Most strain measurements require off-line analysis, are time consuming and 
involve additional training and expertise. Yet, strain imaging itself continues to be refined; it can be 
derived from tissue Doppler measurements (figure 3A.4), and now from 2D images. The latter 
requires lower frame rates (40 – 70 frames per second), is relatively angle independent and appears 
to be more reproducible (Argyle & Ray, 2009). Additionally, 2D strain can evaluate longitudinal, 
radial and circumferential strain (3 planes) as opposed to Doppler derived strain that largely 
quantifies longitudinal strain – 2D strain therefore provides a comprehensive measure of LV 
function. 
Figure 3A.4 Tissue Doppler imaging longitudinal strain (%) measurement: The colored lines 
represent measurements of regional myocardial deformation. ECG at the bottom shows 
measurements can be made throughout the cardiac cycle.
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! As myocardial strain imaging is still in its infancy, there is limited data regarding strain 
assessment in the setting of cancer therapy. However, promising results from early work indicate 
that strain imaging is capable of detecting sub-clinical LV dysfunction, and warrant further 
investigation. In a study of 56 asymptomatic paediatric patients 5 years post anthracycline 
treatment, significant reductions in regional Doppler-derived strain and strain rate measurements 
(especially in the longitudinal direction) were observed while LVEF remained normal (Ganame et 
al., 2007). Reductions in myocardial function as measured by Doppler and 2D derived strain rate, 
were observed in 35 breast cancer patients following treatment with trastuzumab while LVEF 
measurements remained unchanged, with the 2D technique proving more sensitive to acute 
changes (Hare et al., 2009). In a study of the efficacy of modified anthracyclines with 16 
participants, significant reductions were observed in strain and strain rate after 6 cycles of the 
modified (pegylated) anthracycline, without a significant reduction in LVEF (Jurcut et al., 2008). 
!
! As mentioned above, recently published work reveals global 2D strain and strain rate to be 
superior predictors of LV filling than the current standard measure (Dokainish et al., 2008). Since 
further research into the diastolic function of patients receiving anthracyclines is warranted, the 
findings by Tassan-Mangina et al. serve as an important precursor. In a study using both 
conventional parameters and pulsed tissue Doppler velocity imaging to evaluate 20 adult 
participants (Tassan-Mangina et al., 2006), early changes in LV diastolic function (that progressed 
with follow up) occurred prior to changes in LV systolic function. 
!
! Moreover, the importance of long term follow up of patients following anthracycline 
treatment with imaging techniques that are sensitive to early changes, is indicated by another 
observation from the above mentioned research; 3 years after completion of anthracycline 
chemotherapy 25% of patients had a significant reduction in LVEF even though LVEF was 
unchanged 3 months post chemotherapy. Other significant findings include observations from 
work in rodent models. Abnormal Doppler derived strain indices predicted future cardiac 
dysfunction and death, when conventional measures (LVEF) remained normal (Neilan et al., 2006). 
Further, strain and strain rate imaging proved more sensitive to changes in systolic function than 
standard measurements in a doxorubicin-induced cardiomyopathy model (Piegari et al., 2008). 
!
! The value of myocardial strain imaging in clinical practice is yet to be fully realized. 
Clearly, in the research setting it already provides a more refined tool to evaluate regional and 
global cardiac function. At present, there is no strain or strain rate value that provides a cut-off 
beyond which clinically manifest symptoms are more likely to occur, nor clear evidence showing 
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strain or strain rate to be a superior method.  Abnormal values may be difficult to define, 
especially in the setting of multiple coexisting risk factors. However, strain will likely improve 
detection of within patient change by providing a more sensitive measure of the effects of 
cardiotoxic agents. This may improve decision making regarding the cessation of cancer treatment 
if needed and to the addition of potential supportive therapies (including angiotensin converting 
enzyme inhibitors and beta blockers) to improve cardiac function.
! One of the considerable challenges of treatment with anthracyclines relates to the fact that 
there is no clear ‘curative dose’ response relationship, nor a ‘cardiotoxicity dose’ response 
relationship. Any method of achieving the ‘curative dose’, whether by administration of a 
cardioprotective agent or by modification of the administered chemotherapy agent, will require 
monitoring of changes, using methods such as strain imaging that are sensitive to subtle early 
changes.
3A.6 CONCLUSION
The single greatest risk for the development of significant heart failure related to anthracyclines is 
the early development of cardiotoxicity. By the time cardiotoxicity is detected by a significant 
reduction in LVEF, functional deterioration often proceeds quickly. Myocardial strain imaging, 
with its ability to measure systolic and diastolic function, may permit early detection of subclinical 
regional or global cardiotoxicity. However, to date there is no prognostic data that demonstrates 
that the early detection of cardiotoxicity by strain will alter clinical prognosis. Such data would 
facilitate modification of chemotherapy together with the introduction of therapy to minimize the 
impact of cardiotoxicity.
!
! The development of cardiotoxicity is a lifelong concern following anthracycline treatment 
as it occurs at varying times after therapy. Even if a more effective anticancer agent without 
cardiotoxicity is developed to replace anthracyclines, the number of patients who have received 
anthracyclines to date is considerable and this cohort will require continued and accurate long 
term monitoring. Likewise, sensitive measures of cardiac function are needed for the longer-term 
follow up of those treated with trastuzumab.
! The necessary long-term cardiac monitoring of cancer patients treated with anthracyclines 
and/or trastuzumab must be safe, reproducible and cost effective. Echocardiographic myocardial 
strain imaging is a promising clinical modality for early detection of cardiotoxicity and for long-
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term surveillance of cancer patients. Further research is warranted in order to determine its role in 
this important clinical setting.
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CHAPTER 3 (PART B) 
EXTENDED LITERATURE REVIEW
Preamble
The review article entitled ‘The potential role of echocardiographic strain imaging for evaluating 
cardiotoxicity due to cancer therapy’ presented in part A was reduced by editorial constraints. 
Both the length of the review and the number of references included were limited, therefore an 
additional section (part B) is presented below. Moreover, as 3 years have elapsed since the 
publication of the original review Part B provides greater detail and additional recent information 
that was unavailable when part A was published: specific reference is given to anthracycline 
chemotherapy and the development of strain imaging and its potential benefits for evaluating 
cardiotoxicity. While the arrangement of this section is purposely similar to part A, there is very 
little overlap of content in the two chapters, thus part B completes the literature review.
3B.1 ANTHRACYCLINE AGENTS AND CARDIOTOXICITY
3B.1.1 EXTRACTION AND EFFICACY
Anthracycline antibiotics are natural compounds originally derived from Streptomyces bacteria 
(Arcamone, et al., 1974). Their potent anti-tumor properties were recognized soon after their 
discovery, and anthracyclines have been used extensively ever since (Arcamone, et al., 1974). The 
administration of these agents has been central in the improved life expectancy for victims of 
numerous cancers, including breast cancer ((EBCTCG), 2005; Arcamone et al., 1997). Four decades 
after their development, anthracycline agents remain the cornerstone of breast cancer treatment; 
the two anthracyclines most widely used in this setting are doxorubicin and epirubicin, which as 
shown in figure 3B.1, are structurally similar (Burstein et al., 2012; Gianni et al., 2008).
Figure 3B.1  Illustration of the molecular structure of Doxorubicin and Epirubicin anthracycline 
antibiotics. (Adapted from Xu, Pearson & Richardson, 2005).
! While anthracyclines afford clear benefits in the treatment of cancer, the way in which they 
achieve their anti-tumor actions is not completely understood. What is known, is that 
anthracyclines enter neoplastic cells by passive diffusion, where they bind with proteasomes in the 
cytoplasm, and as a drug-proteasome complex are transported into the cells nucleus (Kiyomiya, 
Matsuo, & Kurebe, 2001; Skovsgaard & Nissen, 1982). Their binding with proteasomes is one 
method of inducing apoptosis in neoplastic cells, as it inhibits the normal pro-survival protein 
degrading activity of protease (Kiyomiya et al., 2001). Once inside the nucleus, anthracyclines 
dissociate from proteasomes and bind to deoxyribonucleic acid (DNA) (for which they have a high 
affinity) (Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004); this enables their varied activity on 
neoplastic cell DNA (including the direct inhibition of DNA transcription) (Minotti et al., 2004; Xu, 
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Persson, & Richardson, 2005). Other cytotoxic effects caused by anthracyclines include lipid 
peroxidation and the generation of reactive oxygen species (free radicals) (Gewirtz, 1999).
3B.1.2 CARDIOTOXICITY
Unfortunately, the efficacy of anthracyclines is undermined by their detrimental effects on 
nonmalignant cells - cardiotoxicity (injury to cardiac myocytes that leads to structural changes 
such as vacuolization in the myocytes and weakens contractility) being particularly detrimental 
(Moriyama, Kemi, Okumura, Yoshihara, & Horie, 2010; Singal, Li, Kumar, Danelisen, & Iliskovic, 
2000) (see figure 3B.2). Interestingly though, the cardiotoxic mechanisms of anthracyclines differ 
from their therapeutic actions (Sawyer, Peng, Chen, Pentassuglia, & Lim, 2010). The primary 
means of anthracycline-induced cardiotoxicity is free radical formation that leads to DNA damage 
(Sawyer et al., 2010; Shaikh & Shih, 2012). Other means include the induction of respiratory defects 
in myocardial mitochondria and transcriptional changes in myocardial adenosine triphosphate 
production. Anthracyclines also disrupt the function of the basic mechanical unit of myocytes, the 
sarcomere, by degrading the essential structural protein Titin (see figure 3B.4) (Chen, Peng, 
Pentassuglia, Lim, & Sawyer, 2007; Sawyer et al., 2010; Yeh & Bickford, 2009).
Figure 3B.2 Histology sections of murine cardiac myocytes: a) a control animal, b) an animal 
treated with doxorubicin - the arrow heads point to areas of vacuolization in the myocytes, 
indicative of doxorubicin-induced injury. (Adapted from Moriyama, 2010).
! The most important factor related to anthracycline-induced cardiotoxicity is the cumulative 
anthracycline dose (Swain, Whaley, & Ewer, 2003). Dose-limiting strategies reduce cardiotoxicity, 
however patients still develop cardiac dysfunction, and there is considerable variation in the 
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reported frequency of anthracycline-induced cardiotoxicity. In adults, late onset clinical heart 
failure occurs in up to 5% of patients more than 1 year post therapy (Shaikh & Shih, 2012). In 
pediatrics, 75% of cancer survivors develop at least one chronic physical health condition 30 years 
post treatment - some of which are a direct result of the cardiotoxic effects of anthracycline 
chemotherapy (Shaikh & Shih, 2012). 
!
! Management of cardiotoxicity is further confounded by its temporal variability. Acute 
cardiotoxicity occurs in less than 1% of patients immediately after infusion (Shaikh & Shih, 2012). 
Early-onset chronic cardiotoxicity occurs in 1.6 - 2.1% of patients within 1 year of therapy (with a 
peak incidence at 3 months post treatment). Late-onset chronic cardiotoxicity occurs in ~ 5% of 
patients more than 1 year post therapy (Shaikh & Shih, 2012).
3B.1.3 CURRENT MONITORING STANDARDS AND LIMITATIONS
The beneficial and detrimental effects of anthracyclines are well recognized. However, clear 
guidelines for the detection and management of cardiac dysfunction after anthracycline 
chemotherapy are lacking. Appropriately timed noninvasive evaluation of cardiac function is 
considered to be essential (Wells & Lenihan, 2010), yet the current standard method used in clinical 
practice, the measurement of LVEF, is limited. LVEF essentially measures global LV volumetric 
change; for the reasons previously outlined (in chapter 3, part A), and those given below, this does 
not enable early cardiac dysfunction to be adequately measured. Once LVEF is significantly 
reduced, restoration of normal LV function is difficult (Cardinale et al, 2010).
3B.2 ECHOCARDIOGRAPHY AND THE EVALUATION OF MYOCARDIAL MOTION
3B.2.1 LEFT VENTRICULAR ANATOMY
! Left ventricular (LV) muscular fiber anatomy and function are complex. The mechanical 
action of the LV is the result of work performed by a network of specialized muscle cells, cardiac 
myocytes. The myocytes are filled with long parallel myofibrils, which contain protein rich 
contractile filaments, myosin and actin; the contractile filaments comprise the basic mechanical 
unit of each myocyte, the sarcomere (Guyton & Hall, 1996; Sherwood, 1993) (see figure 3B.3). 
Myofibrils are surrounded by a network of sarcoplasmic reticulum (SR); in response to stimuli, 
calcium is released from the SR and its activating action on the myofilaments is an essential part of 
the energy (ATP) dependent process of myocardial contraction (Sherwood, 1993). By way of 
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desmosomes, myocytes adhere to their neighboring cells (and communicate via gap junction), and 
are supported by fibrous connective tissue (Anderson, Ho, Redmann, Sanchez-Quintana, & 
Lunkenheimer, 2005; Sherwood, 1993). 
Sarcomere
Figure 3B.3  Electron microscope image of a sarcomere, the basic mechanical unit of the myocyte. 
The protein rich contractile elements, myosin and actin, help to give myocytes their characteristic 
striated appearance. (Adapted from Luther, 2013).
Figure 3B.4 Detailed illustration of the elements that comprise the sarcomere. (Adapted from 
Luther, 2013).
! Overall, the LV is conical in shape (Skinner J, 2000). Its muscle mass has a helical 
configuration, with 3 functional muscle ‘layers’ within its wall. The muscle layers do not comprise 
discrete muscle groups, but are classified according to the predominant orientation of myocytes 
(Anderson et al., 2005; Sengupta & Narula, 2012) (see figure 3B.5A). While their overall orientation 
is distinct, for normal contraction the ‘layers’ operate together in a number of simultaneous events 
(Armstrong & Ryan, 2010). At the onset of contraction, the myocardium begins to thicken, the 
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endocardium moves toward the centre of the ventricle, and the LV chamber diameter and length 
are reduced (Armstrong & Ryan, 2010). Together with this inward motion, clockwise rotation at the 
base and anti-clockwise rotation at the apex occur to produce a highly efficient ‘wringing’ motion 
for the essential movement of blood from the ventricles (Sengupta et al., 2007).
3B.2.2 STRAIN IMAGING 
! LVEF provides an estimate of the change in LV volume. While three-dimensional 
echocardiography (3DE) has been shown to be a more accurate method than 2D (Jenkins, Bricknell, 
Chan, Hanekom, & Marwick, 2007) in the measurement of LVEF, neither method is well suited to 
evaluating myocardial function. The left ventricle has considerable functional reserve; significant 
myocardial damage may occur before a reduction in LVEF (Ewer & Lenihan, 2008), and patients 
may remain asymptomatic until a reduction is observed. Myocardial strain imaging promises to 
improve evaluation of LV function by echocardiography: in contrast to LVEF, strain enables a 
direct measurement of myocardial motion (Perk, Tunick, & Kronzon, 2007). LV architecture and 
function is complex (see figure 3B.5 A); strain imaging enables quantification of segmental and 
global longitudinal, circumferential, and radial LV myocardial motion (Geyer et al., 2010a; Gorcsan 
& Tanaka, 2011; Ozkan, Kapadia, Tuzcu, & Marwick, 2011) (see figure 3B.5 B).
A)! ! ! ! ! ! B)
Figure 3B.5 A) An image of the complex 
arrangement of muscle fibers that comprise 
the left ventricle. (Adapted from Gorcsan, 
2011).
Figure 3B.5 B) Illustration of the directions of 
myofiber motion; longitudinal (red arrows), 
circumferential (blue arrows), radial (green 
arrows). (Adapted from Ozkan, 2011).
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! When matter is subjected to a load, it is deformed. Strain is a measure of deformation, 
which may be elastic (recoverable) or plastic (permanent) (van Vluck, 1982). Quantitative measures 
of strain are possible - strain is used extensively in engineering for this purpose. For example, the 
suitability of materials used in the building and automotive industries can be evaluated by testing 
their deformation (van Vluck, 1982). Strain is a dimensionless index that represents the percentage 
change in the length of an object in response to stress (Leung & Ng, 2010; Sengupta et al., 2007), 
and is determined by the following equation (Leung & Ng, 2010):
! ! Strain = (L - Lo) / Lo! (where: L = length after deformation; Lo = original length) 
! Strain is defined as being positive when the distance between the points of measurement 
increases and negative when this distance decreases. In echocardiography transmural thickening 
(radial strain) is denoted as positive, and longitudinal shortening and circumferential movement 
as negative (Leung & Ng, 2010) (see image 3B.5 B). In simple terms, a 10 cm object stretched to 12 
cm would have a 20% positive strain (Mor-Avi et al., 2011b).
3B.2.3 TECHNICAL ASPECTS OF STRAIN IMAGING
! Two echocardiographic methods can be used to measure strain; tissue Doppler imaging 
(TDI) and two-dimensional speckle tracking (Argyle & Ray, 2009). TDI was the first method for 
quantifying myocardial strain (Geyer et al., 2010b) (see figure 3B.6 A). By calculating the relative 
velocity of motion at a location in space as a function of time, TDI derived strain is measured 
without reference to the initial myocardial length; this means of calculating strain is referred to as 
‘spatial’ or ‘Eulerian strain‘ (Geyer et al., 2010b; Leung & Ng, 2010). TDI is almost universally 
available on ultrasound machines, and can be analyzed on or offline. However, the TDI method 
has a number of limitations including the need for parallel orientation of the ultrasound beam with 
the direction of myocardial motion (Geyer et al., 2010b) (see table 3B.1 for pros and cons of the TDI 
method).
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A)! ! ! ! ! ! ! B)
Figure 3B.6 A) Longitudinal myocardial strain calculated using the TDI method, B) circumferential 
myocardial strain (calculated using the two-dimensional speckle tracking method), which displays 
negative deformation. (For an image of radial strain measurement see figures 3A and 3B in part A 
of chapter 3).
! Two-dimensional (2D) echocardiogram images have a speckled pattern that is the result of 
reflections from natural acoustic markers (smaller than the ultrasound wavelength) within the 
myocardium (Leung & Ng, 2010; Mor-Avi et al., 2011b; Sengupta et al., 2007) (see figure 3B.7). By 
grouping the speckles into ‘blocks’, they can be tracked frame-by-frame and used to measure 
myocardial deformation: this second (contemporary) method of measuring strain is referred to as 
2D speckle tracking echocardiography (2DSTE) (Armstrong & Ryan, 2010; Koopman et al., 2010; 
Mor-Avi et al., 2011a) (see figure 3B.8). With 2DSTE, myocardial length is known before, during 
and after deformation, which enables the calculation of strain using the ’material’ or ‘Lagrangian’ 
method (Armstrong & Ryan, 2010; Koopman et al., 2010; Mor-Avi et al., 2011a).
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A)! ! ! ! ! ! ! ! B)
Figure 3B.7 A) Apical 4 chamber image of the LV with an area of the lateral wall highlighted, and 
B) zoomed image of the lateral LV demonstrating the speckled grey-scale pattern.
Figure 3B.8 Depiction of the speckle pattern from a region of the lateral LV (as seen from an apical 
4 chamber image). In 2DSTE, speckles are arranged into blocks which have a unique pattern of 
speckles and can be tracked frame-by-frame to measure myocardial deformation.
! The spatial resolution of the speckle method for measuring strain is superior to the TDI 
method (Geyer et al., 2010b; Reisner et al., 2004). 2DSTE allows angle independent quantification 
of strain and has the additional capacity to calculate global strain (by averaging the results from all 
segments of the left ventricle) (Argyle & Ray, 2009). Inferior temporal resolution limits the 2DSTE 
method more than TDI, and the speckle method is less readily available than the TDI method (see 
table 3B.1 for the pros and cons of the 2DSTE method). 2DSTE is the method used and investigated 
in this research and is the method referred to (unless specifically stated otherwise) throughout the 
thesis.
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Table 3B.1 Advantages (pros) and disadvantages (cons) of the two echocardiographic methods 
for measuring myocardial strain 
Tissue Doppler Imaging 2D Speckle Tracking 
Echocardiography
Pros
- High temporal resolution
- Software readily available
- On or off-line analysis
- Angle independent
- Segmental and global strain 
analysis
- Semi-automated
Cons
- Angle dependency
- Sample volume variability
- No global strain calculation
- High resolution image 
dependency
- Software less available
3B.2.4 STRAIN RESEARCH METHODOLOGY
Detailed description of the methods used in the research presented in this thesis are given in the 
methods section of chapters 4, 5, 6 and 7. These include general details (unrelated to strain 
measurements), as well as those specifically related to the utilization of strain imaging such as the 
views used for image acquisition, the criteria employed to ensure the  appropriate timing of 
analysis, and the criterion for verify acceptable 2D image tracking quality. Moreover, the number 
of images analyzed in each view is also specified. (For these specific details, refer to the methods 
sections of the above mentioned chapters).
! One aspect of strain measurement that is not detailed in the methods sections of the 
published papers presented in chapters 4, 5, 6 and 7, is the myocardial tracking quality assessment 
‘intrinsic’ to the strain imaging software. As this process is determined by the manufacturer (GE 
healthcare), it was omitted from the published papers. However, it is worthwhile noting here, that 
strict criteria are applied in imaging software to ensure appropriate tracking of speckles. That is, 
speckles are given a low tracking quality score or excluded if (Perk et al., 2007): 
- they do not return to a baseline position after forward and backward motion,
- adjacent speckles have significantly different velocities,
- strain measurements differ at the beginning and the end of a cardiac cycle 
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3B.3 STRAIN ANALYSIS FOR THE DETECTION OF CARDIOTOXICITY
Strain imaging offers an opportunity to improve the sensitivity of echocardiography in the 
detection of LV dysfunction: global longitudinal strain (GLS) has proven to be particularly 
valuable in this case. A contemporary study aimed at identifying the echocardiographic technique 
that adds the greatest predictive value to clinical variables, revealed GLS is a superior predictor of 
outcome to either LVEF or wall motion score index (WMSI) (Stanton, Leano, & Marwick, 2009). 
The primary reason why GLS is likely the most useful strain measure, is that longitudinal strain is 
acquired from the apical window, and from the apical window all LV segments can be evaluated 
(Mor-Avi et al., 2011b).
! Myocardial insults such as ischemia and inflammation have been shown to affect the 
subendocardial, longitudinal fibers prior to other fibers. The optimal function of longitudinal fibers 
are measured most effectively with longitudinal strain. For example, myocardial longitudinal 
function (measured by 2D strain) is impaired at rest in most patients with coronary artery disease 
(CAD) (Choi et al., 2009), can be used to predict the presence of significant CAD (Shimoni et al., 
2011), and provides useful information about the extent of myocardial fibrosis in hypertrophic 
cardiomyopathy (even when LVEF is normal (Saito et al., 2012; Yajima et al., 2012). These reports 
are evidence for the value of longitudinal strain imaging, albeit in varying clinical scenarios.
! For the detection of LV dysfunction in the setting of cancer therapy, reduced longitudinal 
and radial strain using the TDI technique has been reported in a small study of 16 patients over the 
age of 65 after treatment with pegylated anthracyclines (Jurcut et al., 2008). Moreover, since the 
publication of the first review (chapter 3 part A), several studies demonstrating the value of the 2D 
speckle technique for detecting cardiotoxicity have been published: reduced longitudinal strain 
and preserved LVEF in long-term cancer survivors treated with anthracyclines and or radiation 
therapy (RT) has been reported (Tsai et al., 2011).
! In the detection of LV dysfunction in the setting of breast cancer therapy, significantly 
reduced GLS after 3 months of trastuzumab (following anthracyclines), has been reported in 
patients with a subsequent decline in LVEF of ≥10% to <55% at 6 months (when LVEF at 3 months 
was normal) (Fallah-Rad et al., 2011). Similarly, significantly reduced GLS after 3 months of 
trastuzumab (following variable anthracycline exposures) has been reported to predict 
cardiotoxicity. In this study cardiotoxicity was defined as a reduction in LVEF ≥5% to <55% with 
symptoms of heart failure or an asymptomatic reduction of the LVEF ≥10% to <55% (as per the 
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Cardiac Review and Evaluation Committee (CREC) criteria), while LVEF at 3 months was not 
predictive of toxicity (Sawaya et al., 2011). More recently, an 11% reduction in GLS (from the 
baseline value) 6 months into trastuzumab, has been proposed as the optimal cut-off value for 
predicting trastuzumab-induced cardiotoxicity (with toxicity classified according to the CREC 
criteria) (Negishi et al., 2013).
3B.4 A MULTI-MODALITY APPROACH FOR PREDICTING CARDIOTOXICITY
Modern medicine utilizes a multi-modality approach for detecting and managing disease. 
Echocardiographic strain imaging shows great potential value in the detection and management of 
cardiotoxicity: its value in this regard would be enhanced when used in combination with other 
monitoring techniques (Wells & Lenihan, 2010). For example, there is growing evidence for the 
usefulness of blood serum biomarkers in the early identification of anthracycline-related 
cardiotoxicity (Dolci, Dominici, Cardinale, Sandri, & Panteghini, 2008). Early and persistent 
elevation of cardiac troponin (the biomarker of choice for identifying myocardial injury) has been 
shown to identify patients who are more likely to develop symptomatic heart failure and benefit 
from supportive therapies (Cardinale & Sandri, 2010). The importance of the early identification of 
anthracycline induced LV dysfunction has recently been underscored by the results of a biomarker 
study, which demonstrated that successful response to supportive therapies (angiotensin-
converting-enzyme inhibitors and beta blockers) is significantly reduced if therapy is not promptly 
introduced (Cardinale et al., 2010).
! As described in part A of the literature review, anthracycline chemotherapy is not the only 
potential source of cardiac damage in breast cancer patients. Approximately 25% of breast cancer 
patients over express the human epidermal growth receptor 2 (HER2/neu) protein - for these 
patients the introduction of trastuzumab has brought considerably improved survival (Piccart-
Gebhart et al., 2005; Slamon et al., 2001). However, trastuzumab also has a ‘dark side’: up to 14% of 
patients will require a delay to, or the suspension of their treatment due to significant LV 
disfunction (Hayes & Picard, 2006; Telli, Hunt, Carlson, & Guardino, 2007). A contemporary study 
(reported following publication of the initial review) of HER2/neu positive patients indicates that 
peak systolic longitudinal strain and cardiac troponin measured after anthracyclines and prior to 
trastuzumab are helpful in predicting patients who develop cardiotoxicity (as defined by  the 
CREC criteria) during trastuzumab therapy (Sawaya et al., 2012). In this report, no patient with a 
peak systolic strain value <-19% after anthracyclines developed trastuzumab-related cardiotoxicity.
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! In addition to anthracyclines and trastuzumab, many breast cancer patients also receive 
breast or chest wall radiotherapy (RT). In this case, the heart is further subjected to potentially 
toxic therapy (Patt et al., 2005). While important advances in RT ensure that modern techniques 
deliver well directed therapy with minimal doses to the heart (Doyle et al., 2007; Patt et al., 2005), 
contemporary reports recognise that with RT there is increased risk of heart disease, and that RT 
augments the cardiotoxic effect of anthracycline chemotherapy (Darby et al., 2013; Tsai et al., 2011). 
Prospective analysis of breast cancer patients exposed to anthracyclines (with or without 
trastuzumab) and RT with myocardial strain imaging and biomarker analysis are needed.
3B.5 CONCLUSION
Anthracyclines remain an essential part of treatment regimens for numerous cancers. Their 
effective anti-tumor properties are a primary reason for improvements in life-expectancy. 
However, significant side effects, especially cardiotoxicity, continue to undermine their 
administration. Myocardial strain imaging is contemporary technology that uses the acoustic 
properties inherent to cardiac myocardium to derive measurements of deformation. Strain imaging 
technology may improve monitoring of cardiotoxicity, and aid in the development of imaging 
protocols aimed at further improving outcomes. At the start of this research this hypothesis had 
been largely untested: the remaining chapters of the thesis detail the results of research aimed at 
examining this hypothesis.
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CHAPTER 4
TWO-DIMENSIONAL MYOCARDIAL STRAIN IMAGING DETECTS 
CHANGES IN LEFT VENTRICULAR SYSTOLIC FUNCTION 
IMMEDIATELY AFTER ANTHRACYCLINE CHEMOTHERAPY
Published in: European Journal of Echocardiography 2011; 12 (12): 945-952.
Preamble
The preceding chapter detailed the potential role of echocardiographic strain imaging for 
evaluating cardiotoxicity due to cancer therapy, with particular reference to its utility when 
anthracycline agents are used in the management of breast cancer. While anthracyclines are used 
in the management of other malignancies, they have been the cornerstone of breast cancer 
treatment for decades. Anthracycline based regimens used in breast cancer management vary little 
between patients, and the majority of breast cancers are detected early, which makes these patients 
an ideal group to study. This chapter presents the published findings of the analysis of left 
ventricular (LV) systolic function with strain imaging, made immediately after anthracycline 
chemotherapy, in the first fifty-two consecutive breast cancer patients.
ABSTRACT
AIMS 
The efficacy of anthracyclines is undermined by potentially life threatening cardiotoxicity. 
Cardiotoxicity is dependent upon several factors, and the timing to its development is variable. 
Moreover, as adjuvant therapy with trastuzumab often follows, close monitoring of cardiac 
function in those treated with anthracyclines is mandatory. LVEF by echocardiography is currently 
used for monitoring cardiotoxicity, however LVEF has numerous limitations. Two-dimensional 
strain imaging may provide a more sensitive measure of altered LV systolic function, so the aim of 
the present study was to compare LVEF and LV systolic strain before and after anthracyclines.
METHODS AND RESULTS
Fifty-two women with histologically confirmed breast cancer were prospectively studied. 
Echocardiographic LVEF (by Simpson’s method), global and regional peak longitudinal, radial and 
circumferential 2D systolic strain was measured 1 week before and 1 week after chemotherapy. 
! Global and regional longitudinal LV systolic strain was significantly reduced after 
treatment; global longitudinal strain decreased from -17.7% to -16.3% (p < 0.01) with 48% of global 
measurements reduced by >10%. Global and regional radial LV systolic strain after treatment was 
also significantly reduced; global radial strain dropped from 40.5% to 34.5% (p < 0.01) with 59% of 
global measurements reduced by >10%. In contrast, no reduction in LVEF >10% after 
chemotherapy was observed. 
CONCLUSION 
Reduced LV systolic strain immediately after anthracycline treatment may indicate early 
impairment of myocardial function before detectable change in LVEF. 
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4.1 INTRODUCTION
Four decades following their discovery, anthracyclines remain among the most widely prescribed 
anticancer agents; however their efficacy is undermined by potentially life threatening 
cardiotoxicity (Lefrak, Pitha, Rosenheim, & Gottlieb, 1973; Shan, Lincoff, & Young, 1996; Singal, Li, 
Kumar, Danelisen, & Iliskovic, 2000). As cardiotoxicity is dependent upon a number of treatment 
and patient related factors and the timing of its development is variable (Bird & Swain, 2008; 
Gianni et al., 2008), close monitoring of cardiac function before, during, and after anthracycline 
treatment is mandatory (Bird & Swain, 2008; Singal & Iliskovic, 1998). 
! !
! Currently, resting left ventricular ejection fraction (LVEF) by two-dimensional (2D) 
echocardiography is the key parameter used to identify and monitor anthracycline-induced 
cardiotoxicity. LVEF, however, has numerous technical limitations and is a measure of global 
function, unable to detect subtle regional changes in myocardial mechanics (Jurcut et al., 2008; 
Malm, Frigstad, Sagberg, Larsson, & Skjaerpe, 2004; McGowan & Cleland, 2003; Otterstad, 2002). 
The recently developed myocardial strain imaging may provide a more sensitive and reproducible 
measurement of altered LV systolic function.  
!
! The aim of the present study was to compare LVEF and LV systolic strain measured with 
two-dimensional (2D) strain imaging before and immediately after anthracycline chemotherapy. 
We hypothesized that global LV systolic strain measures would prove more sensitive than LVEF in 
detecting early anthracycline-induced systolic dysfunction, and would detect subclinical regional 
LV systolic dysfunction prior to overt changes in global function. 
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4.2 METHODS
Ethics approval for the study was granted by the Sydney West Area Health Service Research Ethics 
Committee and the University of Sydney, and written informed consent was obtained from all 
participants. Fifty-two consecutive anthracycline naïve women with histologically confirmed 
breast cancer were prospectively recruited prior to any thoracic radiotherapy. All participants were 
recruited at initial review at Westmead Hospital, although subsequent cancer treatment was 
administered at one of four affiliated sites (depending on proximity to the patient’s residence). A 
detailed record of the administered cumulative anthracycline dose was documented. 
! !
! The clinical history, physical examination and echocardiogram were used to establish 
eligibility. Exclusion criteria included LVEF before chemotherapy of <50%, rhythms other than 
sinus, more than mild valvular stenosis or regurgitation, prosthetic valve or pacemaker.  A detailed 
cardiac history was obtained at recruitment including clinical risk factors for heart disease 
(hypertension, diabetes, cholesterol, smoking history, and diabetes). Height was measured at 
baseline, while weight and blood pressure were measured at the time of each echocardiogram. 
Patients were also evaluated for any cardiac symptoms especially those of cardiac failure.
!
! The initial echocardiogram was performed prior to the commencement of chemotherapy 
(ideally 1 week before). The follow-up echocardiogram was performed 1 week following 
completion of chemotherapy (i.e. 12 or 18 weeks after the first study, depending on whether the 
patient had 4 or 6 cycles of chemotherapy respectively) and always before commencement of 
trastuzumab or thoracic radiotherapy. All echocardiograms were performed at a single site by 
either of two experienced sonographers using a Vivid 7 digital ultrasound system (GE medical 
systems, Norway) with a 2.5MHz variable frequency transducer. 
! !
! A comprehensive transthoracic echocardiogram was performed with patients in the left 
lateral position. Images were obtained from the parasternal, apical and subcostal views. LVEF was 
measured by Simpson’s method according to the recommendations of the European Association of 
Echocardiography (Lang et al., 2006), and measured at the time of acquisition without reference to 
previous measurements. Clinically significant reductions in LVEF were defined as ≥ 10% from 
before chemotherapy, or an absolute LVEF < 50% after chemotherapy.
! !
! Depth adjusted 2D images of the left ventricle in the parasternal short axis at the level of 
the papillary muscles, and in the apical 4, 2- and long axis views were acquired and stored for off-
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line measurement of 2D speckle tracking myocardial strain (with EchoPac PC versions 6.0, GE 
Healthcare, UK) (see figure 4.1). Frame rates were optimized at the time of acquisition to between 
50 and 70fps. To ensure reproducibility and accuracy, systole was defined as the interval from 
aortic valve opening to closure, measured with pulsed wave Doppler sampling of blood flow in LV 
outflow tract.
! !
! The LV regions of interest for strain analysis were manually selected by marking the 
endocardial border at end systole in the appropriate imaging plane. Traces from each segment 
were inspected to confirm that peak systolic strain was measured prior to aortic valve closure and 
the tracking quality of all images was identified before analysis using the software scoring table on 
the off-line measuring package. Tracking quality was overridden in segments with no more than 2 
rejected regions where the observer deemed tracking quality to be clearly acceptable. Images with 
persistently unacceptable tracking quality (more than 2 segments) were excluded from the final 
analysis.
! !
! Strain measurements were made from 3 consecutive cardiac cycles and then averaged in 
order to obtain peak systolic regional strain and strain rate in the longitudinal, radial and 
circumferential planes (see figure 4.1). Global peak systolic strain and strain rate was calculated by 
averaging the 6 regional values in the apical 4 chamber and parasternal short axis view at the mid 
papillary level to measure longitudinal, radial and circumferential strain respectively. Additionally, 
in a subgroup of 19 participants with optimal image quality, longitudinal strain was measured 
from the apical 2 and long axis views and global (apical triplane) longitudinal strain was 
calculated as an average of 18 segments.
! !
! Ten participants in whom longitudinal, radial and circumferential strain measurements 
were all possible were randomly selected in order to calculate interobserver and intraobserver 
variability, with differences reported as mean difference ± standard deviation (SD). LV systolic 
strain and LVEF measurements were repeated by a different observer (blinded to previous results) 
to measure interobserver variability. Intraobserver variability for LV systolic strain and LVEF were 
assessed by the same observer on a different occasion from the same digital data, using an offline 
system. Differences are reported as mean error ± SD of 10 measurements.
! !
! All values were expressed as a mean ± SD unless otherwise stated. The effect of 
anthracycline therapy was examined with a repeated measures analysis of variance (ANOVA). 
Paired t tests were used to compare LV segmental strain parameters before and after 
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chemotherapy. Linear regression analysis and Pearson correlations were performed to examine the 
relationship of LV systolic strain parameters to cumulative anthracycline dose and age. Chi square 
analysis was used to assess the effect of baseline clinical risk factors on altered LV systolic function 
at follow-up, while univariate analysis was performed to evaluate the effect of alteration in strain 
to cumulative anthracycline dose, age and clinical risk factors. Data were analyzed using SPSS 
version 15 (SPSS Inc, Chicago, Illinois), and considered significant if p < 0.05.
! ! ! A)
! ! ! B)
Figure 4.1 2D myocardial strain measurement, longitudinal (A) and radial (B) myocardial strain 
measurements. The colored lines represent measurements of regional myocardial deformation; the 
dotted line on the longitudinal strain image represents their ‘global’ average (all taken from the 2D 
image at the top left).
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Table 4.1 Participant characteristics 
Number of participants 52
Age (years) 49 ± 9
Height (centimetres) 161 ± 5
Weight (kilograms) 76 ± 23
Side of breast cancer
Right 28
Left 24
Both 0
Anthracycline type
Doxorubicin (Dox) 40 (77%)
Max. Dox dose (mg/m2) 318
Mean Dox dose (mg/m2) 236 ± 33
Epirubicin (Epi) 12 (23%)
Max. Epi dose (mg/m2) 581
Mean Epi dose (mg/m2) 408 ± 110  
Risk factors
IHD 3 (6%)
Hypercholesterolemia 11 (21%)
Smoking 13 (25%)
Hypertension 13 (25%)
Diabetes 2 (4%)
IHD (ischemic heart disease)
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4.3 RESULTS
All 52 participants recruited into the study had a baseline echocardiogram before chemotherapy 
and a follow-up echocardiogram immediately after completing chemotherapy. Four (n = 34) or six 
cycles (n = 18) of anthracycline chemotherapy (doxorubicin or epirubicin) was administered, as 
determined by the oncology team. Patient demographics and clinical characteristics are presented 
in table 4.1.
! !
! Measurement of biplane LVEF was possible in 50 of the 52 participants (96%). LV 
myocardial systolic strain measurements were feasible in 47 of the 52 (90%) and before 
chemotherapy strain measurements were consistent with previously reported normal 
measurements (Marwick, 2009). Paired measurements of longitudinal, radial and circumferential 
strain were possible in 41 of these 47 (87%). Limited image quality before and/or after 
chemotherapy meant LVEF and strain measurements were not possible in all participants (image 
quality was limited most often by left sided mastectomy and/or breast implant).
! !
! No participant reported symptoms of cardiac failure during the time of follow-up. No 
significant difference in the LV dimensions before and after chemotherapy was observed. A 
statistically significant reduction in the average LVEF after chemotherapy was observed (table 4.2); 
however, no participant had a reduction in LVEF of ≥ 10% after treatment. In fourteen participants 
LVEF fell to below 55%.  In one participant LVEF was < 50% after chemotherapy; in this case LVEF 
dropped from 56% before to 47% after chemotherapy.
! !
! Global longitudinal 2D strain after chemotherapy was significantly reduced; the average 
global longitudinal strain value dropped from -17.8% to -16.3% (p < 0.01 (see table 4.2)). In 21 of the 
44 participants (48%), global longitudinal strain was reduced by > 10% from before chemotherapy, 
and reduced in 7 of the 44 participants (16 %) by > 20%. Longitudinal strain after chemotherapy 
was reduced by greater than the mean minus 1SD of the baseline strain measurement in 12 of 44 
(27%) and by greater than the mean minus 2 SD in 6 out of 44 participants. In a subgroup, 
longitudinal strain was measured as a global composite from the apical 4, 2 and long axis views. A 
similar reduction of > 10% global longitudinal strain was observed in this measurement in 12 of 19 
patients (table 4.3). Participants with an LVEF <55% after anthracycline chemotherapy (but not 
reduced by >10%), had significantly reduced global longitudinal strain compared to those with 
LVEF after chemotherapy of >55% (p < 0.01).
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Table 4.2 LVEF and global strain measurements before and after chemotherapy
Before After
Percentage with 
10 – 19 % 
reduction
Percentage with 
> 20 % reduction
LVEF (%) 58.6 ± 2.6 56.0 ± 2.8 † 0 0
Global 
longitudinal 
strain (%)
- 17.8 ± 2.1 - 16.3 ± 2.0 † 48 % 16 %
Global radial 
strain (%) 40.5 ± 11.4 34.5 ± 11.4 † 59 % 46 %
Global 
circumferential 
strain (%)
- 20.3 ± 2.6 - 20.3 ± 3.3 32 % 6 %
(Values expressed as mean ± SD, † p <0.01 vs. before value)
! Global radial strain after chemotherapy was also significantly reduced; the average global 
radial strain dropped from 40.5% before to 34.3% (p  < 0.01) after treatment (see table 4.2). In 24 of 
the 41 participants (59 %) global radial strain was reduced by > 10% after chemotherapy, with 
radial strain reduced being reduced in 19 of the 41 participants (46%) by > 20% (table 2). Similar to 
longitudinal strain, a reduction after chemotherapy of more than the mean minus 1SD of the before 
treatment measurement was observed in 16 of 41 participants (39%). In contrast, global 
circumferential LV strain after chemotherapy remained largely unchanged from beforehand (table 
4.2), only three participants’ (6%) global circumferential strain was reduced by ≥ 20% after 
chemotherapy.
Table 4.3 Subgroup (triplane) analysis of longitudinal strain before and after anthracycline 
chemotherapy
n =19 Before After
Percentage with 
10 – 19 % 
reduction
Percentage with 
> 20 % reduction
LVEF (%) 58.4 ± 2.4 56.0 ± 2.5 † 0 0
Global triplane 
longitudinal 
strain (%)
- 18.5 ± 1.6 - 16.6 ± 1.6 † 58 % 11 %
(Values expressed as mean ± SD, † p <0.001 vs. before value)
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! Regional analysis of longitudinal LV 2D strain revealed significant reductions in all but the 
apical lateral segment after chemotherapy (see table 4.4). Regional analysis of radial strain revealed 
significantly reduced measurements in 3 of the 6 regions (the anteroseptal, septal and inferior 
segments) after chemotherapy (see table 4.5). However, regional analysis of circumferential strain 
showed a significant reduction in the septal segment only (see table 4.6).
Table 4.4 Regional longitudinal strain values before and after chemotherapy
Basal 
septum
Mid 
septum
Apical 
septum
Apical 
lateral
Mid lateral
Basal 
lateral
Before
-19.2 %  
± 5.5
-21.0 % 
± 4.5
-22.4 %
± 4.7
-14.7 %  
± 6.4
-15.2 %   
± 6.2
-18.5 %   
± 5.9
After
-17.1 % 
± 5.4 *
-19.3 % 
± 5.2 † 
-20.9 % 
± 5.4 †
-13.6 % 
± 6.9
-13.9 %
± 6.8 †
-16.6 % 
± 6.1 †
* p ≤0.001 vs. before value, † p <0.05 vs. before value
Table 4.5 Regional radial strain values before and after chemotherapy
Anterior 
septum
Anterior Lateral Posterior Inferior Septal
Before
39.4 %   
± 14.1
36.2 %   
± 13.9
36.6 %   
± 13.0
40.0 %     
± 13.7
43.8 %    
± 14.3
45.3 %    
± 15.0
After
32.8 %   
± 12.2 †
32.9 %   
± 12.8
34.9 %   
± 14.8
35.3 %   
± 14.8
35.4 %    
± 13.6 †
36.2 %   
± 12.6 *
* p ≤0.01 vs. before value, † p <0.05 vs. before value
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Table 4.6 Regional circumferential strain values before and after chemotherapy
Anterior 
septum
Anterior Lateral Posterior Inferior Septal
Before -22.5 % 
± 7.7
-19.4 % 
± 7.5
-16.5 % 
± 6.8
-17.2 %
± 6.9
-22.3 % 
± 5.7
-26.5 % 
± 5.7
After -22.6 % 
± 6.6
-19.8 % 
± 6.5
-16.6 % 
± 6.2
-18.0 % 
± 6.3
-21.8 % 
± 5.6
-24.0 % 
± 6.3 *
* p <0.05 vs. before value
! Variation in peak LV systolic strain between regions and also within regions was observed. 
This variation was greatest in the radial plane and least in the circumferential plane, as 
demonstrated by greater radial strain standard deviations. In addition to global and regional 
strain, peak systolic strain rate was measured, although no significant reduction was observed in 
systolic strain rate between paired measurements (table 4.7).
Table 4.7 Systolic strain rate analysis before and after anthracycline chemotherapy
Before After p value
Longitudinal strain rate (s-1) -0.87 ± 0.14 -0.84 ± 0.12 0.15
Radial strain rate (s-1) 2.20 ± 0.56 2.02 ± 0.52 0.13
Circumferential strain rate (s-1) -1.72 ± 0.34 -1.73 ± 0.28  0.54
Values expressed as mean ± SD
! The type of anthracycline and cumulative anthracycline dosage were recorded for all 
participants. The maximum doxorubicin dose was 318mg/m2 and the maximum epirubicin dosage 
was 581mg/m2. No significant correlation between anthracycline type or dosage and reductions in 
LVEF or systolic strain was found. 
!
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! Chi square analysis was used to assess the impact of baseline clinical risk factors 
(hypertension, diabetes, cholesterol, smoking history, and history of ischemic heart disease) and 
reduced echocardiographic LV systolic strain measurements at follow up. No significant 
association between cardiac risk factors and the reduction in strain measurements was observed 
when tested individually or together; there was no significant difference in blood pressure 
measurement before and after chemotherapy. Univariate analysis between age, clinical risk and 
cumulative anthracycline dose to change in global strain before and after treatment showed no 
significant correlation between any of the parameters examined.
! The interobserver and intraobserver differences in measurement of strain were similar 
(interobserver vs. intraobserver); for global longitudinal strain, the mean interobserver difference 
was -1.73 ± 1.0 and the mean intraobserver difference was -0.86 ± 0.59. For global radial strain, the 
mean interobserver difference was 5.0 ± 7.80 and the mean intraobserver difference was 3.40 ± 
12.40.  For global circumferential strain, the mean interobserver difference was 1.48 ± 1.24 and the 
mean intraobserver difference was 1.62 ± 1.10. 
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4.4 DISCUSSION
The principal findings of this study suggest that myocardial strain imaging may be more sensitive 
than LVEF in detecting changes in LV systolic function early after therapeutic doses of 
anthracycline chemotherapy. Greater than 10% reductions in peak longitudinal and peak radial LV 
systolic strain measurements were observed after chemotherapy in ~ 50% of participants. Twenty-
seven percent of these had a reduction in longitudinal strain, and 39% had a reduction in radial 
strain more than the mean minus 1 SD from baseline. No corresponding reduction in LVEF greater 
than or equal to 10% was observed in any participant after chemotherapy. Furthermore, 
participants with an LVEF <55% after anthracycline chemotherapy had significantly reduced 
global longitudinal strain compared with those with an LVEF >55%. While these observations 
suggest that longitudinal and radial strain identify early impairment of myocardial systolic 
function, radial strain measurements had high variability; determining the significance of the 
observed reductions will require long term follow up before strain is used with established 
markers of cardiotoxicity in decisions related to changes in therapy. 
! !
! LV muscular anatomy is complex; overall it has a helical configuration, with 3 ‘layers’ 
within the ventricular wall. The muscle ‘layers’ do not comprise discrete muscle groups, but are 
classified according to the predominant orientation of myocytes (Anderson, Ho, Redmann, 
Sanchez-Quintana, & Lunkenheimer, 2005). LVEF is the current standard method for monitoring 
systolic function in chemotherapy patients; however LVEF relies upon geometric assumptions for 
its calculation (McGowan & Cleland, 2003). Moreover, LVEF is a measure of global function that is 
unable to determine which muscle layer is affected. In contrast, strain imaging can measure both 
regional and global function and does not rely on assumptions about cardiac geometry. The 
contemporary 2D speckle tracking strain imaging technique is distinct from the older ‘tissue’ 
Doppler-based technique, as it is semiautomated, utilizes low frame rates, and importantly is 
relatively angle independent (Argyle & Ray, 2009).
!
! We observed significant reductions in global longitudinal and radial systolic strain 
measurements after chemotherapy in the absence of any reported symptoms (table 4.2). Reduced 
global longitudinal strain with preserved LVEF has been previously reported in other disease 
settings (Koyama, Davidoff, & Falk, 2004; Serri et al., 2006; Weidemann et al., 2003). Reduced 
longitudinal and radial strain using the older tissue Doppler-based strain technique has been 
previously reported in a small study of 16 patients over the age of 65 after pegylated 
anthracyclines (Jurcut et al., 2008). A reduction in radial 2D strain has been reported in an animal 
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model early after anthracycline therapy (Migrino, et al. 2008). Our observation of reduced global 
longitudinal and radial strain early after anthracycline chemotherapy was made in a larger group 
of 52 patients and with the semiautomated 2D strain imaging technique.
! Sawaya et al  recently reported that reduced longitudinal and radial strain after 3 months of 
cancer treatment could predict the later development of cardiotoxicity while reduced LVEF after 3 
months could not (Sawaya et al., 2011). However, their study participants were a heterogeneous 
group that included participants who had received anthracyclines, adjuvant therapy with 
trastuzumab, and thoracic radiotherapy. Therefore, our observations differ significantly for 2 
important reasons; we studied patients after anthracycline treatment only (with no radiotherapy or 
adjuvant trastuzumab), and observed reduced longitudinal and radial strain 1 week following 
anthracycline therapy. It must be noted however, that the variability of radial strain measurements 
using currently available techniques make it difficult to determine if the reductions observed in 
radial strain after chemotherapy represent a true reduction or can be accounted for by the 
variability of the measurement.
! !
! In contrast to longitudinal and radial strain, global circumferential systolic strain remained 
largely unchanged after chemotherapy (table 4.2). Reduced longitudinal strain, with preserved 
circumferential strain and preserved LVEF in long-term cancer survivors treated with 
anthracyclines and/or radiotherapy was reported recently by Tsai et al (Tsai et al., 2011). Reduced 
longitudinal strain in long-term survivors treated with anthracyclines and a subgroup treated with 
adjuvant trastuzumab was also reported recently by Ho et al (Ho et al., 2010). We additionally 
observed a reduction in radial strain parameters, suggesting a more generalized myocardial 
involvement consequent to oxidative stress mediated anthracycline chemotherapy.
! Fallah-Rad et al recently reported significantly reduced longitudinal and radial strain after 
anthracyclines in participants who later developed trastuzumab-induced cardiomyopathy, but did 
not report any circumferential measurements (Fallah-Rad et al., 2011). In our study, global 
circumferential LV strain remained largely unchanged after chemotherapy. Paired analysis for 
within patient differences revealed global circumferential strain was reduced ≥ 20% in only 3 
participants. Interestingly, the 1 participant with an important drop in LVEF to 47% after 
chemotherapy was 1 of these 3. While it is inappropriate to extrapolate an observation in a single 
patient, it suggests that changes in circumferential strain occur later than changes in the other 2 
axes, and that larger reductions in LVEF may occur in association with significantly reduced 
circumferential strain.
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! Significant reductions in regional longitudinal and radial systolic strain after chemotherapy 
were observed (tables 4.4 and 4.5) in the LV lateral wall and most often in the septal regions, 
possibly indicating a regional heterogeneity in the development of systolic dysfunction. These 
novel findings suggest that identifying reduced strain in the LV lateral wall may be a way of 
monitoring myocardial function in this setting. Regional variation in peak LV systolic strain was 
observed, in keeping with observations from previous reports (Marwick, 2009; Serri et al., 2006) 
and is likely due to the variable LV fiber orientation shown to exist within and between subjects 
(Anderson et al., 2005). However, as 2D strain is dependent on image quality, some regional 
variation may be attributable to this as well.
! Contrary to our observations related to strain, no significant reduction in global or regional 
systolic strain rate was observed after chemotherapy. This finding may indicate that the degree of 
systolic myocardial deformation is impaired prior to reduction in the rate at which deformation 
occurs. Alternatively, it may be that frame rates between 50 – 70 frames per second are not high 
enough to detect changes in strain rate. 
! In adults, heart failure induced by the anthracycline doxorubicin has been reported to occur 
in 4 - 5% at a cumulative dose of 500-550 mg/m2, and up to 36% at a cumulative dose 600 mg/m2 
or more (Singal & Iliskovic, 1998; Swain, Whaley, & Ewer, 2003). Fortunately, dose-limiting 
strategies reduce cardiotoxicity; the incidence of heart failure is 1.6% with modern adjuvant 
therapy for breast cancer (doxorubicin between 240 and 360 mg/m2) (Bird & Swain, 2008). 
However, microscopic analysis reveals that myocardial damage occurs with doses of doxorubicin 
as low as 180 mg/m2 (although the precise mechanism responsible for this damage is unknown 
(Frei, 2008; Friedman, Bozdech, Billingham, & Rider, 1978; Gianni et al., 2008)) and support our 
observation of reduced LV systolic strain early after therapeutic doses of anthracycline 
chemotherapy
! In keeping with previous reports, our results indicate that clinically significant reductions 
in LVEF (LVEF reductions >10% or absolute reductions in LVEF to < 50%) following low dose 
anthracyclines are rare. Our results also indicate that strain may detect early impairment of 
myocardial systolic function. The clinical relevance of these findings will require longer-term 
follow up for future cardiovascular events in this patient group. 
! Early initiation of heart failure treatment appears important for the recovery of LV function 
in patients who experience a significant reduction in LVEF due to anthracyclines (Cardinale et al., 
Chapter 4
81
2010). Therefore, early identification of impaired systolic function is vital. Furthermore, given that 
many breast cancer patients first treated with anthracyclines will then receive trastuzumab, 
identifying patients at greater risk of developing cardiotoxicity is of considerable advantage. Early 
identification of those with significant reductions in strain (even in the absence of reduced LVEF) 
would enable targeted monitoring, together with the institution of supportive therapy with 
angiotensin-converting-enzyme inhibitors (ACEI’s) or beta-blockers should further treatment with 
trastuzumab be required.
! No significant association between cardiac risk factors (see methods) when tested 
individually or together and reduced global strain was found; no difference in blood pressure 
measurements before and after treatment was observed, however in order to confirm a lack of 
association between these cardiovascular risk factors and reduced strain measurements, larger 
studies of more participants with coexistent morbidities would be required. Only one participant 
in this study had a post chemotherapy LVEF < 50%. Larger scale studies over an extended period 
are required in order to determine the clinical relevance of the observed early reduction in strain 
measurements. 
! Our present study has some limitations. It was performed in a relatively small group of 
patients and does not provide longer-term follow up on the clinical implications of early 
anthracycline induced changes in myocardial strain. Our study does not include another imaging 
modality, such as magnetic resonance imaging, or the serial evaluation of cardiac biomarkers or 
ECG, which may provide additional information. Performance of biomarker testing was beyond 
the scope of the present study. Variability of strain measurements is an inherent limitation of the 
technique; however, our measurements are similar to other published data (Fallah-Rad et al, 2011; 
Ho et al, 2010; Marwick 2009). As the variability with radial strain is highest, despite the reduction 
in the mean value, it remains difficult to determine its real clinical value.
! Our results indicate that 2D strain detects early reductions in global and regional systolic 
strain that may signify early impairment of myocardial systolic function immediately after 
anthracycline chemotherapy. Longer-term follow-up is needed to determine the clinical 
significance of the results of this study and whether early reduction in strain parameters result in 
the identification of future LV dysfunction in this clinical setting. Early identification of impaired 
systolic function will enable monitoring as well as targeted cardioprotective therapy in patients 
who require further (potentially life saving) treatment with trastuzumab.
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CHAPTER 5
ALTERED LEFT VENTRICULAR LONGITUDINAL DIASTOLIC 
FUNCTION CORRELATES WITH REDUCED SYSTOLIC FUNCTION 
IMMEDIATELY AFTER ANTHRACYCLINE CHEMOTHERAPY
Published in: European Heart Journal – Cardiovascular Imaging, 2013 March; 14(3): 228-34, Epub date 
12 July 2012
Preamble
During the analysis of LV systolic function made immediately after anthracycline treatment 
(presented in the previous chapter), it was evident that an analysis of LV diastolic function would 
be a logical extension of the research. Both phases of the cardiac cycle, systole and diastole, have 
complementary roles that ensure optimal cardiac performance: to date, monitoring cardiotoxicity 
has centered on measuring systolic function alone. The published findings from the analysis of 
diastolic function made at this initial time-point (immediately after anthracycline chemotherapy) 
are presented in the current chapter. 
ABSTRACT
AIMS 
The benefits from anthracycline chemotherapy are undermined by potentially life threatening 
cardiotoxicity. Transthoracic echocardiography is the most commonly used method for monitoring 
cardiotoxicity, and centers on the measurement of left ventricular systolic function. The aim of this 
study was to utilize two-dimensional speckle tracking echocardiography (2DSTE) at baseline and 
immediately after anthracycline chemotherapy to investigate whether patients with significant 
changes in systolic function after anthracycline therapy would also develop alterations in diastolic 
parameters.
METHODS AND RESULTS 
Fifty-two women with histologically confirmed breast cancer were prospectively recruited. 
Echocardiograms were performed 1 week prior to and 1 week following chemotherapy (always 
before adjuvant trastuzumab or thoracic radiotherapy). Conventional Doppler, tissue Doppler 
imaging (TDI) and 2DSTE were used to measure diastolic function. 2DSTE measurements included 
longitudinal diastolic strain, early (E-Sr) and late (A-Sr) myocardial strain rate. 2DSTE and left 
ventricular ejection fraction (LVEF) were used to measure biplane longitudinal systolic function.
! Altered LV diastolic function (including E-Sr) was observed in the entire cohort after 
chemotherapy, with a differential reduction in participants with a post therapy LVEF < 55%. 
Univariate predictors of E-Sr were LVEF post therapy (p = 0.049) and biplane systolic strain (p  = 
0.01). In a multivariate analysis, biplane systolic strain after chemotherapy was the strongest 
independent predictor (p = 0.001).
CONCLUSION 
Altered LV diastolic function was observed immediately after administration of therapeutic 
doses of anthracycline chemotherapy. Furthermore, our analysis indicates that the changes in 
diastolic function are associated with reduced systolic function. 
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5.1 INTRODUCTION
Anthracycline agents are an essential part of breast cancer treatment due to their highly effective 
antineoplastic properties (Gianni et al., 2008). However, as anthracyclines are potentially 
cardiotoxic, close monitoring of cardiac function with their administration is mandatory (Bird & 
Swain, 2008; Singal & Iliskovic, 1998). Transthoracic echocardiography (TTE) is the most common 
method for monitoring cardiotoxicity (Jurcut et al., 2008a), and in this setting is centered on 
measuring left ventricular (LV) systolic function. Yet, both components of the cardiac cycle, systole 
and diastole are essentially linked and together must function normally for optimal cardiac 
performance (Lester et al., 2008).
! Conventional Doppler measurements have demonstrated changes in diastolic function 6 
years after childhood anthracycline chemotherapy (Dorup, Levitt, Sullivan, & Sorensen, 2004), and 
tissue Doppler imaging (TDI) measured 3 months and then 3 years after anthracyclines in a small 
adult population, revealed persistently reduced E’ velocities (Tassan-Mangina et al., 2006). Strain 
imaging may enhance the evaluation of diastolic function (Nagueh et al., 2009; Zile & Brutsaert, 
2002); however, there is a lack of published literature to support this. Previously, we reported 
reduced LV systolic strain immediately after anthracyclines (Stoodley et al., 2011), our aim in this 
study was to investigate LV diastolic function using conventional Doppler, TDI, strain and strain 
rate before and immediately after anthracyclines. We hypothesized that those with significant 
changes in systolic function immediately following therapy would also develop changes in 
diastolic parameters.
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5.2 METHODS
The Sydney West Area Health Service and the University of Sydney Research Ethics Committees 
approved the study, and written informed consent was obtained from all participants. Fifty-two 
consecutive anthracycline naïve women with histologically confirmed breast cancer were 
prospectively recruited. All echocardiograms were performed at a single site, although 
chemotherapy was administered at one of four sites (depending on proximity to the patient’s 
residence). The cumulative anthracycline dose was documented. 
! Clinical history, physical examination and echocardiographic characteristics were used to 
establish eligibility. Exclusion criteria included LV ejection fraction (LVEF) <50% prior to 
chemotherapy, rhythms other than sinus, more than mild valvular stenosis or regurgitation, 
prosthetic valve, previous ischemic heart disease or pacemaker. Height was measured at baseline, 
while weight and blood pressure were measured at the time of each echocardiogram. A detailed 
cardiac history, including clinical risk factors for heart disease (hypertension, diabetes, cholesterol, 
smoking and family history) was obtained at recruitment. Participants were also evaluated for any 
cardiac symptoms especially those of heart failure. 
! The initial echocardiogram was performed 1 week prior to the commencement of 
chemotherapy. The follow-up echocardiogram was performed 1 week following completion of 
chemotherapy (i.e. 12 or 18 weeks after the first study, depending on whether 4 or 6 cycles of 
chemotherapy were administered) and always performed before commencement of trastuzumab 
or thoracic radiotherapy. Echocardiograms were performed by two accredited sonographers using 
a Vivid 7 digital ultrasound system (GE medical systems, Norway) with a 2.5MHz variable 
frequency transducer optimized for image quality.
! All TTE’s were performed with patients in the left lateral position and images were 
obtained from the parasternal, apical and subcostal views. The transmitral early (E) and late (A) 
peak diastolic filling velocities, E/A ratio, E wave deceleration time and A wave duration were 
measured using conventional pulsed wave Doppler echocardiography with the sample volume 
placed at the mitral leaflet tips in the apical 4 chamber view. The velocity time integral of the A 
wave was measured and the atrial emptying fraction estimated as the A wave velocity time 
integral divided by the total mitral inflow velocity time integral. Maximum left atrial (LA) volume 
(just prior to mitral valve opening) and minimum LA volume were measured using the biplane 
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method of disks, according to the European Association of Echocardiography recommendations 
(Lang et al., 2006) and indexed to body surface area.
! Peak velocity and the velocity time integral of the systolic, diastolic and atrial components 
of pulmonary vein flow were measured with pulsed wave Doppler by placing the sample volume 
in the proximal 1 cm of the right upper pulmonary vein. The systolic fraction was calculated as the 
systolic wave velocity time integral divided by the total forward pulmonary vein flow velocity 
time integral. Isovolumic relaxation time was measured from the continuous wave Doppler LV 
outflow tract signal. Pulsed wave tissue Doppler imaging (TDI) was used to measure the early (E’) 
and late (A’) peak velocities from the septal annulus.
! Two-dimensional speckle tracking echocardiography (2DSTE) was used to measure biplane 
global longitudinal systolic and diastolic strain from the apical 4 and 2 chamber views, with 
observers blinded to LVEF results. The LV regions of interest for strain and strain rate analysis 
were manually selected by marking the endocardial border in the apical 4 and apical 2 chamber 
views. The tracking quality of individual LV segments was identified prior to analysis using the 
software scoring table on the off-line measuring package. Tracking quality was overridden in 
segments with no more than 2 rejected segments where the observer deemed tracking quality to be 
clearly acceptable. Images with persistently unacceptable tracking quality (more than 2 segments) 
were excluded from the final analysis. Measurements were made from 3 consecutive cardiac cycles 
and then averaged in order to obtain global strain and strain rate results.
! ! ! Figure 5.1 A)
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! ! ! Figure 5.1 B)
Figure 5.1 Diastolic strain (Ds) measurement: calculation is made by measuring the time interval 
from the ECG R wave to the peak E velocity (figure A). This time interval is then applied to the 
2DSTE trace to measure early global LV longitudinal diastolic strain (DS) from the dotted white 
line, as indicated by horizontal yellow line and the white arrow (figure B).
Figure 5.2 Global 2DSTE diastolic strain rate measurements: early peak diastolic strain rate (E-Sr) 
indicated by the white arrow and late peak diastolic strain rate (A-Sr) indicated by the yellow 
arrow. The coloured lines represent segmental measurements of strain rate and the dotted line the 
global average strain rate.
Chapter 5
92
! Systolic strain was measured as the peak negative strain during systole. Diastolic strain 
(DS) was estimated by measuring the time interval from the ECG R wave to peak E velocity with 
conventional transmitral Doppler echocardiography. The same time interval was applied to the 
2DTSE trace to measure early global LV longitudinal DS as previously described  (Dokainish, 
Sengupta, Pillai, Bobek, & Lakkis, 2008) (see figure 5.1). Heart rate was largely unchanged during 
both measurements. E/DS was calculated as a measure of elevated LV end diastolic pressure 
(Dokainish et al., 2008). 2DSTE was also used to measure biplane longitudinal diastolic strain rate. 
Global peak velocities in early (E-Sr) and late (A-Sr) diastole were measured with reference to the 
ECG (see figure 5.2).
! Fifteen participants were randomly selected to determine interobserver and intraobserver 
variability in E-Sr and A-Sr, with the differences reported as mean difference ± standard deviation. 
One observer performed repeated measurements of E-Sr, A-Sr on a different occasion in order to 
measure intraobserver variability. Interobserver and intraobserver variability for systolic 
longitudinal strain has been previously reported (Stoodley et al., 2011).
! All values were expressed as a mean ± SD unless otherwise stated. Paired t-tests were used 
to compare conventional Doppler, TDI and 2DSTE parameters before and after chemotherapy in 
the entire cohort (and within subgroups) to compare within patient changes. Linear regression and 
Chi square analysis were performed to determine univariate determinants of E-Sr as appropriate. 
Univariate variables with a significant correlation were entered into a stepwise multiple regression 
analysis to determine independent predictors of E-Sr. Data were analyzed using SPSS version 19 
(SPSS Inc, Chicago, Illinois), and considered significant if p < 0.05.
Chapter 5
93
5.3 RESULTS
All 52 participants had a baseline TTE before chemotherapy and a follow-up TTE 1 week following 
completion of chemotherapy. Limited image quality, most often due to left-sided mastectomy and/
or breast implant, before and/or after chemotherapy meant that all measurements were not 
possible in all participants. Three participants (6%) had a history of ischemic heart disease, 11 
(22%) had hypercholesterolaemia, 6 (12%) were smokers, 13 (26%) had hypertension and 2 (4%) 
were diabetic. Four (n = 34) or six (n = 18) cycles of anthracycline chemotherapy (doxorubicin or 
epirubicin) were administered, as determined by the oncology team. No participant reported 
symptoms or demonstrated signs of cardiac failure during follow-up. Maximum doxorubicin dose 
was 318mg/m2 and maximum epirubicin dosage was 581mg/m2 (see table 5.1).
Table 5.1
Participant demographics, cancer location and chemotherapy data 
Number of participants 52
Age (years) 49 ± 9
Height (cm) 161 ± 5
Weight (kg) 76 ± 23
Side of breast cancer
Right 28
Left 24
Anthracycline type
Doxorubicin (Dox) 40 (77%)
Mean Dox dose (mg/m2) 236 ± 33
Epirubicin (Epi) 12 (23%)
Mean Epi dose (mg/m2) 408 ± 110
Chapter 5
94
! Paired measurements of conventional Doppler transmitral diastolic filling velocities were 
possible in 49 of the 52 participants (94%) and of pulmonary vein flow in 43 of the 52 participants 
(83%). Among the transmitral measurements, peak A (p < 0.05) and the atrial fraction (p < 0.001) 
were significantly increased, while the E/A ratio (p < 0.05) was significantly reduced after 
chemotherapy. Of the pulmonary vein flow measurements, systolic fraction was significantly 
increased (p  < 0.001) and the diastolic velocity time integral (VTI) was significantly reduced (p  < 
0.05) after chemotherapy. LA maximum and minimum volumes and isovolumetric relaxation time 
did not change after chemotherapy (see table 5.2).
! Paired measurements of TDI diastolic parameters measured at the septal annulus were 
possible in 46 of the 52 participants (88%). No significant change in E’ velocity, the E/E’ ratio or in 
A’ velocity was observed after chemotherapy (see table 5.2). 2DSTE diastolic strain (DS) and early 
and late diastolic strain rate (E-Sr and A-Sr respectively) measurements were feasible in 45 of the 
52 participants (87%). E-Sr was significantly reduced (p < 0.01) after chemotherapy, with an E-Sr 
reduction greater than the mean minus 1SD of the baseline measurement in 13 participants (25%). 
No significant change was observed in DS or E/DS (see table 5.2).
! Previous analysis of LV systolic function in this cohort revealed significantly reduced global 
LV longitudinal systolic strain after chemotherapy (Stoodley et al., 2011). In order to investigate the 
relationship between reduced systolic function and diastolic function measurements after 
chemotherapy, participants were divided into two groups; group 1 (n = 38) comprised participants 
with an LVEF after chemotherapy > 55% and group 2 (n = 14) of those with an LVEF of < 55% after 
chemotherapy. Within group 1, only E-Sr was significantly reduced (p= 0.03) after chemotherapy. 
In contrast, within group 2, the A velocity and atrial fraction were significantly increased. The 
pulmonary vein atrial reversal duration minus the transmitral A duration was increased, almost 
reaching statistical significance (p = 0.05). The E/A ratio was significantly reduced. The diastolic 
VTI and atrial reversal duration decreased and systolic fraction increased significantly after 
chemotherapy in group 2. Moreover, E’ and E-Sr were significantly reduced in group 2 (see table 
5.3).
! No significant association was present on Chi-square analysis for baseline clinical risk 
factors (hypertension, diabetes, cholesterol, smoking and family history) and reduced E-Sr post 
therapy. There was no significant difference in blood pressure measurements. As expected, linear 
regression analysis demonstrated a correlation with age and baseline LVEF and post therapy E-Sr 
(r = -0.35, p = 0.04 and r = -0.54, p < 0.001 respectively). Baseline systolic strain was also found to be 
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related to post chemotherapy E-Sr (r = -0.35, p = 0.04). No association was found between E-Sr post 
therapy and baseline LVEF, LV mass or cumulative anthracycline dose. Univariate predictors of 
post chemotherapy biplane E-Sr were LVEF (p = 0.049) and biplane systolic strain (p = 0.01); with 
age proving to be the strongest predictor (see figure 5.3 A and B). Multivariate predictors of 
biplane E-Sr post therapy were LVEF and biplane systolic strain, with post therapy biplane systolic 
strain being the strongest predictor (standardized coefficient "=-0.48, p = 0.002) (age was excluded 
from the multivariate analysis based on its established co-dependence with diastolic function).
Table 5.2 Conventional Doppler, tissue Doppler imaging and 2D speckle tracking 
echocardiography measurements (2DSTE) of diastolic function in the entire study cohort before 
! ! ! ! and after anthracycline chemotherapy
Before After
Doppler measurements
Peak E velocity (m.s-1) 0.72 ± 0.15 0.70 ± 0.13
Peak A velocity (m.s-1) 0.66 ± 0.13 0.69 ± 0.15 *
E / A ratio 1.13 ± 0.30 1.05 ± 0.28 *
Deceleration time (m.s-1) 220 ± 36 225 ± 38
Atrial fraction 36.0 ± 6.9 38.4 ± 7.5 †
PV systolic VTI (cm s-1) 15.8 ± 3.5 16.5 ± 4.7
PV diastolic VTI (cm s-1) 11.5 ± 3.5 10.5 ± 2.5 *
Systolic fraction 57.5 ± 9.3 62.3 ± 8.5 †
PV atrial reversal duration (ms) 119 ± 19 116 ± 15
Tissue velocity imaging
E’ velocity (cm s-1) 8.3 ± 2.0 8.2 ± 4.7
E/E’ ratio 8.8 ± 2.3 9.2 ± 2.6
A’ velocity (cm s-1) 9.8 ± 4.2 9.0 ± 1.8
2DSTE measurements
Diastolic strain (%) 10.9 ± 2.5 10.4 ± 2.0
Early strain rate (ESR) (s-1) 1.00 ± 0.24 0.90 ± 0.22*
Active strain rate (ASR) (s-1) 0.63 ± 0.16 0.63 ± 0.16
* p <0.05 vs. before chemotherapy value, † p <0.01 vs. before chemotherapy value
(where PV = pulmonary vein, VTI = velocity time integral)
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Table 5.3 Measurements of systolic and diastolic function with significant variation after 
chemotherapy in group 2 (n = 14)
Before After
Systolic function
Bi-plane longitudinal systolic strain (%) -18.8 ± 2.81 -15.6 ± 2.47†
Diastolic function
Peak A velocity (ms-1) 0.64 ± 0.14 0.69 ± 0.13*
E / A ratio 1.17 ± 0.28 1.04 ± 0.26*
Atrial fraction 35.8 ± 5.72 39.2 ± 5.45*
Diastolic VTI 12.76 ± 2.89 11.07 ± 2.53††
Atrial reversal duration 125 ± 37.2 117 ± 19.3*
E’ velocity (cm s-1) 8.24 ± 1.57 7.48 ± 1.43*
Early strain rate (E-Sr) (s-1) 1.04 ± 0.19 0.80 ± 0.17††
†† p < 0.01 vs. before chemotherapy, † p = 0.01 vs. before chemotherapy, * p <0.05 vs. before chemotherapy value
! Interobserver and intraobserver differences in the measurement of diastolic strain rate were 
calculated. For E-Sr, the mean interobserver difference was 0.08 ± 0.12 s-1 and the mean 
intraobserver difference was 0.01 ± 0.05 s-1. For A-Sr, the mean interobserver difference was 0.06 ± 
0.12 s-1 and the mean intraobserver difference 0.01 ± 0.08 s-1 (see figures 5.4 and 5.5). For global 
longitudinal systolic strain, the mean interobserver difference was -1.73 ± 1.0 and the mean 
intraobserver difference was -0.86 ± 0.59 (as previously reported (Stoodley et al. 2011)).
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Figure 5.3 A) Pearson’s linear regression analysis revealed a significant correlation between 
biplane ESR and LVEF post chemotherapy, p = 0.049.
Figure 5.3 B) Pearson’s linear regression analysis revealed a significant correlation between biplane 
ESR and peak longitudinal systolic strain post chemotherapy, p = 0.01.
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Figure 5.4 A) Bland Altman plot of interobserver differences in E-Sr.
Figure 5.4 B) Bland Altman plot of interobserver differences in A-Sr. (Note: figures 5.4 A and B 
were published as supplementary material and available on-line only).
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Figure 5.5 A) Bland Altman plot of intraobserver differences in E-Sr.
Figures 5.5 B) Bland Altman plot of intraobserver differences in A-Sr. (Note: images 5.5 A and B 
were also published as supplementary material and available on-line only).
Chapter 5
100
5.4 DISCUSSION
Assessment of LV diastolic function is an essential part of a standard TTE examination. However, 
when monitoring cardiotoxicity, evaluation has typically focused on measuring LV systolic 
function by LV ejection fraction (LVEF). We previously reported reduced systolic function using 
strain imaging immediately after anthracycline chemotherapy (Stoodley et al., 2011); in the present 
study we observed alterations in diastolic function immediately after treatment. Reduced baseline 
systolic strain was found to be predictive of lower post chemotherapy E-Sr. Moreover, a differential 
reduction in diastolic function parameters in participants with LVEF < 55% after chemotherapy 
was observed. 
! Early identification of patients most likely to develop significant LV dysfunction following 
anthracyclines is of considerable clinical value, as it will enable targeted monitoring as well as 
cardioprotective therapy. Anthracycline-related diastolic dysfunction in paediatric (Dorup et al., 
2004) and adult populations  (Tassan-Mangina et al., 2006) in the intermediate and long term has 
been described. To our knowledge, our study is the first to report altered diastolic 2DSTE strain 
measurements and its association with systolic dysfunction immediately after anthracycline 
therapy: thus, our results provide an important insight to early myocardial changes following 
anthracyclines. Longer term follow up for the development of symptomatic heart failure is 
required to determine whether the early changes we have demonstrated will help identify patients 
at risk. For now, identifying altered diastolic function early may assist in the recognition and 
confirmation of anthracycline induced systolic dysfunction. 
! Using TDI to measure systolic and diastolic function is now routine in TTE examinations. 
Reduced TDI E’ velocities 3 months after anthracycline chemotherapy that persisted at 3 years, 
with similar reductions in LVEF and S’ velocity have been reported in a study comprising 20 
patients (Tassan-Mangina et al., 2006). However, while the reduction in LVEF reached statistical 
significance in that study, it was not clinically significant (mean LVEF post therapy 56 ± 8%). In 
contrast, we demonstrate a differential reduction in E’ and E-Sr measurements in patients with 
LVEF < 55% post chemotherapy (group 2). Ho et al recently reported reduced E velocity, E/A ratio 
and E’ velocity in women treated with anthracyclines over a longer duration with subjects having 
been treated with anthracyclines up to 6 years earlier (Ho et al., 2010). They also reported reduced 
2DSTE longitudinal and radial systolic strain, but failed to report a link between diastolic and 
systolic measurements. 
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! The E/E’ ratio is an accurate and widely used estimate of LVEDP, although it has been 
suggested that using 2DSTE to calculate E/DS may provide a more robust measure of LVEDP 
(Dokainish et al., 2008). In the present study, no significant change in E/E’, DS, E/DS or A-Sr in the 
entire study population or in either of the subgroups was observed. The absence of change in E/E’ 
or E/DS may reflect the fact that these parameters are altered with chronic disease rather than 
changes that occur acutely (as the follow up echocardiogram was performed within 1 week of 
completion of chemotherapy). It is unclear why changes in E-Sr precede changes in DS, but it is 
likely that the rate of myocardial deformation is altered prior to a reduction in the deformation per 
se. Isolated reduction in E-Sr with normal A-Sr levels has been reported in hypertension (Saghir, 
Areces, & Makan, 2007) and may represent early change in diastolic function. 
! In contrast to systole, diastole comprises two distinct phases. The first phase of diastole, 
active relaxation, occurs in a series of energy consuming steps that are dependent upon numerous 
cellular processes for normal function (Zile & Brutsaert, 2002). Alterations in myocardial collagen 
properties, abnormal calcium handling and an increase in ventricular fibrosis are known to result 
in reduced LV compliance and relaxation, and occur to a greater degree with advancing age 
(Gilbert & Glantz, 1989; Innelli, Sanchez, Marra, Esposito, & Galderisi, 2008; Martos et al., 2007; 
Tighe et al., 2003). The exact mechanism responsible for myocardial dysfunction as a result of 
anthracycline administration is unclear, however the myocardial damage is thought to be 
mediated by intracellular oxidative stress that results in mitochondrial dysfunction, apoptosis and 
myocyte necrosis (Zuppinger, Timolati, & Suter, 2007). 
! What is evident from this study is that a decline in early LV relaxation occurs as a result of 
anthracyclines. This decline can be measured one week after the completion of therapy, and results 
in a compensatory increase in the atrial contribution - similar to alterations in diastolic function 
that occurs with advancing age (Klein et al., 1994; Tighe et al., 2003). Reports that document an 
increased risk of morbidity and mortality in association with isolated diastolic dysfunction 
(Redfield et al., 2003) further validate the importance of our observation in a cohort of patients 
with a mean age of 52 years. Reduced baseline systolic strain was found to be predictive of lower 
post chemotherapy E-Sr. Moreover, measurements of early LV relaxation (E’ and E-Sr) were 
differentially reduced in patients with LVEF < 55% post chemotherapy (group 2), and were 
strongly associated with reduced LV systolic strain. 
! Our study is limited by the relatively small number of participants, particularly for 
subgroup analysis, however within patient differences were still observed. The study reports 
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changes immediately after anthracycline chemotherapy and does not include longer-term follow-
up on the clinical implications of early anthracycline induced changes in myocardial strain. Our 
study includes TDI E’ measurements sampled only at the septal annulus; an average of septal and 
lateral E’ velocity is lacking. The variability in E-Sr in this study although similar to previous 
reports, is an inherent limitation of strain measurements and therefore clinical decisions cannot be 
based on this parameter alone. Our study does not include another imaging modality or the serial 
evaluation of cardiac biomarkers, which may provide additional information, as performance of 
these additional tests was beyond the scope of the present study.
! In the present study we observed changes in LV diastolic function using 2DSTE 
immediately after administration of therapeutic doses of anthracycline chemotherapy. Our analysis 
also indicates that the changes in diastolic function are related to reduced systolic function. 
Recognition of altered diastolic function could serve as an indicator of altered systolic function, 
thereby ensuring that patients who require closer monitoring when additional treatment with 
trastuzumab is required are identified. In the context of the future development of heart failure, 
our data support the need for longer-term follow-up with 2DSTE in an important clinical setting 
that requires close collaboration between oncology and cardiology.
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CHAPTER 6
LEFT VENTRICULAR SYSTOLIC FUNCTION IN HER2/NEU NEGATIVE 
BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINE 
CHEMOTHERAPY: A COMPARATIVE ANALYSIS OF LVEF AND 
MYOCARDIAL STRAIN IMAGING OVER 12 MONTHS
Published in: European Journal of Cancer [In Press] 2013 doi:10.1016/j.ejca.2013.06.046
Preamble
In the previous two chapters short-term findings were presented; that is, the findings from 
measurements made immediately before and immediately after anthracyclines. In this chapter, the 
published observations from participants followed for 12 months are presented. These results are 
the necessary extension of the earlier observations, and provide intermediate-term measurements 
of LV systolic function after anthracyclines. 
In distinction to the previous two chapters, observations presented in this chapter were made in 
human epidermal growth factor receptor (HER2/neu) negative participants only. The majority of 
contemporary research utilizing strain imaging has focused on HER2/neu positive patients and 
the effects of anthracyclines plus trastuzumab. Therefore, in order to pursue novel research, LV 
systolic function in HER2/neu negative participants (treated with anthracyclines, but not 
trastuzumab) was undertaken in participants followed for 12 months.
ABSTRACT
AIM
Anthracycline agents are undermined by their cardiotoxicity. As life expectancy following 
treatment is greatly improved, techniques that ensure early detection and timely management of 
cardiotoxicity are essential. The aim of the present study was to evaluate left ventricular (LV) 
systolic function with LV ejection fraction (LVEF) and two-dimensional myocardial strain up to 12 
months after anthracycline chemotherapy, specifically in HER2/neu negative breast cancer 
patients.
METHODS 
Seventy-eight consecutive anthracycline naïve breast cancer patients were studied before and 
immediately after anthracycline chemotherapy. Fifty HER2/neu negative patients were studied 
over 12 months with serial echocardiograms at 4 time points. All patients were treated with 
standard regimens containing anthracyclines.
 
RESULTS 
Global systolic strain was significantly reduced immediately after, and 6 months after 
anthracyclines (-19.0 ± 2.3% to -17.5 ± 2.3% (p  < 0.001) and -18.2 ± 2.2% (p = 0.01) respectively). A 
non-uniform reduction in strain was observed each time with relative sparing of the LV apex. 
LVEF remained largely unchanged at both time points. Global strain normalised by 12 months in 
the majority of patients. Persistently reduced strain was observed in 16% (n = 8); these patients had 
a greater reduction in strain at 6 months (≤ -17.2%), and had received higher cumulative 
anthracycline doses.
CONCLUSION 
Myocardial strain imaging is more sensitive than LVEF for the early detection and intermediate 
term monitoring of LV systolic function following anthracycline chemotherapy in HER2/neu 
negative breast cancer patients, and may aid in the development of improved monitoring 
protocols.
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6.1 INTRODUCTION
A greater understanding of tumor biology has helped to improve breast cancer treatment; in fact 
with current treatment regimens, the prognosis for many breast cancer patients is very favorable 
(Jemal et al., 2011). Yet, four decades after their development, anthracycline chemotherapy remain 
the cornerstone of breast cancer treatment (Burstein et al., 2012; Gianni et al., 2008). Anthracyclines 
possess potent anti-tumor properties, and their benefits are confirmed by a significant body of 
evidence ((EBCTCG), 2005; Gianni et al., 2009). However, their efficacy is undermined by dose 
dependent cardiotoxicity (Singal & Iliskovic, 1998; Singal, Li, Kumar, Danelisen, & Iliskovic, 2000; 
Zuppinger, Timolati, & Suter, 2007).
Although dose-limiting strategies reduce cardiotoxicity, a small number of patients still 
develop cardiac dysfunction. Management of cardiotoxicity is further confounded by its temporal 
variability, as well as the need in some cases to supplement anthracycline chemotherapy with 
adjuvant radiation and trastuzumab therapy, which are also potentially cardiotoxic (Bird & Swain, 
2008; Slamon et al., 2001). Moreover, clear guidelines for the detection and management of cardiac 
dysfunction after anthracyclines are lacking (Wells & Lenihan, 2010).
Previously, we reported reduced left ventricular (LV) systolic function using myocardial 
strain imaging, in the absence of clinically significant changes in LV ejection fraction (EF), within 7 
days of completing anthracycline chemotherapy (Stoodley et al., 2011). The primary aim of the 
present study was to evaluate LV systolic function in HER2/neu negative breast cancer patients up 
to 12 months after anthracyclines: we hypothesized that strain imaging would reveal LV systolic 
dysfunction not discernible with LVEF, and provide a means for identifying patients at risk of 
developing overt changes in systolic function. 
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6.2 PATIENTS AND METHODS
Seventy-eight consecutive anthracycline naïve patients with histologically confirmed breast cancer 
were prospectively recruited over 2.5 years. Recruitment commenced in October 2008 and ended 
in March 2011. All participants were treated with standard regimens containing anthracyclines. 
Transthoracic echocardiograms and thoracic radiotherapy (RT) were performed at a single site, 
while chemotherapy was administered at one of four sites (depending on proximity to the 
patient’s residence). The  study was approved by the Sydney West Area Health Service and the 
University of Sydney Research Ethics Committees, and written informed consent was obtained 
from all participants.
Clinical history, physical examination and echocardiographic characteristics were used to 
establish eligibility (103 potential patients were referred during the recruitment period; 6 did not 
meet inclusion criteria, 9 elected not to participate and 11 were lost to follow-up). Exclusion criteria 
included previous anthracycline exposure, LVEF <50% prior to chemotherapy, rhythms other than 
sinus, more than mild valvular stenosis or regurgitation, prosthetic valve, ischemic heart disease or 
pacemaker. Height was measured at recruitment; weight and blood pressure were measured at the 
time of each echocardiogram. Cardiac history was obtained at recruitment, including clinical risk 
factors for heart disease (hypertension, diabetes and smoking history) and participants were 
evaluated throughout the study for any cardiac symptoms especially those of heart failure.
Echocardiograms were performed at 4 time points. A baseline exam was performed prior 
to the commencement of anthracycline chemotherapy (T1). The second exam was performed 
within 7 days of completing anthracycline therapy (T2), and always before the commencement of 
RT. Participants received four or six cycles of anthracycline chemotherapy (as determined by the 
oncology team), therefore the second exam occurred either 12 or 18 weeks after the first. The 3rd 
and 4th echocardiograms (T3 and T4) were performed at 6 and 12 months after the initial exam in 
HER2/neu negative participants only. All echocardiograms were performed by either of two 
experienced research sonographers using a Vivid 7 digital ultrasound system (GE medical systems, 
Norway) with a phased-array transducer.
Echocardiograms were performed with patients in the left lateral position and images 
were obtained from the standard parasternal, apical and subcostal views. Images from the 
parasternal short axis and apical 4 chamber views were used to measure LV dimensions and tissue 
Doppler S’ velocity. LVEF was measured by Simpson’s method according to the recommendations 
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of the European Association of Echocardiography (Lang et al., 2006), and measured at the time of 
acquisition. Depth adjusted two-dimensional (2D) images of the left ventricle from the apical 4 and 
2 chamber views were acquired and stored for off-line measurement of biplane LV longitudinal 
peak systolic strain (LPSS) using 2D speckle tracking echocardiography (with EchoPac PC version 
6.0, GE Healthcare, UK). Frame rates were optimized at the time of acquisition to ≥ 45 frames/
second. To ensure reproducibility and accuracy, systole was defined as the interval from aortic 
valve opening to closure, measured by pulsed wave Doppler sampling of blood flow in the LV 
outflow tract.
The LV regions of interest for longitudinal strain analysis were manually selected by 
marking the endocardial border at end systole in the appropriate imaging plane. Strain traces from 
each segment were inspected to confirm that peak systolic strain was measured prior to aortic 
valve closure and the tracking quality of all images was identified prior to analysis using the 
software scoring table on the off-line measuring package. Tracking quality was overridden in 
segments with no more than 2 rejected regions where the observer deemed tracking quality to be 
clearly acceptable. Images with persistently unacceptable tracking quality (more than 2 segments) 
were excluded from the final analysis. Strain measurements were made from 3 consecutive cardiac 
cycles and then averaged to obtain segmental LPSS. Global LPSS was calculated by averaging the 
12 segmental values in the apical 4 and 2 chamber views (see figure 6.1).
Figure 6.1 2D longitudinal myocardial strain measurement (%) from the apical 4 chamber view. 
The colored lines on the graph represent segmental deformation, the dotted line represents their 
‘global’ average (global LPSS is indicated by the white arrow). Strain measurements made in the 
longitudinal plane are negative as myofibers shorten in the longitudinal plane.
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Fifteen participants were randomly selected in order to calculate interobserver and 
intraobserver variability. LVEF and global LV LPSS measurements were repeated by a different 
observer (blinded to previous results) in order to measure interobserver variability. Intraobserver 
variability for LVEF and global LV LPSS were assessed by the same observer on a different 
occasion from the same digital data, using an offline system.
The mean and standard deviation (SD) was used to summarize each continuous variable. 
Chi squared tests were used to test for association between categorical variables. Mann-Whitney 
tests were used to test for differences in the distribution of continuous variables between two 
groups of patients. Linear mixed effects models were used to investigate within patient changes in 
LPSS and LVEF over four time points (in these models, time was considered as a factor with four 
levels corresponding to the four time points). Repeated measures ANOVA (with Bonferroni 
correction) was used to measure within patient changes in segmental LPSS, LV dimensions, tissue 
Doppler S’ and heart rate. Data were analyzed using SPSS version 20 (SPSS Inc, Chicago, Illinois) 
and SPLUS version 8 (TIBCO Software, California) and considered significant if p < 0.05.
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6.3 RESULTS
 
Seventy-eight participants (77 female and 1 male) with a mean age at recruitment of 52 ± 10 years 
were studied. Participants were treated with one of two regimens: Doxorubicin was used to treat 
63 (81%) participants; the mean dose was 238mg/m2 (range 140 - 340mg/m2). Epirubicin was used 
to treat 15 (19%) participants; the mean dose was 392 mg/m2 (range 255 - 572mg/m2). All 78 
participants had an echocardiogram at the first and second time points.
$ Measurement of biplane LVEF at T1 and T2 was possible in 76 of the 78 participants (97%). 
Mean LVEF at baseline (T1) was 58 ± 3% and within 7 days of completing anthracycline 
chemotherapy (T2) was 57 ± 3% (p < 0.001), a 2% relative reduction (with mean LVEF remaining 
within a clinically normal range). LV LPSS from the apical 4 chamber view was not possible in 9 of 
78 (12%): left sided mastectomy was a limiting factor in 7 of the 9. Global biplane LV LPSS (from 
the apical 4 and 2 chamber views) at baseline was -18.6 ± 2.4% and within 7 days of completing 
anthracyclines was -17.0 ± 2.2% (p < 0.001), a 9% relative reduction.
Twenty-eight of the 78 participants (36%) were found to be HER2/neu positive by in situ 
hybridization, and therefore proceeded to treatment with trastuzumab following anthracycline 
therapy. These 28 participants were excluded from the analysis at T3 and T4. Fifty HER2/neu 
negative participants were studied at 4 time points over 12 months, all 50 (100%) had an 
echocardiogram at a minimum of 3 time points. Measurement of biplane LVEF was possible in 44 
of the 45 (98%) who were followed for 12 months. The mean LVEF at each of the 4 time points is 
shown in table 6.1. A 2% relative reduction in LVEF from baseline was observed at T2 and T3. No 
significant changes in LV dimensions or systolic blood pressure were observed over the 12 month 
period (BSA was modestly reduced). A significant increase in heart rate (p = 0.03) was observed at 
T2; heart rate returned to its baseline value at 12 months. A significant reduction in tissue Doppler 
septal S’ velocity (p = 0.01) was seen after anthracycline therapy at T3 (see table 6.2 for 
demographic and standard echocardiographic measurements).
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Table 6.1 LVEF and biplane global LV LPSS in HER2/neu negative patients before (T1), 7 days 
after (T2), 6 months (T3) and 12 months (T4) after anthracycline chemotherapy
 (n = 50) T1 T2 T3 T4
 LVEF 58 ± 3% 57 ± 3% 57 ± 3% # 58 ± 3%
 Global LV LPSS - 19.0 ± 2.3% - 17.5 ± 2.3% * - 18.2 ± 2.2% # - 19.1 ± 1.9%
# p = 0.01, * p < 0.001
Table 6.2 Demographic and standard echocardiographic measurements at 4 time points over 12 
months
 (n = 50) T1 T2 T3 T4
 BSA (m2) 1.78 ± 0.22 1.77 ± 0.21 1.77 ± 0.21 1.75 ± 0.19 #
 Heart rate (bpm) 73 ± 11 78 ± 10 † 75 ± 8 73 ± 9
 Systolic BP 
 (mmHg)
119 ± 12 117 ± 12 118 ± 11 120 ± 18
 LVEDD (mm) 44 ± 4 44 ± 4 45 ± 4 44 ± 4
 LVESD (mm) 31 ± 4 32 ± 2 32 ± 4 30 ± 3
 Septal S’ (cm s-1) 8.2 ± 1.6 7.6 ± 1.0 7.3 ± 1.1 # 7.4 ± 1.2 
† p < 0.05, # p = 0.01: T1 = 7 days before anthracyclines, T2 = 7 days after anthracyclines, T3 = 6 months after 
anthracyclines and T4 = 12 months after anthracycline chemotherapy, BP = Blood Pressure, bpm = beats per minute, 
LVEDD = left ventricular end diastolic dimension, LVESD = left ventricular end systolic dimension
Of the participants who were followed for 12 months, global biplane LV LPSS was 
possible on at least 3 of the time points in 42 of 45 (93%). LPSS could not be measured in 3 
participants: left sided mastectomy (n = 1) and left sided lumpectomy (n = 2) were limiting factors. 
The global biplane LV LPSS at each of the 4 time points is shown in table 1. Significant reductions 
in global LV LPSS from baseline were observed at T2 (p < 0.001) and T3 (p = 0.01) in this extended 
follow-up group of HER2/neu negative participants (see Table 1).
Segmental strain analysis showed regional differences in the left ventricle following 
anthracycline chemotherapy: the basal and mid left ventricular segments were significantly 
reduced, whereas the LV apex was largely unchanged. A base to apex gradient was observed in LV 
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LPSS, with maximal strain values at the LV apex: a modest increase in this gradient was observed 
at all 3 time points (T2, T3, and T4) following anthracyclines (see table 6.3). Twelve months after 
anthracycline therapy, basal and mid segmental LV LPSS had normalized (see table 3 and figure 
6.2).
Table 6.3 Longitudinal peak systolic strain (LPSS) values in the basal, mid and apical left 
ventricle at 4 time-points over 12 months
 (n = 50) T1 T2 T3 T4
 Basal LV -18.5 ± 2.4%[32%]
-16.6 ± 2.7% * 
[31%]
-16.9 ± 2.6% # 
[31%]
-17.9 ± 2.6% 
[31%]
 Mid LV -19.0 ± 2.7% [33%]
-17.2 ± 2.5% * 
[33%]
-17.4 ± 2.4% # 
[32%]
-18.2 ± 2.2% 
[32%]
 Apical LV -19.9 ± 4.1% [35%]
-18.9 ± 3.7% 
[36%]
-20.2 ± 3.5% 
[37%]
-21.2 ± 3.5% 
[37%]
# p < 0.01, * p < 0.001 : T1 = 7 days before anthracyclines, T2 = 7 days after anthracyclines, T3 = 6 months after 
anthracyclines and T4 = 12 months after anthracycline chemotherapy; the values in parentheses represent the relative 
contribution of the basal, mid and apical segments to the overall LPSS at each time point.
Figure 6.2 Percent relative reduction in global LV LPSS compared to baseline in the basal, mid and 
apical left ventricle; 2 = 7 days after anthracyclines, 3 = 6 months after anthracyclines, 4 = 12 
months after anthracyclines.
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Thirty-four of the 50 participants who were studied over 12 months received breast or 
chest wall radiotherapy (RT), with nodal irradiation as indicated. The standard radiation dose was 
50 Gray (Gy) in 25 fractions. Twenty breast conservation participants received an additional dose 
to the tumor bed (10 Gy in 5 fractions). All RT was given after the completion of anthracycline 
chemotherapy. No significant reduction in LVEF or LV LPSS measurements was observed in 
participants who received RT compared to anthracyclines alone; no significant reduction was 
observed in the 15 participants who received left sided RT.
At twelve months, eight of the 50 HER2/neu negative group (16%) were found to have 
an LPSS ≥1 SD below the mean LPSS value (i.e ≤ 17.2%). Their mean LVEF showed no clinically 
significant change at the 4 time points (measuring 58 ± 2%, 56 ± 3%, 55 ± 2% and 57 ± 2% 
respectively). The mean global LV biplane LPSS at the 4 time points for these eight participants 
were -19.0 ± 1.8%, -16.8 ± 1.1%, -15.3 ± 1.0% and -16.6 ± 0.7% respectively, with significant 
reductions in LPSS compared to baseline noted at all 3 follow-up time-points (p  < 0.01, p < 0.001 
and p < 0.01). Furthermore, a low LV LPSS value at 12 months could be predicted by an LV LPSS 
value < -17.2% at 6 months with 100% sensitivity and 80% specificity (see figure 6.3). Only one 
participant had an LVEF measurement <50%, which was recorded at T3: LVEF measured 46% with 
a corresponding global LV LPSS measurement of -14.8%. An additional echocardiogram was 
performed at 9 months; LVEF and global LV LPSS at 9 and at 12 months measured 52% and -17.4% 
and 53% and -17.2% respectively.
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Figure 6.3 Box plot demonstrating the significant difference in global strain at 6 months in 
participants with a 12 month global strain value > -17.2% (n = 42) or ≤ -17.2% (n = 8).
Patients were divided into 2 groups based on whether their LV LPSS was > or ≤ -17.2% at 
12 months (that is, -17.2% being 1 SD below the mean LV LPSS T4 value). The cumulative 
anthracycline dose for participants with a biplane global LV LPSS ≤ -17.2%  at T4 was 318 ± 
115mg/m2, which although within therapeutic range, was significantly greater (p = 0.03) than the 
cumulative dose for those with an LPSS > -17.2 % (258 ± 75mg/m2). The anthracycline agent 
(doxorubicin (75%) versus epirubicin (25%)) used was not significantly different between the two 
groups. There were no differences in age, BSA or smoking history between those with LV LPSS > 
or ≤ -17.2% at 12 months.
Nine HER2/neu negative participants were on treatment for hypertension (HT); three of 
the 9 had a biplane global LV LPSS ≤ -17.2% at 12 months and the presence of HT did not result in 
a persistently low LV LPSS of ≤ 17.2% at 12 months. Three of the 50 participants had diabetes 
(DM): 2 DM participants had a biplane global LV LPSS ≤ -17.2% at 12 months.
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The interobserver and intraobserver measurements of LVEF and global LV LPSS revealed 
acceptable agreement. The coefficients of variation values were < 10%, which represents a range of 
variation similar to the range previously reported in the literature (see figure 6.4).
Figure 6.4 Bland-Altman figures of A) inter and B) intra-observer variation for global LV LPSS. 
(Note: these figures are published as appendix items, and available on-line only).
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6.4 DISCUSSION
 
In the present study, we used LVEF and myocardial strain imaging, measured at 4 time points over 
twelve months, to evaluate LV systolic function in 50 consecutive HER2/neu negative breast 
cancer patients treated with anthracycline chemotherapy. The principal findings from this study 
indicate that: 1) myocardial systolic dysfunction can be detected with strain imaging within 7 days 
of completing anthracyclines without a similar discernible change in LVEF, 2) myocardial injury 
occurs non-uniformly within the LV with relative sparing of the apical segments, 3) in the majority 
of patients, low dose anthracycline induced myocardial injury is transient, without permanent 
dysfunction, and 4) persistently reduced global strain occurs in ~ 16% of HER2/neu negative 
patients when systolic strain is reduced ≤ -17.2% at 6 months following anthracycline therapy; this 
persistent reduction is associated with higher cumulative anthracycline doses. While there are 
several reports in the literature of chemotherapy related cardiotoxicity, ours is the first to focus on 
the effect of anthracyclines in HER2/neu negative patients over 12 months.
The observed reduction in LV LPSS within 7 days of completing anthracycline 
chemotherapy provides confirmation of observations we have reported previously (Stoodley et al., 
2011): the current study involved a larger cohort. Approximately 30% of the cohort were HER2/
neu positive, and reduced LV strain immediately after anthracyclines is particularly important for 
these patients, as they will require additional potentially cardiotoxic treatment with trastuzumab. 
A previous report demonstrated that longitudinal systolic strain is able to detect pre-clinical 
changes in LV systolic function in patients receiving trastuzumab in the adjuvant setting, whereas 
LVEF cannot  (Fallah-Rad et al., 2011). Our results, which are consistent with these findings, 
highlight the sensitivity of strain to early changes in LV systolic function: a 9% relative reduction in 
global LPSS was observed immediately after chemotherapy, when the relative reduction in LVEF 
was only 2%.
Normally, regional LV myocardial systolic strain values increase modestly along the 
longitudinal axis from base to apex (Sengupta et al., 2007): we observed this characteristic 
pattern at baseline and after the administration of anthracycline chemotherapy. However, strain 
was not significantly reduced in the apical segments after anthracycline therapy. In fact, a greater 
difference between basal and apical strain values was evident after anthracyclines, indicating a 
non-uniform disruption of LV myocardial systolic function (table 6.3). A similar selective 
segmental disruption of systolic function has been reported in adolescent patients treated with 
anthracyclines  (Poterucha, Kutty, Lindquist, Li, & Eidem, 2012), in HER2/neu positive patients 
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treated with trastuzumab with a variable history of anthracycline exposure (Sawaya et al., 2011), as 
well as in hypertrophic cardiomyopathy (Afonso et al., 2012).
Global LV LPSS normalized in the majority of participants at 12 months; however 16% (n 
= 8) were noted to have persistently reduced myocardial strain. In these participants, global LV 
LPSS was reduced by at least one standard deviation below the mean 12 month global strain value. 
Global strain in these participants prior to anthracycline chemotherapy was no different to the rest 
of the cohort; within 7 days of completing anthracyclines (T2), and at 6 months after anthracyclines 
(T3) their global strain was significantly reduced. Thus, global LV LPSS ≤ -17.2% at T3 was 
predictive (with 100% sensitivity and 80% specificity) of a 12 month (T4) strain value one standard 
deviation below the mean. Furthermore, analysis also showed that the cumulative anthracycline 
dose, although within the therapeutic range, was significantly higher in these participants.
$ Risk stratification protocols for the early detection of cardiotoxicity are important given 
increased life expectancy following breast cancer treatment. While HER2/neu positive patients 
treated with adjuvant trastuzumab are monitored closely, we have demonstrated subclinical LV 
dysfunction by strain analysis in HER2/neu negative patients, who comprise ~ 75% of all breast 
cancer patients. Thus, monitoring HER2/neu negative patients who receive anthracycline 
chemotherapy with echocardiograms that utilize strain imaging both at baseline and at 6 months 
following commencement of their treatment may help treating physicians identify patients with 
subclinical cardiac dysfunction who would benefit from additional cardiac monitoring and 
treatment. Furthermore, ensuring participants treated with higher cumulative anthracycline doses 
receive longer-term monitoring seems necessary. These are preliminary observations, which 
require longer-term follow-up, and may help in the development of risk stratification protocols for 
the early detection of cardiotoxicity, thereby improving management and outcomes in this patient 
population.
$ Recognizing the possible transient nature of LV systolic dysfunction after low dose 
anthracycline chemotherapy in HER2/neu negative patients is important. When treating patients 
with anthracyclines, oncologists aim to achieve an ideal anthracycline dosage; that is, a dosage that 
is therapeutic without being cardiotoxic (Eidem, 2008). While our study demonstrates a persistent 
reduction in LV strain in 16% of patients at 12 months, longer-term data are needed to provide 
confirmation of these observations in the longer term as well as their clinical relevance.
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The present study is limited by its relatively small sample size. However, 16% of HER2/
neu negative participants had reduced strain at 12 months. An additional imaging modality such 
as CMRI, which may have provided further information regarding LV systolic function was not 
included, nor were cardiac biomarkers. Left sided mastectomy or lumpectomy limit the biplane 
measurement of strain more than LVEF (which has been reported previously (Sawaya et al., 2011)). 
An examination of the efficacy of cardio-protective therapies (such as ACE inhibitors or beta 
blockers) used to treat LV dysfunction in this setting was beyond the scope of the current study, 
although future multi-centre studies have been planned. Furthermore, the development of an 
international registry, used to collect similar datasets, may be a way to advance research in this 
setting. Radiation therapy has been reported to augment the cardiotoxic effect of anthracycline 
chemotherapy (Tsai et al., 2011); we did not observe such an effect, which may be due to the 
relatively small cohort with a short duration of follow-up.
As is well known, anthracycline-induced cardiotoxicity results in changes to the 
structure and function of cardiac myocytes (Chen, Peng, Pentassuglia, Lim, & Sawyer, 2007; 
Sawyer, Peng, Chen, Pentassuglia, & Lim, 2010). Our findings in HER2/neu negative breast cancer 
patients indicate that myocardial strain imaging is a more sensitive method than the currently 
accepted measure of LV systolic function (LVEF) for the early detection and intermediate term 
monitoring of LV systolic function following anthracycline chemotherapy. The utilization of 
myocardial strain imaging may aid in the identification of those with preclinical LV systolic 
dysfunction: our data support the need for longer-term follow-up, where improved monitoring 
protocols and close collaboration between oncology and cardiology is essential.
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CHAPTER 7
TRASTUZUMAB INDUCED CARDIOTOXICITY: THE ROLE OF 2D 
MYOCARDIAL STRAIN IMAGING IN DIAGNOSIS AND MANAGEMENT
Published in: Echocardiography, 2012 July, 29 (6), E137-E140.
Preamble
Modern treatment for breast cancer often involves a combination of anti-neoplastic agents. As 
such, anthracyclines are one of several agents used in the treatment of breast cancer. Trastuzumab 
is a contemporary biological agent that was introduced in chapter 3 part A of the thesis. As 
described therein, its introduction has led to an important advance in breast cancer treatment, 
however its use is also undermined by potential cardiotoxicity. The following published work 
details the findings of serial LVEF and strain measurements made over the course of 
approximately 18 months in a patient who developed heart failure during treatment with 
trastuzumab, which had been administered following completion of anthracyclines.
ABSTRACT
A 45 year-old female breast cancer patient developed heart failure during adjuvant trastuzumab 
therapy. Her initial left ventricular ejection fraction (LVEF) was 39% and corresponding global 
longitudinal and circumferential systolic strain measurements were also significantly reduced. 
Trastuzumab was ceased and supportive cardiac therapy commenced. The ensuing LVEF and 
systolic strain measurements showed consistent improvement, so trastuzumab was recommenced 
(while supportive cardiac therapy continued). At this point, reduced circumferential systolic strain 
with preserved LVEF was observed. Subsequent echocardiograms revealed further reductions in 
circumferential and longitudinal systolic strain without reductions in LVEF.
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7.1 PATIENT HISTORY
A 45-year-old female was referred for cardiovascular management following a recent hospital 
admission for heart failure. Eight months earlier she had been diagnosed with localised (lymph 
node negative, human epidermal growth factor receptor (HER-2/neu) positive) left-sided breast 
cancer. Her medical treatment for cancer had included 4 cycles of fluorouracil, adriamycin and 
cyclophosphamide (FAC) with a total adriamycin dose 670 mg (394mg/m2), 7 cycles of Paclitaxel 
(total dose 910 mg) and 2 cycles of 3 weekly trastuzumab (total dose 1000 mg). Transthoracic 
echocardiogram (TTE) while in hospital had revealed mild to moderate global left ventricular (LV) 
systolic dysfunction. Heart failure was treated with carvedilol and frusemide. Angiotensin 
converting enzyme inhibitors (ACEI’s) were not tolerated because of cough. Paclitaxel treatment 
was ceased and the trastuzumab therapy temporarily withheld.
 
Management over the ensuing 9 months included clinical evaluation of heart failure and 
serial TTE’s. The initial TTE revealed moderate global LV systolic dysfunction; biplane LV ejection 
fraction (LVEF) by Simpson’s method was 39%. At the subsequent 3 visits, clinical status and 
cardiac function as measured by TTE gradually improved and LVEF on the 4th visit measured 52%. 
Given the improved clinical status and LVEF, trastuzumab therapy was recommenced and 
supportive cardiac therapy (carvedilol and frusemide) was continued. 
Evaluation of cardiac function was extended to include two-dimensional (2D) myocardial 
strain imaging to test for evidence of subclinical cardiac dysfunction. Peak global LV systolic strain 
in the longitudinal and circumferential planes was measured by averaging peak strain from 3 
consecutive cardiac cycles from 6 segments in each plane. Images were acquired using a Vivid 7 
digital ultrasound system (GE Healthcare, Norway) with a 2.5MHz variable frequency transducer 
and measurement of 2D speckle tracking myocardial strain was performed off-line with EchoPac 
version BT 10 (GE Vingmed, Norway). Retrospective analysis revealed significantly reduced strain 
measurements on the initial TTE (compared to published normal values (Marwick, 2009)), with a 
consistent increase in strain on each of the following 3 echocardiograms, in keeping with the 
increasing LVEF. After trastuzumab was restarted however, a marked reduction in LV systolic 
strain was observed, when in contrast LVEF was unchanged (see figures 7.1 A and B).
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! ! Figure 7.1 A)
! ! Figure 7.1 B)
Figure 7.1 A) LVEF measurements from the 8 TTE’s. The vertical dotted line indicates when 
trastuzumab was recommenced, after which LVEF remained unchanged. B) 2D longitudinal and 
circumferential strain measurements from 8 TTE’s. The vertical dotted line indicates when 
trastuzumab was recommenced, after which longitudinal and circumferential strain measurements 
were reduced.
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Five months after recommencing trastuzumab, an exercise stress test was performed. LVEF 
immediately before exercise measured 56%. Heart rate peaked at 139 beats per minute (79% of the 
maximal age predicted heart rate; blunted response likely due to carvedilol) at maximal exercise, 
9min 15sec into the Bruce protocol. Maximum blood pressure was 140/60mmHg and no evidence 
of myocardial ischemia was identified. Biplane LVEF (by Simpson’s method) immediately after 
exercise measured 56%, indicating an absence of normal LV contractile reserve (at 79% of maximal 
age predicted heart rate). Longitudinal and circumferential strain measurements immediately after 
exercise were reduced when compared with those measured immediately beforehand (see images 
7.2 A and B, 7.3 A and B).
Figure 7.2 A)! ! ! ! ! ! Figure 7.1 B)
Figure 7.2 2D longitudinal systolic strain measurements from the apical 4-chamber view. A) The 
dotted white line marks global strain. Peak longitudinal strain before exercise (indicated by the 
arrow) was -14.8%. B) The dotted white line marks global strain. Peak longitudinal strain after 
exercise (indicated by the arrow) was -12.3%.
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Figure 7.3 A)! ! ! ! ! ! Figure 7.3 B)
Figure 7.3 2D circumferential systolic strain measurements from the parasternal short-axis view. 
A) The dotted white line marks global strain. Peak circumferential strain before exercise (indicated 
by the arrow) was -17.8%. B) The dotted white line marks global strain after exercise. Peak 
circumferential strain after exercise (indicated by the arrow) was - 13.9%.
7.2 DISCUSSION
LVEF is currently used to identify and monitor chemotherapy related cardiotoxicity. However, 
LVEF has numerous limitations, which include geometrical assumptions regarding cardiac 
anatomy and its inability to detect subtle changes in segmental function (Stanton, Leano, & 
Marwick, 2009). 2D myocardial strain imaging is a novel echocardiographic technique that may 
overcome many of the limitations of LVEF. Strain is a measure of myocardial deformation that 
enables multi-plane assessment of segmental and global LV function (Choi et al., 2009; Mizuguchi 
et al., 2008) and has been recommended for application in this setting (Jurcut et al., 2008b). 
Recently, reduced longitudinal strain with preserved LVEF and preserved circumferential 
strain has been reported in both short-term (Stoodley et al., 2011) and long-term (Tsai et al., 2011) 
cancer survivors treated with anthracyclines. We observed reduced longitudinal and 
circumferential strain with preserved LVEF after the recommencement of adjuvant trastuzumab 
(while the patient received supportive cardiac therapy (see figures 7.1A and 7.1B)). Moreover, 
further reductions in longitudinal and circumferential strain were observed after an exercise stress 
test that also demonstrated a lack of contractile reserve by LVEF.
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Unlike anthracycline cardiotoxicity, toxicity induced by trastuzumab is not dose related 
and is regarded as being largely reversible, although this has been called into question (Telli, Hunt, 
Carlson, & Guardino, 2007). The improved cardiac function observed in this case after temporary 
cessation of trastuzumab indicates that the cardiotoxicity was most likely due to trastuzumab and 
not to late anthracycline toxicity. However, the reduced strain measurements and absence of 
contractile reserve following trastuzumab’s recommencement indicate that trastuzumab-induced 
cardiotoxicity may not be fully reversible and that a resting LVEF may be unable to detect these 
early changes in LV systolic function.
Trastuzumab therapy is life saving; however its efficacy is limited by its cardiotoxic 
potential, which means that close monitoring of cardiac function is necessary when trastuzumab 
therapy is administered. This case study supports prior publications that demonstrate strain 
imaging, with its unique multiplane quantification of myocardial deformation, is superior to the 
measurement of LV volumetric change (as measured by LVEF) in detecting reduced myocardial 
systolic function. It is likely that early damage involves the subendocardial fibers selectively as 
demonstrated by reduction in longitudinal strain with preserved LVEF. Moreover, it indicates that 
strain imaging may aid decision making regarding the reintroduction of trastuzumab therapy in 
the setting of chemotherapy induced cardiotoxicity.
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CHAPTER 8
SUMMARY, CONCLUSIONS AND FUTURE WORK
8.1 SUMMARY
The rationale for undertaking the research was addressed in the opening chapter. In brief, an 
enhanced understanding of tumor biology has helped to improve breast cancer treatment, and 
with current treatment regimens, the cancer prognosis for many breast cancer patients is very 
favorable. Anthracycline chemotherapy remains the cornerstone of breast cancer treatment four 
decades after its development. Anthracyclines possess potent anti-tumor properties, and their 
benefits are confirmed by a considerable body of evidence. However, their efficacy is undermined 
by dose dependent cardiotoxicity that mandates close monitoring of cardiac function: the method 
of choice for monitoring cardiac function is the measurement of left ventricular ejection fraction 
(LVEF) by transthoracic echocardiography. A new echocardiographic technique, myocardial strain 
imaging, may provide a more sensitive measurement of LV function than LVEF and improve 
measures aimed at countering cardiotoxicity. The aim of this research was to investigate strain 
imaging by comparison with LVEF, in breast cancer patients treated with anthracyclines.
! Certain key aspects of echocardiography were described in chapter 2. These included 
descriptions of the significant technical advances during its development that have helped to 
achieve its current status. Echocardiography continues to develop, and an important limitation in 
its current practice was also described. That is, the assessment of left ventricular (LV) systolic 
function has always been a principal indication for echocardiography, although assessment of LV 
systolic function is not straightforward and its accurate and reproducible measurement remains 
technically challenging. Currently, resting two-dimensional (2D) LV ejection fraction (LVEF) is the 
key echocardiographic parameter used to quantify LV systolic function. While three-dimensional 
echocardiography (3DE) has been shown to be a more accurate method than 2D for measuring 
LVEF, neither method is well suited to evaluating myocardial function: the left ventricle has 
considerable functional reserve, and significant damage may occur before a reduction in LVEF.
! The recent development of a novel echocardiographic technique, myocardial strain 
imaging, which may provide more sensitive, accurate and reproducible measurements of LV 
systolic function, was introduced in chapter 3. Additional details related to anthracyclines, prior 
research in the area of echocardiographic measurement of cardiac function in breast cancer patients 
and the use of strain imaging in other disease settings were also described. It is anticipated that 
strain imaging may enable the more timely introduction of measures aimed at countering 
cardiotoxicity. 
! Initially, fifty-two women with histologically confirmed breast cancer were prospectively 
studied. In chapter 4, the findings from LVEF and strain measurements made 1 week before and 1 
week after anthracycline chemotherapy were presented. Reduced systolic strain immediately after 
treatment, indicative of early impairment of myocardial function (before detectable changes in 
LVEF) was observed. That is, global longitudinal LV systolic strain was reduced from -17.7 to 
-16.3% (p < 0.01) with 48% of measurements reduced by > 10%, in the absence of any reduction in 
LVEF > 10%.
! The next chapter related the analysis of diastolic function, made 1 week before and 1 week 
after anthracycline chemotherapy from the same group of participants as the initial measurements 
of systolic function. Conventional Doppler, tissue Doppler and myocardial strain imaging were 
used to measure diastolic function and revealed altered LV diastolic function 1 week after 
anthracycline chemotherapy. Moreover, the analysis indicated that changes in diastolic function 
are associated with reduced systolic function - reduced early diastolic strain rate (E-Sr) being most 
strongly associated with reduced post chemotherapy systolic strain.
! In chapter 6, the measurements of systolic function made over 12 months were presented. 
Her2/neu positive patients who proceeded to receive trastuzumab therapy after anthracycline 
treatment were excluded from the 6 and 12 month analysis (to ensure that any cardiotoxicity 
related to trastuzumab was excluded). Once more, LV systolic dysfunction was detected with 
strain imaging within 7 days of completion of chemotherapy (without a similar discernible change 
in LVEF). Moreover, systolic function remained reduced 6 months after treatment, and the reduced 
systolic strain 7 days after and 6 months after treatment occurred non-uniformly within the LV. In 
the majority of participants, LV dysfunction was noted to be transient, with strain values returning 
to normal by 12 months. In the 16% of participants with persistently reduced strain 12 months after 
anthracyclines, significantly higher cumulative anthracycline doses had been administered.
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In brief, observations of the short and intermediate term effects of anthracyclines showed that: 
1) Myocardial systolic dysfunction can be detected with strain imaging within 7 days of 
completing anthracyclines without a similar discernible change in LVEF.
2) Alterations in diastolic function occur immediately after anthracyclines and are related to 
changes in systolic function.
3) Dysfunction occurs non-uniformly within the LV (with relative sparing of the apical 
segments). 
4) In the majority of patients, low dose anthracycline-induced myocardial dysfunction is 
transient, without permanent dysfunction.
5) Persistently reduced global strain occurs in ~ 16% of HER2/neu negative patients when 
systolic strain is reduced to a value below -17.2% at 6 months following anthracycline 
treatment; this persistent reduction is associated with higher cumulative anthracycline 
doses.
! In chapter 7, the case study of a young female breast cancer patient who developed heart 
failure during trastuzumab therapy (following anthracyclines) was presented. Trastuzumab was 
ceased and supportive cardiac therapy started when the LVEF measured 39% (systolic strain 
measurements were also significantly low at this point). Ensuing LVEF and systolic strain 
measurements showed consistent improvement on therapy, so trastuzumab was recommenced 
(while supportive therapy continued). Subsequent echocardiograms revealed reductions in systolic 
strain measurements prior to changes in LVEF. An absence of contractile reserve, as measured by 
LVEF, was eventually noted after exercise (with further reduction in strain). This case study, while 
limited by an absence of pre therapy data, indicates that strain imaging may aid decision making 
about the reintroduction of trastuzumab after significant LV dysfunction.
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8.2 CONCLUSIONS
At the outset of the research, the primary aim was to evaluate cardiac function in breast cancer 
patients treated with potentially cardiotoxic chemotherapy. Specifically, the current 
echocardiographic method, LVEF, and a contemporary method, myocardial strain imaging, were 
compared in order to determine which of the two techniques is better suited to monitoring 
potential anthracycline-induced cardiotoxicity. The five most salient observations from the 
research are listed above: these 5 observations enable the following conclusions to be made.
! Conclusions from observations 1 and 2: To date, studies that have reported LV dysfunction 
immediately after anthracyclines chemotherapy have used different methods of analysis (such as 
the older tissue Doppler method for calculating strain). We observed reduced LV systolic and 
diastolic function with the 2D strain imaging technique, prior to discernible change in LVEF, 
within 7 days of completion of anthracyclines. To our knowledge, our study is the first to report 
that altered diastolic strain measurements are associated with systolic dysfunction. Moreover, 
while the incidence of heart failure related to anthracyclines occurs most often with higher 
cumulative doses, microscopic analysis reveals that myocardial damage occurs with doses of 
doxorubicin as low as 180 mg/m2 (Friedman, Bozdech, Billingham, & Rider, 1978). The 
observations of reduced systolic and diastolic function reported in this thesis indicate that strain 
imaging technology is more sensitive to anthracycline-induced myocardial dysfunction than LVEF, 
and therefore more likely to detect early signs of myocardial damage.
! Conclusions from observation 3: At baseline we observed the characteristic segmental 
increase in myocardial systolic strain values from base to apex in the longitudinal axis. However, 
after anthracyclines, a greater difference between basal and apical strain values was evident, 
indicative of a non-uniform disruption of LV myocardial systolic function. A similar selective 
segmental disruption of systolic function has been reported in adolescent patients treated with 
anthracyclines (Poterucha, Kutty, Lindquist, Li, & Eidem, 2012), in human epidermal growth factor 
receptor (HER2/neu) positive patients treated with trastuzumab with a variable history of 
anthracycline exposure (Sawaya et al., 2011), as well as in hypertrophic cardiomyopathy (Afonso et 
al., 2012). This research provides confirmation that dysfunction associated with anthracycline 
chemotherapy occurs non-uniformly within the LV that may represent a transient increase in wall 
stiffness, early tissue edema and reversible focal cellular damage2, and emphasizes the value of 
using strain imaging in this setting (as LVEF is not well suited to measuring subtle segmental LV 
dysfunction).
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! Conclusions from observation 4: Marked anthracycline induced cardiotoxicity, indicated by 
a significant reduction in LVEF, is associated with rapid functional deterioration that is often 
difficult to treat (Jurcut et al., 2008; Singal & Iliskovic, 1998). Interestingly, significantly reduced 
systolic strain 7 days post, and 6 months post anthracycline chemotherapy was observed to resolve 
in the majority of patients by 12 months post treatment. That is, in the majority of patients, low 
dose anthracycline-induced myocardial injury is transient, without permanent dysfunction. What 
is also of note is the absence of any discernible change in LVEF at the three post chemotherapy 
time points, which reinforces the superior sensitivity of strain imaging.
! Conclusions from observation 5: As frequently mentioned in the thesis, a high cumulative 
anthracycline dose is the most critical factor related to the development of cardiomyopathy and 
heart failure induced by anthracyclines (Singal & Iliskovic, 1998; Swain, Whaley, & Ewer, 2003). 
Dose-limiting strategies aimed at preventing cardiomyopathy are an important part of routine 
clinical practise. This study revealed persistently reduced global strain at 12 months occurs in ~ 
16% of HER2/neu negative patients - a reduction that was associated with higher doses of 
chemotherapy. As such, the value of ensuring anthracycline doses are kept as low as possible is 
supported by the strain imaging measurements made in this research. 
! Furthermore, significantly reduced strain at 12 months was predicted by a global 
longitudinal strain (GLS) value below -17.2% at 6 months following anthracyclines. Risk 
stratification protocols for the early detection of cardiotoxicity are important given increased life 
expectancy following breast cancer treatment. Monitoring HER2/neu negative patients who 
receive anthracyclines with echocardiograms that utilize strain imaging, both at baseline and at 6 
months following commencement of their treatment, may help treating physicians to identify 
those with subclinical cardiac dysfunction. Patients with GLS values greater than -17.2% may not 
need additional cardiac monitoring; those with GLS values below -17.2% may benefit from 
additional cardiac monitoring to ensure that any further LV dysfunction is promptly treated (see 
figure 8.1).
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(Anthracycline   chemotherapy)
Figure 8.1. Algorithm of the monitoring protocol indicated by the results of the intermediate term 
follow-up of HER2/neu negative patients (where: echocardiograms 1 and 2 are performed immediately 
before and immediately after anthracycline treatment, echocardiogram 3 is performed 6 months after 
echocardiogram 1).
! Additional observations: In keeping with previous reports, our results indicate that 
clinically significant reductions in LVEF (that is, LVEF reductions >10% or absolute reductions in 
LVEF to < 50%) following low dose anthracyclines are rare. Yet, the results also indicate that strain 
imaging technology is more sensitive to anthracycline-induced myocardial dysfunction than LVEF. 
Significantly reduced longitudinal strain after anthracycline chemotherapy has been reported in 
patients who later develop trastuzumab-induced cardiac dysfunction (Fallah-Rad et al., 2011), and 
reduced longitudinal strain after 3 months of trastuzumab therapy has been shown to predict the 
later development of cardiotoxicity, when LVEF was unable to do so (Sawaya et al., 2011). The 
majority of breast cancer patients (HER2/neu negative patients) do not require trastuzumab 
therapy; these are the patients we elected to focus our intermediate term study upon - which is a 
novel aspect of this research.
Echocardiogram 1
Echocardiogram 2
Echocardiogram 3
(Global LPSS ≤ -17.2%) (Global LPSS > -17.2%)
Additional echocardiograms No additional echocardiograms
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! ! Two important conclusions can be drawn from the observations reported in chapter 
7. In brief, after the reintroduction of trastuzumab, systolic strain measurements were reduced 
prior to changes in LVEF. An absence of contractile reserve, as measured by LVEF, was eventually 
noted after exercise (with further reductions in strain). Firstly, reductions in strain prior to 
reductions in LVEF provide further evidence that strain imaging may aid decision making about 
the reintroduction of trastuzumab after significant LV dysfunction. Secondly, while the toxic effect 
induced by anthracyclines is dose related and considered irreversible, cardiotoxicity induced by 
trastuzumab is not dose related and regarded as being reversible (Hayes & Picard, 2006). The 
absence of contractile reserve after exercise indicates that further investigation into trastuzumab’s 
reversibility is needed.
! Several echocardiographic measurements that may have enhanced the research, such as the 
Tei index and isovolumetric relaxation time, were not included in the study: their inclusion is 
anticipated in future work. Minor gender specific differences in strain were not accounted for; yet 
as there was only one male participant this is unlikely to have had a significant influence, 
especially as strain values were compared within patients (with patients serving as their own 
controls). Other limitations of the research are described in the discussion sections of chapters 4, 5 
and 6, however two limitations are worth repeating. The first is the variability of radial systolic 
strain measurements (indicated by the high standard deviation) presented in chapter 4. This 
limitation means the results of radial strain should be interpreted with caution and is one reason 
why researchers are concentrating their efforts on longitudinal strain (which is far less variable). 
Secondly, left-sided mastectomy or lumpectomy were seen to limit strain measurements of systolic 
and diastolic function (due to reduced image quality) more than LVEF. While strain measurements 
were possible in the majority of participants, the need to use LVEF and strain in patients who have 
undergone left sided breast surgery is evidenced by this observation. It is an aim of the group 
involved in the research presented in the thesis, to further study and describe this limitation.
! In conclusion, the results of this research have added to the small amount of existing data 
that indicates that myocardial strain imaging is a more sensitive method than the currently 
accepted measure of LV systolic function (LVEF) for the early detection and intermediate term 
monitoring of LV systolic function following anthracycline chemotherapy. Myocardial strain 
imaging may aid in the identification of those with preclinical LV systolic dysfunction by 
providing an alternative measure of myocardial function to LVEF. Our data support the need for 
longer-term follow-up to provide confirmation of these results, and additional evidence for a more 
extensive use of strain imaging in this clinical setting.
Summary, conclusions and future work
140
8.3 FUTURE WORK
The findings of the research presented in this thesis have led to the above mentioned conclusions, 
and have established a valuable knowledge base to inform future work. Yet, numerous questions 
arise in relation to these conclusions, and additional research is required to advance this early 
work. While the research indicates that myocardial strain imaging is more sensitive to early 
changes in myocardial function than LVEF, in the absence of significant intermediate term falls in 
LVEF (LVEF <50% or an absolute drop in LVEF >10%), the results of this research remain 
preliminary. Therefore, data which demonstrate that reduced LV function using strain imaging 
precedes significant drops in LVEF following anthracyclines are needed. Longer term follow-up, 
using the current protocol, in a larger group of participants may help to determine:
- the significance of reduced systolic and diastolic strain within 7 days of completing 
anthracyclines on longterm cardiovascular outcomes,
- whether the return to normal function 12 months post anthracyclines, as measured by 
global longitudinal systolic strain, in HER2/neu negative patients is permanent 
(following early reductions in strain),
- whether the addition of diastolic strain measurements 12 months post anthracyclines 
provides additional predictive information (such as a change in diastolic grade) for the 
early detection of significant LV dysfunction,
- whether myocardial function in HER2/neu negative patients with persistently reduced 
global LV longitudinal strain 12 months post anthracyclines deteriorates further,
!
- whether HER2/neu negative patients with persistently reduced global LV longitudinal 
strain 12 months post anthracyclines benefit from supportive therapy, and
- whether cardiovascular risk factors like diabetes, hypertension and smoking history 
(which were relatively low in the limited number of participants analysed to date) 
increase the risk of anthracycline-induced cardiotoxicity.
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Answers to these questions may help to establish strain imaging cut-off values and acceptable 
anthracycline dosage ranges. This would enable further development of the management 
algorithm proposed in image 8.1, which with further development could help to identify patients 
for whom additional monitoring is required, and facilitate modification of chemotherapy together 
with the introduction of therapy to minimize the impact of cardiotoxicity.
! The intermediate term observations presented in the thesis are from HER2/neu negative 
participants only. Including intermediate term measurements in participants found to be HER2/
neu positive would be a way to build upon current findings. Due to the increased cardiotoxic 
potential of trastuzumab (following anthracyclines) used to treat HER2/neu positive patients, 
most longer term research to date has been focused on these patients. The results of the case study 
presented in chapter 7 of this thesis indicate a novel way of investigation. That is, adding exercise 
testing to the study protocol may enhance investigation of cardiotoxicity in HER2/neu positive 
patients.
! Along with extending the duration of the research, the addition of different monitoring 
techniques to the protocol may further enhance the research. For example, there is growing 
evidence for the usefulness of blood serum biomarkers in the early identification of anthracycline-
related cardiotoxicity (Dolci, Dominici, Cardinale, Sandri, & Panteghini, 2008). More specifically, 
early and persistent elevation of cardiac troponin (the biomarker of choice for identifying 
myocardial injury) has been shown to identify patients who are more likely to develop 
symptomatic heart failure and benefit from supportive therapies (Cardinale & Sandri, 2010). 
Furthermore, N-terminal pro-brain natriuretic peptide (NTpro-BNP) is associated with increased 
LV wall stress, and may be another useful marker for detecting anthracycline-induced 
cardiotoxicity (Januzzi et al., 2006; Mladosievicova, Urbanova, Radvanska, Slavkovsky, & Simkova, 
2012). 
! In addition to including biomarker analysis, the introduction of another imaging modality 
would further enhance the research. Cardiac magnetic resonance imaging (CMRI), which provides 
highly reliable imaging of the cardiac anatomy, is the imaging modality likely to be most suitable. 
CMRI, when combined with late gadolinium contrast enhancement, can detect areas of irreversible 
myocardial damage. In a recent study of 10 patients with known LV dysfunction while receiving 
trastuzumab therapy, delayed gadolinium uptake indicative of myocarditis was observed in all 10 
(Fallah-Rad, Lytwyn, Fang, Kirkpatrick, & Jassal, 2008). Another recent retrospective analysis of a 
modest number of patients with known LV dysfunction associated with trastuzumab also showed 
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delayed gadolinium enhancement (Wadhwa et al., 2009). For this reason, further investigation of 
the utility of CMRI in these patients has been recommended (Altena, Perik, van Veldhuisen, de 
Vries, & Gietema, 2009).
! As echocardiographic imaging improves, technologies currently under development like 
three dimensional (3D) echocardiography strain will require closer investigation. The limitations 
that constrain 3D echocardiography (as outlined in chapter 2) (Picard, Popp, & Weyman, 2008), are 
certain to be overcome (Marwick & Narula, 2009), therefore 3D echocardiography may prove an 
important part of future work. For now, 2D strain imaging is significantly closer to becoming an 
important part of standard echocardiographic monitoring of patients treated with anthracycline 
chemotherapy. Future work built upon the findings presented in this thesis promise exciting 
discoveries and improved management of patients treated for breast cancer.
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APPENDICES
Preamble
At the commencement of the research, an application for ethics approval was made to the Sydney 
West Area Health Service Human Research Ethics Committee (SWAHS HREC). Following SWAHS 
HREC approval, ratification was requested from the University of Sydney Human Research Ethics 
Committee. The approval letters from both institutions are provided as appendix items 1 and 2. 
As per ethics requirements, every patient recruited into the study was given an information form, 
and all participants provided signed consent. The original Patient Information and Consent Form 
approved for use in the study (version 02 dated 30/06/2008) is included as appendix item 3.
Preliminary observations from the research were submitted as abstracts to various scientific 
conferences at appropriate times during the course of the study. The published abstracts are 
included as appendix items 4 - 8.
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APPENDIX 3 - INFORMATION AND CONSENT FORM
 Westmead Private Hospital
PARTICIPANT INFORMATION SHEET AND CONSENT FORM
 Study Title: Anthracycline Cardiac Echo Study (ACES)
Chief Investigator 
A/Prof David Richards, Westmead Private Hospital
Other researchers 
Mr Paul Stoodley, Sonographer, Westmead Private Hospital
A/Prof Liza Thomas, Cardiologist, Westmead Private Hospital
Dr Warwick Benson, Haematologist, Westmead Private Hospital
A/Prof Steve Meikle, Research Physicist, University of Sydney
Ms Jillian Clarke, Senior Lecturer, University of Sydney
Dr Aiden O’Loughlin, Cardiologist, Westmead Private Hospital 
Invitation 
You are invited to participate in a research study of new ultrasound techniques used to assess the systolic 
(contractile) function of the heart. Before you decide whether or not  you wish to participate in this study, it is 
important  for you to understand why the research is being done and what it  will involve. Please take the time 
to read the following information carefully and discuss it with others if you wish.
What is the purpose of the study?
Anthracycline drugs sometimes cause the heart  to contract  less effectively. The purpose of the study is to 
investigate new ultrasound techniques that  may detect reduced systolic (contractile) function of the heart at 
an earlier stage and more reliably than current methods.
Who will be invited to enter the study?
You are eligible to participate in this study because you have recently been diagnosed with cancer and will 
receive Anthracycline chemotherapy.
Do you have a choice?
Participation in this study is voluntary. It  is completely up to you whether or not  you participate. If you 
decide not  to participate, it  will not affect the treatment you receive now or in the future. Whatever your 
decision, it  will not  affect  your relationship with the staff caring for you. New information about  the 
treatment being studied may become available during the course of the study. You will be kept informed of 
any significant new findings that  may affect  your willingness to continue in the study. If you wish to 
withdraw from the study once it has started, you can do so at  any time without  having to give a reason. 
However, it  may not be possible to withdraw your data from the study results if these have already had your 
identifying details removed.
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Westmead Private Hospital
PARTICIPANT INFORMATION SHEET AND CONSENT FORM
 Study Title: Anthracycline Cardiac Echo Study (ACES)
What will happen in the study?
If you agree to participate in this study, you will be asked to sign the Participant
Consent Form. The study will be conducted over two years. 
Participation will involve having up to seven cardiac ultrasound examinations (echocardiograms) over the 
course of the study. The first  exam will occur before the commencement  of chemotherapy and will take 
between 45 minutes and 1 hour. It will be a full study of the heart and you will be asked to answer a brief 
questionnaire beforehand. 
The following are likely to be less than 45 minutes. They will occur on the same day, at a time as near as 
possible to the routine appointments and treatment that are part of the cancer management. 
For every exam you will undress from the waist  up and wear a hospital gown. The echocardiogram involves 
lying on a couch with your left  arm extended on the couch. The ultrasound images are obtained using a 
transducer held firmly (without undue pressure) against  the chest  and abdomen. Three ECG dots will also be 
placed on the chest during the exam.
No specific preparation is required, and following the exam you are free to resume all regular daily activities.
Are there any risks?
Echocardiography (cardiac ultrasound) is a routine non-invasive imaging method. There may be mild 
discomfort where the transducer is applied (due to firm pressure).  
Confidentiality / Privacy
Only the investigators named above whom work at Westmead Private Hospital will know whether or not you 
are participating in this study. Any identifiable information that  is collected about  you in connection with this 
study will remain confidential and will be disclosed only with your permission, or except as required by law. 
Only the researchers named above whom work at Westmead Private Hospital will have access to your 
details, and the results will be held securely at Westmead Private Hospital.
Compensation  
If you suffer any injuries or complications as a result of this study, you should contact the study doctor as 
soon as possible, who will assist you in arranging appropriate medical treatment.  You may have a right to 
take legal action to obtain compensation for any injuries or complications resulting from the study.  
Compensation may be available if your injury or complication is sufficiently serious and is caused by unsafe 
drugs or equipment, or by the negligence of one of the parties involved in the study (for example, the 
researcher, the hospital, or the treating doctor). If you receive compensation that includes an amount for 
medical expenses, you will be required to 
pay for your medical treatment from those compensation monies. 
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Westmead Private Hospital
PARTICIPANT INFORMATION SHEET AND CONSENT FORM
 Study Title: Anthracycline Cardiac Echo Study (ACES)
If you receive compensation that includes an amount for medical expenses, you will be required to 
pay for your medical treatment from those compensation monies.  You do not give up any legal rights to 
compensation by participating in this study.
If you are not eligible for compensation for your injury or complication under the law, but are eligible for 
Medicare, then you can receive any medical treatment required for your injury or complication free of charge 
as a public patient in any Australian public hospital.
Will taking part in this study cost me anything, and will I be paid?
Participation in this study will not cost you anything. You will not be paid to participate.
What will happen at the conclusion of the study?  
Results of the study will be provided to you, if you wish.
What happens with the results?
If you give us your permission by signing the consent document, we plan to analyze the results and publish 
them in peer-reviewed journals, present the results at conferences or other professional forums. The research 
will also be part of one of the researcher’s master’s degree thesis.
In any publication, information will be provided in such a way that you cannot be identified. Results of the 
study will be provided to you, if you wish.
Complaints
Complaints may be directed to Westmead Private Hospital Patient Representative, Ms Carmel Kennedy, 
telephone (02) 6687 9101 or email KennedyC@ramsayhealth.com.au, or to The Secretary, SWAHS Human 
Research Ethics Committee, telephone (02) 9845 8183 or email researchoffice@westgate.wh.usyd.edu.au
Contact details
When you have read this information, the researcher Paul Stoodley will discuss it with you and any queries 
you may have. If you would like to know more at any stage, please do not hesitate to contact him on 02 9687 
0866. Alternatively, please contact A/Prof David Richards on the same number.
Thank you for taking the time to consider this study. If you wish to take part in it, please sign the attached 
consent form (this information sheet is for you to keep).
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Westmead Private Hospital
PARTICIPANT INFORMATION SHEET AND CONSENT FORM
 Study Title: Anthracycline Cardiac Echo Study (ACES) 
CONSENT TO PARTICIPATE IN RESEARCH
Name of Researcher:
1. I understand that the researcher will conduct  this study in a manner conforming to ethical and scientific 
principles set out by the National Health and Medical Research Council of Australia and the Good 
Clinical Research Practice Guidelines of the Therapeutic Goods Administration.
2. I acknowledge that I have read, or have had read to me the Participant  Information Sheet relating to this 
study.   I acknowledge that I understand the Participant  Information Sheet.  I acknowledge that  the 
general purposes, methods, demands and possible risks and inconveniences which may occur to me 
during the study have been explained to me by Paul Stoodley and I, being over the age of 16 
acknowledge that I understand the general purposes, methods, demands and possible risks and 
inconveniences which may occur during the study.
3. I acknowledge that I have been given time to consider the information and to seek other advice.
4. I acknowledge that refusal to take part in this study will not affect the usual treatment of my 
 condition.
5. I acknowledge that I am volunteering to take part in this study and I may withdraw at any 
 time.
6. I acknowledge that this research has been approved by the Sydney West  Area Health Service Human 
 Research Ethics Committee.
7. I acknowledge that  I have received a copy of this form and the Participant Information Sheet, which I 
 have signed.
8. I understand my identity will not be disclosed to anyone else or in publications or  presentations. 
Name of participant ___________________________________ Date of birth______________________
Address of participant __________________________________________________________________
Signature of participant ________________________________  Date: ____________________
Name of researcher ____________________________________Date: ____________________
Signature of researcher ________________________________  Date: ____________________
Name of witness ____________________________________    Date: ____________________
Signature of witness ___________________________________Date: ____________________
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APPENDIX ITEM 4
ACUTE EFFECTS OF ANTHRACYCLINE THERAPY ON CARDIAC FUNCTION
Published in: Heart, Lung & Circulation 2010 Vol. 19 (supplement 2) page s162
BACKGROUND 
Chemotherapy using anthracycline regimens have cardiotoxic effects. Cardiotoxicity is largely 
monitored using left ventricular ejection fraction (LVEF), a coarse measure of global systolic 
function. Myocardial strain imaging is a more sensitive tool in identification of systolic 
dysfunction, but to date has had limited use with respect to chemotherapy.
METHODS
20 female breast cancer patients (mean age 51 ± 9 years), with no background cardiac history, 
underwent an echocardiogram prior to, and within 2 weeks following chemotherapy (mean of 4.6 
cycles of anthracycline). LV systolic function was evaluated by biplane LVEF and by global 
longitudinal 2-dimensional strain as an average from 3 beats.
RESULTS
Baseline LVEF was normal (59 ± 2%) and global longitudinal strain was -17.6 ± 2%. At follow up, a 
clinically insignificant reduction was noted in LVEF (post LVEF: 56 ± 3%; mean difference -3.5%); 
no patient had a >10% reduction in LVEF or an LVEF <50%. Paired t test between groups 
demonstrated a statistically significant reduction in global strain (-16.3 ± 2%; p = 0.016; mean 
difference -1.3%). 1 in 4 patients demonstrated a >10% reduction in strain compared to baseline 
value.
CONCLUSION
Although LVEF decreased, it failed to reach clinical significance immediately after chemotherapy. 
An overall significant reduction was noted in myocardial strain, with 20% of patients having a 
>10% reduction. Myocardial strain imaging may be a more sensitive measure for detecting 
cardiotoxicity, the early recognition of which could lead to supportive therapy.
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APPENDIX ITEM 5
REDUCED SEGMENTAL LEFT VENTRICULAR SYSTOLIC STRAIN AFTER ANTHRACYCLINE 
CHEMOTHERAPY
Published in: European Heart Journal 2011 32 (abstract supplement): page 1449
PURPOSE
The efficacy of anthracyclines is undermined by potentially life threatening cardiotoxicity. Close 
monitoring of cardiac function in those treated with anthracyclines is mandatory. Currently, 
despite numerous limitations, left ventricular ejection fraction (LVEF) by echocardiography is used 
for monitoring. 
" Myocardial strain imaging has been shown to detect left ventricular (LV) systolic 
dysfunction prior to noticeable changes in LVEF. Moreover, unlike LVEF, strain imaging is able to 
measure both segmental and global myocardial deformation.   Our aim was to determine 
whether strain imaging would detect segmental changes in LV systolic function prior to clinically 
significant changes in global function as measured by LVEF.
METHODS
52 women with histologically confirmed breast cancer were prospectively studied. The first 
echocardiogram was performed immediately before anthracycline treatment and the second 
immediately afterwards. LVEF (by Simpson's method), and segmental  (longitudinal, radial and 
circumferential) LV systolic strain were measured before and after.
RESULTS
Longitudinal systolic strain  was significantly reduced (p <0.05) in 5 of 6 longitudinal segments 
after chemotherapy; in 3 of the 5 segments by >10%. Radial systolic strain was significantly 
reduced (p <0.05) in 3 of 6 regions after chemotherapy; in all 3 segments by >10%. Circumferential 
systolic strain was significantly reduced (p  <0.05) in 1 segment only. Systolic strain was 
significantly reduced (p <0.05) in 9 of 18 segments (50%), 7 of 18 segments (38%) by >10%. LVEF 
did not fall by >10% in any patient after chemotherapy (see table).
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Measurement Observation after chemotherapy
LVEF 0 of 52 reduced by > 10%
Longitudinal strain 5/6 (83%) segments reduced (p <0.05); 3/5 reduced >10%
Radial strain 3/6 (50%) segments reduced (p <0.05); 3/3 reduced >10%
Circumferential strain 1/6 (17%) segments reduced (p <0.05)
CONCLUSION
LV systolic strain was significantly reduced in 50% of imaged   segments   after anthracycline 
chemotherapy. No reduction in global function (LVEF) >10% after chemotherapy was observed. 
Longer term follow up is needed to determine the clinical significance of segmental changes in LV 
systolic strain after chemotherapy.
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APPENDIX ITEM 6
MYOCARDIAL STRAIN IMAGING DETECTS EARLY CHANGES IN GLOBAL LEFT 
VENTRICULAR SYSTOLIC FUNCTION AFTER ANTHRACYCLINE CHEMOTHERAPY
Published in: European Heart Journal 2011 32 (abstract supplement): page 4684
PURPOSE
The efficacy of anthracycline chemotherapy is undermined by potentially life threatening 
cardiotoxicity. Cardiotoxicity is dependent upon several factors, and its timing is variable; so close 
monitoring of cardiac function in those treated with anthracyclines is mandatory. Currently, 
despite numerous limitations, left ventricular ejection fraction (LVEF) by echocardiography is used 
for monitoring cardiotoxicity.
" Myocardial strain imaging has been shown to detect left ventricular (LV) systolic 
dysfunction in several diseases prior to noticeable changes in LVEF. Our aim was to determine 
whether strain imaging could detect early changes in LV systolic function prior to detection by 
LVEF in patients after receiving anthracycline chemotherapy. 
METHODS
52 women with histologically confirmed breast cancer were prospectively studied. The first 
echocardiogram was performed immediately before anthracycline treatment and the second 
immediately afterwards. LVEF (by Simpson’s method), global   peak longitudinal, radial and 
circumferential systolic strain were measured before and after.
RESULTS
Global longitudinal LV systolic strain was significantly reduced after treatment; global 
longitudinal strain dropped from -17.7% to -16.3% (p < 0.01) with 48% of global measurements 
reduced by >10%. Global radial LV systolic strain after treatment was also significantly reduced; 
global radial strain dropped from 40.5% to 34.5% (p < 0.01) with 59% of global measurements 
reduced by >10%. In contrast, no statistically significant reduction in global circumferential 
strain was observed (although strain was reduced >10% in 32% of participants after treatment). No 
reduction >10% in LVEF after chemotherapy was observed (see table).
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Measurement Before chemotherapy After chemotherapy % with >10% drop
LVEF (%) 58.6 ± 2.6 56.0 ± 2.8 0
Longitudinal strain (%) -17.8 ± 2.1 16.3 ± 2.0 48
Radial strain (%) 40.5 ± 11.4 34.5 ± 11.4 59
Circumferential strain (%) -20.3 ± 2.6 -20.0 ± 3.3 32
! ! * p < 0.01 versus before chemotherapy value (Values expressed as mean ± SD)
CONCLUSION
We observed significantly reduced global LV systolic strain early after anthracycline treatment, 
prior to  significant reductions in  LVEF. These observations  may indicate early impairment of 
myocardial function, and warrant longer-term surveillance to determine their clinical relevance.
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APPENDIX ITEM 7
ALTERED LV DIASTOLIC FUNCTION AFTER ANTHRACYCLINE CHEMOTHERAPY
Published in: Heart, Lung & Circulation 2011 Vol. 20 (supplement 2) page s158
BACKGROUND
Anthracycline chemotherapy is potentially cardiotoxic. Cardiotoxicity has traditionally been 
monitored by measuring change in left ventricular (LV) systolic function. Recent evidence 
suggests, however, that abnormalities of LV diastolic function can precede systolic abnormalities.
METHODS
Thirty consecutive female breast cancer patients (age: 48±10 years) with no background cardiac 
history were prospectively studied. Each had an echocardiogram prior to and immediately after 
completing chemotherapy. Twenty-five were treated with Doxorubicin (≤310 mg.m-2) and five with 
Epirubicin (≤360 mg.m-2). LV systolic function was evaluated with biplane LVEF and diastolic 
function with transmitral, tissue Doppler (TDI) and strain rate (SR-1) measurements.
RESULTS
Average LVEF was significantly lower after chemotherapy (56±3% vs 59±3%, p  <0.01). Significant 
changes in transmitral, TDI and SR-1 measures of diastolic function were also observed (see table).
Measurement Before chemotherapy After chemotherapy
Transmitral ‘A’ velocity (m.s-1) 0.63 ± 0.13 0.67 ± 0.14*
E/E’ septal 8.3 ± 2.4 9.3 ± 2.1*
E’ average (m.s-1) 9.9 ± 2.7 9.2 ± 2.8*
E/E’ average 7.1 ± 2.5 8.0 ± 2.2*
ESR (1/s) 1.03 ± 0.24 0.90 ± 0.25*
* p<0.05 vs before chemotherapy (Values expressed as mean ± SD)
CONCLUSION
The observed reduction in LV systolic function (LVEF) after chemotherapy did not reach clinical 
significance. The observed reductions in multiple measures of LV diastolic function indicate an 
increased LV end diastolic pressure. These findings warrant further investigations in order to 
determine whether they are predictive of reduced LV systolic function.
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APPENDIX ITEM 8
EVALUATION OF LEFT VENTRICULAR SYSTOLIC FUNCTION IN THE INTERMEDIATE 
TERM AFTER ANTHRACYCLINE CHEMOTHERAPY: A COMPARISON OF LVEF AND 
GLOBAL LONGITUDINAL STRAIN
Published in: Heart, Lung & Circulation 2012; 21 (supplement 1): page S202
BACKGROUND
Anthracycline chemotherapy is potentially cardiotoxic. As toxicity has variable timing, close 
monitoring of those treated with anthracyclines is mandatory. Global longitudinal strain (GLS) 
measured by speckle tracking echocardiography can detect reduced LV systolic function before 
LVEF in numerous diseases. We aimed to determine, 1) whether GLS would detect reduced LV 
systolic function before LVEF immediately after anthracyclines and 2) whether any changes would 
persist at 6 and 12 months.
METHOD
Forty-one consecutive breast cancer patients were prospectively studied. The baseline 
echocardiogram was performed 1-week before and the 2nd 1-week after chemotherapy. The 3rd and 
4th echocardiograms were performed at 6 and 12 months. GLS (measured from the apical 4 
chamber view), and LVEF (by Simpson’s method) were measured at each time point.
RESULTS
Repeated measures analysis showed GLS was significantly reduced 1 week after chemotherapy 
(-16.7 ± 4.0% from -18.3 ± 4.3%, p <0.01), although LVEF was not. Six months after chemotherapy, 
GLS was no longer reduced, while a clinically non-significant reduction in LVEF compared to 
baseline was observed (56.1 ± 3.4% from 58.0 ± 2.6%, p <0.05). Twelve months after chemotherapy, 
both GLS and LVEF had returned to values similar to before therapy.
CONCLUSION
Reduced GLS 1 week after anthracycline chemotherapy indicates early identification of reduced 
LV systolic function, undetected by LVEF, and may enable better risk assessment of patients who 
require additional therapies that are potentially cardiotoxic. Reductions in GLS and LVEF did not 
persist 12 months after chemotherapy, suggesting that these effects are transient.
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